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ABSTRACT 
 Staphylococcus aureus (S. aureus), a major human pathogen, is a common cause 
of infections worldwide due to its high virulence intensity. By adapting to rapidly 
changing and uniformly hostile environments, strains of S. aureus acquire resistance to 
antimicrobial agents shortly after their exposure.  For example, within a year of its 
introduction, S. aureus developed resistance to methicillin which triggered the 
development of other antimicrobial treatments. In spite of the various antibiotics 
currently used to treat methicillin-resistant S. aureus (MRSA) infections, antimicrobial 
resistance is an unavoidable consequence due to the selective pressure of antibiotic 
exposure. Thus, other prevention modalities are warranted to prevent MRSA 
transmission.  
Titanium dioxide (TiO2) nanoparticles decompose organic compounds by the 
formation and constant release of hydroxyl radicals and superoxide ions when exposed to 
non-lethal ultraviolet (UV) light of 365nm at 370>w/cm2. Commercially available 
anatase phase TiO2 nanoparticles can serve as antimicrobial agents via UV light 
activation. However, brookite phase nanoparticles, due to their smaller particle size, may 
increase the efficiency of TiO2 nanoparticles to inhibit bacterial growth by promoting a 
greater surface area contact ratio which subsequently causes cell death in less time than 
anatase phase nanoparticles.  
Both the TiO2-free suspension and drop-coated slide bioassays were conducted to 
determine the effects of UV light activated TiO2 nanoparticles on gram-negative, 
Escherichia coli, and gram-positive, S. aureus, cells and the results revealed non-
iii
selective killing properties of the nanoparticles. Furthermore, UV light activated brookite 
nanoparticles (1mg/mL) caused a 100% reduction in MRSA cell growth within 30 
minutes while anatase nanoparticles, under the same conditions, required approximately 
75 minutes for such complete cell death. Additionally, physical damage to the cells by 
UV light activated TiO2 nanoparticles was confirmed by scanning electron microscopy 
images.  
Due to MRSA’s ability to acquire resistance to antibiotics, these agents remain a 
temporary solution for the treatment of such pathogenic infections. In contrast, brookite 
phase TiO2 nanoparticles offer promise for the prevention of MRSA due to their physical, 
non-selective inhibitory effects on cells. Additionally, the utilization of TiO2
nanoparticles, as a means to prevent transmission could further reduce the emergence of 
multiple drug-resistant bacteria. 
The long term goal of this research is to develop visible light activated surface 
coatings of TiO2 nanoparticles that could be used in clinical settings to reduce the 
transmission of bacterial infections. Therefore, visible light activation of brookite 
nanoparticles for practical usage was also evaluated.  
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1CHAPTER 1 
 
LITERATURE REVIEW 
 
1.1 Staphylococcus aureus 
1.1.1 Morphology and Characteristics 
Staphylococcus aureus (S. aureus) has been recognized as a major human 
pathogen since it was discovered by Sir Alexander Ogston in the 1880s as the major 
cause of wound suppuration (Archer 1998). S. aureus is a gram-positive coccus, 
approximately 0.5 to 1.5>m in diameter (Figure 1A) and appears as grape-like clusters 
(Figure 1B) when viewed under a microscope. S. aureus forms large, round, golden-
yellow colonies, often with J-hemolysis, when grown on blood agar plates (Carr et al.,
2005; Holt et al., 1994; Kaiser, 1999).  
 
Figure 1: Images of Staphylococcus aureus in 
(A) Scanning Electron Microscopy and (B) Gram Stain (Carr et al., 2005; Kaiser, 1999) 
 
BA
2The golden appearance is the etymological root of the bacteria’s name. S. aureus 
are non-motile and non-spore forming facultative anaerobes that grow by aerobic 
respiration or by fermentation that yields lactic acid (Holt et al., 1994). The bacteria can 
grow at temperature ranges of 15 to 45ºC and at sodium chloride concentrations as high 
as 15%. S. aureus is catalase positive and therefore, able to convert hydrogen peroxide to 
water and oxygen. Also, it is coagulase positive and thus, able to coagulate blood serum 
into a clot (Holt et al., 1994).  
 
1.1.2 Pathogenesis 
Due to its virulence intensity, S. aureus, is a common cause of infections not only 
in the United States, but in countries all over the world (Archer, 1998). Its resistance to 
antibiotics is currently increasing which indicates that its prevalence will continue to rise. 
Due to the high occurrences and severity of S. aureus infections, it is necessary to 
understand the pathogenesis of S. aureus (Archer, 1998).   
The five stages in the pathogenesis of S. aureus infections are (a) colonization, (b) 
local infection, (c) systemic dissemination and/or sepsis, (d) metastatic infection, and (e) 
toxinosis. S. aureus can be asymptomatically carried for weeks or months on mucous 
membranes and intact skin (Archer, 1998).  S. aureus mainly colonizes the nasal passages 
but it may also be found in other anatomical locales (Archer, 1998). The colonization 
may be transient and may spread faster during times of upper respiratory tract infections.  
Staphylococcal infections usually remain localized at the port of entry due to the 
normal host defenses (Todar, 2005). Colonization precedes infection (Archer, 1998). The 
3localized host response to staphylococcal infections is inflammation, characterized by an 
elevation of temperature at the site, swelling, accumulation of pus, and necrosis of tissue 
(Todar, 2005). Around the inflamed area, a fibrin clot may form, walling off the bacteria, 
as a pus-filled boil or abscess (Figure 2) (Todar, 2005). Thereafter, superficial skin 
lesions such as boils, styes, and furunculosis (Figure 2) can occur (Archer, 1998). The 
infection can spread locally or can gain access to the blood. If it spreads locally, it can 
progress to pneumonia, mastitis, phlebitis, meningitis, and urinary tract infections 
(Figure 2) (Archer 1998). In the blood, the organism spreads widely to peripheral sites in 
distant organs and septic shock can occur. Due to hematogenous dissemination, a number 
of specific staphylococcal infections can result such as endocarditis, osteomyelitis, renal 
carbuncle, septic arthritis, or epidural abscess (Figure 2). Finally, even if the organism 
does not invade the bloodstream, syndromes can result from the local or systemic effects 
of specific toxins such as toxic shock syndrome, scalded skin syndrome, and food-borne 
gastroenteritis (Figure 2) (Archer, 1998).  
 
4Figure 2: Sites of Infection and Diseases Caused by Staphylococcus aureus                 
(Archer, 1998) 
 
1.1.3 Virulence Factors 
The success of S. aureus as a pathogen and its ability to cause such a wide range 
of infections are due to its virulence factors (Archer, 1998). According to Archer (1998), 
S. aureus displays a wider variety of virulence mechanisms than any other human 
pathogen (Archer, 1998). Specific factors are present that allow the organism to thwart 
opsonophagocytosis. These factors include invasion through the tissue from the initial 
site of infection inducing sepsis syndrome by promoting a massive cytokine release. 
Opsonophagocytosis can also be avoided by extravasation into the endothelial cells and 
underlying tissues or by the production and excretion of toxins (Archer, 1998).  
S. aureus expresses (a) membrane-damaging toxins (hemolysins, kinases, and 
leukocidins) that invade tissues and promote bacterial spread, (b) surface factors 
(adhesins, microcapsules, and proteins) that promote colonization of host tissues, inhibit 
5phagocytic engulfment, and thwart host defenses, and (c) exoproteins (enterotoxins, toxic 
shock syndrome toxin-1, and exofoliative toxins) (Figure 3) that induce specific 
toxinosis (Quinn, 2006; Todar, 2005).  
 
Figure 3: Virulence Factors of Staphylococcus aureus (Quinn, 2006) 
 
S. aureus produces the hemolytic toxins (Figure 3), N-, J-, O-, and P- (Dinges et 
al., 2000; Todar, 2005). Platelets and monocytes are sensitive to N-toxin. Susceptible 
cells have a specific receptor for N-toxin which allows the toxin to bind causing small 
pores through which monovalent cations can pass. After binding the toxin, a series of 
reactions ensue, causing a release of cytokines which generate the production of 
inflammatory mediators. These events cause the symptoms of septic shock that occur 
during severe infections (Dinges et al., 2000; Todar, 2005). The N-hemolysin is the most 
toxic S. aureus hemolysin (Quinn, 2006). The J-toxin is a sphingomyelinase which is 
produced by approximately 20% of all S. aureus isolates, is toxic to monocytes, and is 
6commonly found in strains causing mastitis (Dinges et al., 2000; Quinn, 2006; Todar, 
2005). The O-toxin affects neutrophils and macrophages and is capable of lysing various 
mammalian erythrocytes (Dinges et al., 2000; Todar, 2005). The small peptide, P-toxin, 
is capable of lysing erythrocytes, mammalian cells, and subcellular structures such as 
membrane-bound organelles, spheroplasts, and protoplasts (Dinges et al., 2000; Todar, 
2005).  
Furthermore, many strains of S. aureus express a plasminogen activator protein 
called staphylokinase (Figure 3). It consists of 136 amino acids and lyses fibrin (Dinges 
et al., 2000; Todar, 2005). Staphylokinase is carried by a converting phage that inserts 
into the J-hemolysin structural gene. Expression of staphylokinase is positively regulated 
by the accessory gene regulator (Agr) and negatively regulated by the staphylococcal 
accessory gene regulator (Sar). The complex formed between staphylokinase and 
plasminogen initiates plasmin-like proteolytic activity which causes dissolution of fibrin 
clots. This localized fibrinolysis may aid in bacterial spreading and invasion of host 
tissues (Dinges et al., 2000, Jin et al., 2004; Todar, 2005).  
Another membrane-damaging toxin, Panton-Valentine Leukocidin (PVL) (Figure 
3), is a member of the synergohymenotropic toxin family that induces pores in the 
membranes of cells (Bradley, 2005). Pairs of secretory proteins, S and F, work 
synergistically on cell membranes as superantigens which release intracellular 
interleukin-8, leukotrienes, proteases, and oxygen metabolites. This leads to chemotaxis, 
vasodilation, tissue necrosis, and death of neutrophils. SF protein pairs composed of S 
and F PVL-associated proteins (LukSPV + LukFPV) and S and F N-hemolysin-associated 
7proteins, HIgA (class S), HIgB (class F), HIgC (class S), have been discovered in various 
combinations of necrotizing pneumonia (Bradley, 2005). Panton-Valentine Leukocidin-
positive S. aureus strains belong to the 4 Agr allele type. The Agr locus controls the 
expression of most virulence factors in S. aureus. It encodes a two-component signaling 
pathway whose activating ligand is a density-sensing peptide also encoded by Agr 
(Dufour, 2002). Panton-Valentine Leukocidin has been linked to infections such as 
furunculosis, cellulitis, and abscesses (Dinges et al., 2000; Dufour, 2002; Todar, 2005).  
Surface proteins (Figure 3) promote attachment to host proteins such as laminin 
and fibronectin which form the extracellular matrix in epithelial and endothelial surfaces 
(Todar, 2005). Most strains of S. aureus express fibronectin and fibrinogen-binding 
proteins which promote attachment to blood clots and traumatized tissue. An adhesin that 
promotes attachment to collagen has been found in strains of S. aureus that cause 
osteomyelitis and septic arthritis. In addition, interaction with collagen is important in 
promoting bacterial attachment to damaged tissue when the underlying layers of tissue 
have been exposed (Todar, 2005). 
The extracellular capsule (CP) (Figure 3) of S. aureus consists of polysaccharides 
and enhances virulence by allowing the bacteria to resist phagocytosis and killing by 
polymorphonuclear phagocytes (Karakawa et al., 1982; Koenig, 1962; Nilsson et al.,
1997; Peterson et al., 1978). So far, eleven capsular serotypes have been identified. S.
aureus expressing CP type 5 or CP type 8 polysaccharides account for 80% to 85% of 
clinical blood isolates in septicemia (Fattom et al., 1990; Fournier, 1990; Karakawa et al.,
1982; Nilsson et al., 1997). The capsule impedes the interaction between cell wall-bound 
8C3b and immunoglobulin on the phagocytic cells (O’ Riordan et al., 2004). As a result, 
the bacteria evade phagocytic uptake. 
Another surface factor, Protein A (Figure 3), consists of a single polypeptide 
chain with a molecular weight of 42kDa, containing four repetitive domains rich in 
aspartic and glutamic acids but devoid of cysteine. It contains little or no carbohydrates, 
four tyrosine residues, and no tryptophans (Bjork et al., 1972; Boyle et al., 1987; Goden, 
1978). It is a surface protein that binds immunoglobulins, especially IgG molecules by 
their Fc region. The IgG binding domain of Protein A consists of three anti-parallel N-
helices, the third of which is disrupted when the protein is complexed with the Fc region 
of the immunoglobulins (Boyle et al., 1987). The binding event prevents the IgG 
molecules from reacting with the Fc receptor on phagocytes (Quinn, 2006; Todar, 2005). 
In serum, the bacteria will bind IgG molecules in the wrong orientation on their surface 
which disrupts opsonization and phagocytosis (Todar, 2005). 
Enterotoxins (Figure 3) are a series of extracellular monomeric proteins that were 
first discovered in 1959 (Bergdoll, 1959; Munson et al., 1998; Su et al., 1995). According 
to serological classification, six enterotoxins have been recognized: A, B, C, D, E, and H. 
These enterotoxins are small peptides, with sizes ranging from 26kDa to 29kDa, and have 
a great deal of similarity at the amino acid level (Marrack et al., 1990; Mehrotra et al.,
2000; Schmitz et al., 1997; Vannuffel et al., 1995). Enterotoxins cause staphylococcal 
food poisoning (Bergdoll, 1983; Bohach et al., 1990; Munson et al., 1998). 
Toxic Shock Syndrome Toxin-1 (TSST-1) (Figure 3) is a 22kDa peptide 
expressed systemically and is the cause of toxic shock syndrome (TSS) (Quinn, 2006; 
9Todar, 2005). This toxin may induce the production of interleukin-1B and tumor necrosis 
factor by monocytes which have a negative effect on neutrophil chemotactic function 
(Fast et al., 1989; Todar, 2005).  Toxic Shock Syndrome Toxin-1 is responsible for 75% 
of all TSS cases, including all menstrual cases. Toxic Shock Syndrome can occur as a 
sequel to any staphylococcal infection if an enterotoxin or TSST-1 is released 
systemically and the host lacks appropriate neutralizing antibodies (Todar, 2005).  
There are two antigenically distinct forms of exfoliative toxins (Figure 3), ETA 
and ETB. Exfoliative toxin A is chromosomally encoded and ETB is plasmid encoded 
(Quinn, 2006; Todar, 2005). These toxins possess the same biological activity but they 
differ in amino acid composition and amino acid sequences. ETA consists of 242 amino 
acid residues while ETB consists of 246 amino acid residues (Lee, 1987). The ETA and 
ETB toxins have specific esterase and protease activity. Therefore, the toxins may target 
a specific protein (Todar, 2005). The exfoliative toxins cause blistering and loss of the 
epidermis which eventually persist to scalded-skin syndromes (Todar, 2005). 
Enterotoxins, TSST-1, and exfoliative toxins are also known as superantigens 
(Lowy, 1998; Quinn, 2006).  They belong to a group of polypeptide products that can 
activate subsets of T lymphocytes to liberate cytokines, leading to major systemic effects 
such as fever, hypotension, skin lesions, shock, multiorgan failure, and death (Lowy, 
1998; Quinn, 2006). A superantigen (Figure 4) is a molecule that binds with high affinity 
to MHC class II receptors of monocytes and macrophages at sites distinct from the classic 
antigen binding groove. This complex (Figure 4) is recognized by the variable region, 
VJ, of the T lymphocytes. This action causes prolific activation or sometimes the 
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apoptosis of T cells because of the recognition of the VJ chains by the toxin (Lowy, 
1998; Quinn, 2006). 
 
Figure 4: Superantigens and the Non-Specific Stimulation of T Lymphocytes        
(Quinn, 2006) 
 
1.2 Emergence of Antibiotic-Resistant Staphylococcus aureus 
The introduction of large quantities of diverse antimicrobial agents into the 
human environment in the past century has presented a new set of challenges to 
pathogens such as S. aureus. Effective lineages of pathogens must excel in several 
capacities. They must be able to acquire resistant genes in order to survive against 
antibiotics. In the environment, the resistance determinants must find their way into 
genetic backgrounds that assure the capacity to compete with other bacteria. Finally, the 
pathogens must be able to spread, establish ecological reservoirs, colonize, and cause 
disease.  
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Most S. aureus strains are opportunistic pathogens that can colonize individuals, 
with or without symptoms, for either short or extended periods of time, causing disease 
when the immune system becomes compromised (Oliveira et al., 2002). S. aureus has 
affected human beings and caused high mortality rates before the antibiotic era. S. aureus 
is unsurpassed by any other human pathogen due to its flexibility in pathogenic strategies, 
numbers of virulence factors, and capacity to survive and multiply in a wide range of 
environments (Oliveira et al., 2002). The ability of S. aureus to adapt to rapidly changing 
and uniformly hostile environments has repeatedly been shown by the emergence of 
strains that acquire resistance to any antimicrobial agent shortly after its introduction 
(Oliveira et al., 2002). 
S. aureus like all bacterial cells grow and divide, replicating repeatedly to reach 
the large numbers present during an infection in the body. Antimicrobial agents interfere 
with specific processes (Figure 5) that are essential for growth and division which is 
lethal to the cells or inhibitory to their growth (Lambert, 2005; Neu et al., 2004).  
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Figure 5: Sites of Action for Antimicrobial Agents (Neu et al., 2004)
The various antimicrobial agents can be separated into groups such as inhibitors 
of nucleic acid synthesis, inhibitors of ribosome function, inhibitors of cytoplasmic 
membranes, inhibitors of folate metabolism, and inhibitors of bacterial cell wall synthesis 
(Table 1) (Neu et al., 2004). Antimicrobial agents may be either bactericidal, killing the 
target bacterium or bacteriostatic, inhibiting the growth of microorganisms (Neu et al.,
2004).  
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Table 1: Mechanisms of Action of Antimicrobial Agents (Neu et al., 2004)
Antibiotics can interfere with nucleic acid synthesis at several different levels. 
They can inhibit nucleotide synthesis by interfering with purine or pyrimidine synthesis 
or with the interconversion of nucleotides. Some antimicrobial agents can act as 
nucleotide analogs that are incorporated into polynucleotides. Other drugs bind to DNA 
by intercalation and inhibit nucleic acid synthesis (Neu et al., 2004).  
Several antimicrobial agents act by inhibiting ribosome function. Bacterial 
ribosomes contain two subunits, 50S and 30S. Antibiotics that can act on the 30S subunit, 
bind to specific proteins in the ribosomal subunit which causes the ribosome to misread 
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the genetic code. Some antibiotics can combine with binding sites on the ribosomes and 
kill the bacteria by inducing the formation of aberrant, nonfunctional complexes. 
Antibiotics that act on the 50S subunit inhibit peptide bond formation by binding to a 
peptidyltransferase enzyme on the 50S ribosome (Neu et al., 2004).  
 A number of antimicrobial agents can cause disorganization of the membrane. 
These agents can be divided into cationic, anionic, and neutral agents. Certain drugs 
disorganize the permeability of membranes so that nucleic acids and cations leak out 
which eventually results in death. Other antibiotics act by producing aqueous pores in the 
membranes (Neu et al., 2004). Some drugs interfere with folate metabolism by blocking 
the biosynthesis of tetrahydrofolate, which acts as a carrier of one carbon fragments and 
is necessary for the ultimate synthesis of DNA, RNA, and bacterial cell wall proteins 
(Neu et al., 2004).  
Drugs such as J-lactams affect bacterial cell wall synthesis. Bacterial cell walls 
contain a peptidoglycan layer (Figure 6) which is the critical attack site of anti-cell wall 
synthesis agents. Peptidoglycan, also known as murein, serves a structural role in the 
bacterial cell wall, providing the wall shape and structural strength, as well as 
counteracting the osmotic pressure of the cytoplasm (Neu et al., 2004). The 
peptidoglycan layer is substantially thicker in Gram-positive bacteria than in Gram-
negative bacteria (Neu et al., 2004). The Gram-positive cell wall consists of a single 
20nm to 80nm thick homogenous peptidoglycan layer lying outside the plasma 
membrane while the Gram-negative cell wall consists of a 2nm to 7nm peptidoglycan 
layer surrounded by a 7nm to 8nm thick outer membrane. Due to this thickness, the walls 
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of Gram-positive bacteria are stronger and can, therefore, protect the bacteria from toxic 
substances with more ease than Gram-negative bacteria (Prescott et al., 2002).   
The peptidoglycan layer in the bacterial cell wall is a crystal lattice structure 
formed from linear chains of two alternating amino sugars, namely N-acetyl muramic 
acid (MurNAc or NAM) and N-acetyl glucosamine (GLcNAc or NAG) (Figure 6). The 
alternating sugars are connected by a J-(1, 4)-glycosidic bond. Each MurNAc is attached 
to a short (4 to 5 residue) amino acid chain, normally containing D-alanine, D-glutamic 
acid, and mesodiaminopimelic acid. These three amino acids do not occur in proteins and 
help protect against attacks by most peptidases. Cross-linking between amino acids in 
different linear amino sugar chains by an enzyme known as transpeptidase results in a 
peptidoglycan layer that is strong and rigid (Neu et al., 2004).  
 
Figure 6: The Peptidoglycan Layer of Bacterial Cell Walls (Prescott et al., 2002)
16
1.2.1 Penicillin-Resistant Staphylococcus aureus 
The introduction of benzylpenicillin (also known as penicillin G) into 
chemotherapy in the early 1940s found S. aureus fully susceptible and several of the first 
successes of penicillin therapy were related to the cure of formerly untreatable 
staphylococcal diseases (Abraham et al., 1941; Oliveira et al., 2002).  
Penicillin refers to a group of J-lactam antibiotics used in the treatment of 
bacterial infections usually caused by susceptible Gram-positive organisms. It was 
Alexander Fleming who, in 1928, discovered that the mold, Penicillium notatum, 
produced a diffusible substance, under certain circumstances, which inhibited the growth 
of some bacterial species. This substance was named penicillin. Very little was done with 
this substance in the subsequent years, probably because it was found to be unstable 
(Harrison, 2007).  
In 1939, Chain and Florey, as part of a comprehensive program of research on 
antibacterial substances, began work on penicillin at Oxford and established the efficacy 
of penicillin as a chemotherapeutic agent. The choice of penicillin was, for Chain, mainly 
determined by the challenges posed by its instability, and, for Florey, by the fact that it 
was the only substance at that time that might be effective against S. aureus (Abraham et 
al., 1941). In order to strengthen the chemical side of the work, Florey attracted Abraham 
who set about the difficult task of purifying penicillin and then determining its structure. 
Abraham was successful in both these aims, and was the first to propose the correct 
chemical structure for penicillin. Abraham's structure of penicillin involved the novel J-
lactam ring (Abraham et al., 1941; Harrison, 2007).  
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J-lactam antibiotics are a broad class of antibiotics that include penicillin 
derivatives (Figure 7A) such as methicillin, cloxacillin, oxacillin, and fludoxacillin; 
cephalosporins (Figure 7B) including oxacephams and cephamycins; monobactems 
(Figure 7C) such as aztreonam; carbapenams (Figure 7D) such as thienamycins, 
meropenem, ertapenem, faropenem, and doripenem; and other J-lactam antibiotics such 
as clavulanic acid (Figure 7E), tazobactam, and sulbactam. These antibiotics share a 
three carbon and one nitrogen structure known as the J-lactam ring (Harrison, 2007; Neu 
et al., 2004). An intact J-lactam ring is required for these antibiotics to effectively exert 
their bactericidal activity (Harrison, 2007).  
 
Figure 7: J-Lactam Ring Structure in (A) Penicillin; (B) Cephalosporin;                             
(C) Monobactem; (D) Carbapenam; and (E) Clavulanic Acid (Neu et al., 2004) 
R and R´ represent carbon groups. X represents hydrogen or a methoxy group. 
J-lactam antibiotics act by inhibiting the synthesis of the peptidoglycan layer of 
bacterial cell walls. The final transpeptidation step in the synthesis of the peptidoglycan 
layers of bacterial cell walls is facilitated by transpeptidases known as penicillin binding 
proteins (PBPs). J-lactam antibiotics are analogs of D-alanyl-D-alanine, the terminal 
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amino acid residues on the precursor NAM/NAG peptide subunits of the peptidoglycan 
layer (Harrison, 2007). The structural similarity between J-lactam antibiotics and D-
alanyl-D-alanine facilitates their binding to the active site of PBPs. The J-lactam nucleus 
of the molecule irreversibly binds to the Ser403 residue of the PBP active site. This 
irreversible inhibition of the PBPs prevents the final crosslinking of the nascent 
peptidoglycan layer, disrupting cell wall synthesis. Therefore, the effectiveness of these 
antibiotics relies on their ability to reach the PBP intact and their ability to bind to the 
PBP (Harrison, 2007). 
However, by the mid 1950s, the number of S. aureus clinical isolates showing 
high levels of resistance to penicillin rapidly increased to such an extent that penicillin 
ceased to be a useful therapeutic agent against staphylococcal infections (Oliveira et al.,
2002). One study indicated that within approximately 6 years after the introduction of 
penicillin, 25% of hospital strains were resistant to penicillin (Chambers, 2001). Today, 
virtually all strains of S. aureus are resistant to natural penicillins, aminopenicillins, and 
antipseudomonal penicillins. The mechanism of penicillin resistance involved the 
acquisition of a plasmid-borne, J-lactamase enzyme, penicillinase, (Figure 8) which was 
capable of breaking down the J-lactam ring of penicillin thus, degrading the antibiotic 
before it could reach its cellular targets (Neu et al., 2004).  
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Figure 8: Site of J-Lactamase Attack (Neu et al., 2004)
The genes encoding these enzymes may be inherently present on the bacterial 
chromosome or may be acquired by plasmid transfer (Jessen et al., 1969; Oliveira et al.,
2002). The effects of this plasmid epidemic were first seen on hospital isolates of S.
aureus, which rose dramatically from 1946 to 1958, but soon afterwards the 
penicillinase-based mechanisms found their way into the community (Figure 9)
(Chambers, 2001; Jessen et al., 1969; Oliveira et al., 2002). Penicillin-resistant 
community-acquired strains of S. aureus were not reported until 1949, when the rate of 
penicillin resistance in hospitals approached 50%. The prevalence of penicillin-resistant 
S. aureus in communities continued to increase throughout the next 20 years (Figure 9), 
finally approaching resistance rates close to those seen among hospital strains (Chambers, 
2001).  
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Figure 9: Penicillin-Resistant Staphylococcus aureus in Hospitals and in Communities 
(Chambers, 2001) 
 
Currently most S. aureus isolates that cause disease or colonize healthy 
individuals are resistant to penicillin. A study of S. aureus colonizing flora of 1001 
healthy volunteers showed that 97% of the S. aureus isolates recovered carried the 
penicillin-resistant trait (Oliveira et al., 2002; Sa-Leon et al., 2001). Bacteria resistant to 
a particular J-lactam antibiotic may sometimes remain sensitive to other antibiotics. 
Therefore, once penicillin-resistant strains came about, other antibiotics started being 
utilized against S. aureus.
However, the power of S. aureus against various antibiotics, besides penicillin is 
also evident. Records of the Danish Health Board registered the years of introduction of 
various antimicrobials into clinical practice, beginning with penicillin in 1945-1946, 
streptomycin in 1948, tetracycline in 1950, and erythromycin in 1953 (Jessen et al., 1969;
Oliveira et al., 2002). The same records indicate that S. aureus bloodstream isolates 
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resistant to penicillin, streptomycin, tetracycline, and erythromycin were recovered as 
early as 1957. The introduction of methicillin into clinical practice in 1959 was followed 
by the appearance, in 1961, of the first bloodstream isolate of S. aureus that was resistant 
not only to penicillin, streptomycin, tetracycline, and erythromycin but to methicillin as 
well (Oliveira et al., 2002).  
 
1.2.2 Methicillin-Resistant Staphylococcus aureus 
Methicillin, originally called celbenine, is a semisynthetic derivative of penicillin, 
chemically modified to withstand the degradative action of penicillinase. The drug was 
introduced into therapy in Europe in 1959-1960 and in the United States in 1961 
(Oliveira et al., 2002; Rice, 2006).  
The first cases of Methicillin-Resistant Staphylococcus aureus (MRSA) were 
reported in the United Kingdom in 1961, followed soon by reports in other European 
countries, Japan, and Australia (Palavecino, 2004; Rice, 2006). The first report of MRSA 
in the United States appeared in 1968 (Barrett et al., 1968; Rice, 2006). Periodic 
outbreaks of MRSA were observed in various countries throughout the world in the 
1970s, but it was not until the 1980s that MRSA became a significant problem in United 
States hospitals (Palavecino, 2004; Rice, 2006).  
The emergence of MRSA is due to the mecA gene, a 2.1kb stretch of DNA that is 
not native to S. aureus and is embedded in 60kb of additional DNA called the mec 
element or staphylococcal chromosomal cassette (SCCmec), which is incorporated into 
the S. aureus chromosome at a site-specific location (Beck et al., 1986; Ito et al., 1999;
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Ito et al., 2001; Katayama et al., 2000; Oliveira et al., 2002). The mecA gene encodes for 
a 78kDa alternative penicillin binding protein (PBP2a), which has a very low affinity for 
J-lactam antibiotics. J-lactams cannot bind as effectively to these PBP2as, and as a 
result, the J-lactams are ineffective at disrupting cell wall synthesis (Oliveira et al.,
2002).  
According to Enright and colleagues (2002), evolutionarily, the mec genes that 
are responsible for SCCmec typing are thought to have initially been introduced into 
coagulase-negative Staphylococci from an unknown source, where deletion of the mec 
regulatory genes occurred, and then they were introduced into S. aureus. The 
Staphylococcal species that donated SCCmec found in MRSA today is unknown but their 
patterns of presence indicates multiple introductions into S. aureus and that horizontal 
gene transfer of mec is possible in S. aureus (Enright et al., 2002).  
 
1.2.3.1 Incidence of Hospital-Associated Methicillin-Resistant Staphylococcus aureus 
A survey of 500 women attending prenatal clinics in London in 1989 to 1990 
found 2% of the staphylococcal strains isolated were MRSA (Abudu, 2001). Since that 
time, the epidemiology of MRSA in the United Kingdom has been changing with the 
number of hospitals in England and Wales reporting MRSA incidents increasing each 
year. Over a third of staphylococcal bloodstream infections in England and Wales in 
early 1999 were due to MRSA compared to 8% in 1994 (Abudu, 2001). A survey 
undertaken in nursing homes in Birmingham, UK (1996) found a 17% prevalence of 
MRSA colonization which is markedly higher than the 4% prevalence found in a survey 
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of nursing home residents in Northamptonshire, UK  in 1991 (Abudu, 2001). Today, 
MRSA continues to be a problem within hospitals in the United Kingdom. 
According to the Centers for Disease Control and Prevention (CDC), the National 
Nosocomial Infections Surveillance System reported the increase of MRSA incidence 
(Figure 10) from 1995 to 2004 in Intensive Care Units (ICU) in the United States 
(Centers for Disease Control and Prevention, 2005). In 2004, the report identified 
methicillin resistance in 59.5% of S. aureus infections in ICU patients. This represented 
an 11% increase in resistance compared with rates during 1998 to 2002 (Chambers, 
2001). 
 
Figure 10: Methicillin-Resistant Staphylococcus aureus in Intensive Care Unit Patients 
(Centers for Disease Control and Prevention, 2005) 
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In 2005, to assess the frequency of hospital-associated MRSA (HA-MRSA) 
infections among dialysis patients in the United States, data was analyzed from the 
Active Bacterial Core Surveillance System (Collins et al., 2005). A report that 
summarizes the results of that analysis, estimated that, in 2005, the incidence of MRSA 
infections among dialysis patients was 45.2 cases per population of 1,000 (Collins et al.,
2005). 
In 2005, nine states in the United States, Connecticut, California, Colorado, 
Georgia, Maryland, Minnesota, New York, Oregon, and Tennessee, monitored MRSA 
infections (Collins et al., 2005). Of the 5,287 cases of invasive MRSA reported from the 
sites, a total of 813 (15.4%) occurred in dialysis patients. The majority (86%) of the 
infections were bloodstream infections, identified via positive blood cultures. About 90% 
of those patients required hospitalization. The mortality rate was 17% (Collins et al.,
2005). 
At Oconee Memorial Hospital (OMH), a rural 160-bed hospital in Seneca, South 
Carolina, data has shown that in a total number of MRSA cases, a significant number of 
them are hospital-acquired (Figure 11). The rates of hospital-acquired MRSA cases was 
increasing until 1999 when the figures started declining (Figure 11) due to strict 
preventative measures implemented within the hospital. These preventative measures 
include strict hand-washing and hand-sanitizing policies.  
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Figure 11: Incidence of Facility-Acquired Methicillin-Resistant Staphylococcus aureus 
Compared to Total Methicillin-Resistant Staphylococcus aureus Cases (Oconee 
Memorial Hospital, 2007) 
 
1.2.3.2 Incidence of Community-Associated Methicillin-Resistant             
Staphylococcus aureus 
Initially, MRSA was only observed in the hospital setting, but it is now clear that 
MRSA may infect people in the community without identifiable risk factors (Rice, 2006). 
According to Graffunder and Venezia (2002), several reports have suggested an increase 
in the appearance and number of cases of MRSA among patients in the community. 
Chambers (2001) suggests that the epidemiology of S. aureus is now changing in order to 
adapt to the community.  
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Several research studies of community-associated MRSA (CA-MRSA) revealed 
their prevalence in children attending day care centers. In 1999, Shahin and researchers 
reported CA-MRSA in a 2-year old child from Toronto, Canada, and transmission via a 
day care center. A survey of two day care centers in Dallas, Texas, revealed that 3% and 
24% of the children were colonized with isolates that were susceptible to multiple 
antibiotics, which is in contrast to the typical (multiple drug-resistant) MDR HA-MRSA. 
From that group of children, 40% had no previous contact with a health care facility, 
which suggests that transmission and colonization of MRSA in those children occurred in 
the community (Chambers, 2001).  
Herold and colleagues (1998) reviewed cases of MRSA from pediatric inpatients 
at the University of Chicago Children's Hospital in Chicago, Illinois. From 1988 through 
1990, 8 of 32 (25%) cases of MRSA were community-acquired. From 1993 through 
1995, 35 of 52 (67%) cases of MRSA were community-acquired and 10 of these 35 
patients had an identified exposure (Herold et al., 1998). In the second part of this study 
(1993-1995) of the 52 pediatric patients hospitalized with MRSA, 25 (48%) patients had 
CA-MRSA without an identified exposure (Herold et al., 1998).  Those strains illustrated 
susceptibility to multiple antibiotics and under pulsed field gel electrophoresis (PFGE) 
revealed patterns that were distinct from nosocomial isolates (Chambers, 2001).  
Finally, the deaths of four children from rural Minnesota and North Dakota 
caused by infection with CA-MRSA attracted national attention in 1999.  Out of those 
children two died from necrotizing pneumonia and severe sepsis (Rice, 2006). Those 
children lacked risk factors for MRSA colonization and the infections were caused by 
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strains susceptible to all antibiotics, except J-lactams. The PFGE patterns of these strains 
also indicated that they were related to one another but different from hospital isolates 
(Chambers, 2001).  
The reports of strains of MRSA in children provided compelling evidence that 
MRSA strains, like penicillinase-producing strains almost 30 years ago, were now 
prevalent in the community (Chambers, 2001). MRSA is currently recognized as a major 
problem in both hospitalized patients and in healthy persons within the community 
(Diekema et al., 2001; Nilsson et al., 1997; Rice, 2006). The increased morbidity, 
mortality, and costs associated with MRSA infections are major incentives to control the 
spread of this organism within health care facilities and in the community (Brumfitt et al.,
1990; L’ Heriteau et al., 1999; Warshawsky et al., 2000).  
 
1.2.3.3 Hospital-Associated Methicillin-Resistant Staphylococcus aureus versus    
Community-Associated Methicillin-Resistant Staphylococcus aureus 
The classical definition from the CDC of nosocomially-acquired versus 
community-acquired infections has been based on the presumed site of acquisition of the 
infection (Bradley, 2005). According to the CDC, a nosocomial infection is an infection 
that develops in the hospital and was not incubating at the time of admission while a 
community-acquired infection is one that is incubating at the time of admission and was 
not caused by an organism acquired during previous health care (Salgado et al., 2003). 
There are plenty of reasons for the incidence of HA-MRSA and these reasons can 
be attributed to hospitalization within the past 12 months, admission into the intensive 
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care unit, previous surgery, enteral feedings, prolonged use of antibiotics, indwelling 
medical devices (such as dialysis tubing, catheters), and proximity to an infected or 
colonized patient (Brumfitt et al., 1990; L’Heriteau et al., 1999; Salgado et al., 2003; 
Warshawsky et al., 2000). Previous hospitalization and longer length of stay before 
infection may represent a chronic illness and indicates exposure to antibiotics which 
increases the opportunities to be colonized with antibiotic-resistant microorganisms 
(Asensio et al., 1996; Ayliffe, 1997; Boyce et al., 1981; Graffunder et al., 2002). Prior 
surgery may represent a breakdown of the normal host defenses, surgical techniques, or 
post-operative care. Enteral feedings may also serve as a portal of entry for MRSA 
(Asensio et al., 1996; Ayliffe, 1997; Boyce et al., 1981; Graffunder et al., 2002). 
In general, HA-MRSA is MDR. Results from a recent study in the United 
Kingdom examining a new epidemic strain of MRSA, EMRSA-17, illustrated this 
characteristic of multiple drug resistance in HA-MRSA (Aucken et al., 2002; Rice, 
2006). In particular, fluoroquinolone resistance is a hallmark of nosocomial MRSA, 
although this was not always the case. When ciprofloxacin, a fluoroquinolone, was first 
licensed, it was recommended as the first orally administered treatment effective against 
MRSA. However, within one year many hospitals observed dramatic increases in the rate 
of ciprofloxacin resistance in MRSA. In one study, high levels of ciprofloxacin resistance 
were observed within 3 months of ciprofloxacin introduction, and within one year, 70% 
of all MRSA from hospitalized patients exhibited resistance (Blumberg et al., 1991; Rice, 
2006).  
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Fluoroquinolones act by inhibiting DNA gyrase and topoisomerase IV, two 
enzymes involved in bacterial DNA synthesis (Lambert, 2005). DNA gyrase is comprised 
of two GyrA and two GyrB subunits, encoded by the gyrA and gyrB genes, respectively. 
DNA gyrase is responsible for introducing negative superhelical twists in the bacterial 
DNA double helix ahead of the replication fork (Lambert, 2005). Topoisomerase IV is 
comprised of two GrlA and two GrlB subunits encoded by the grlA and grlB genes, 
respectively. Topoisomerase IV is responsible for the decatenation of interlinked 
daughter chromosomes produced at the end of a round of replication. Fluoroquinolones 
interact with the complexes formed between DNA and DNA gyrase or topoisomerase IV 
enzymes creating conformational changes that result in the inhibition of normal enzyme 
activity which leads to breaks in the double strands of DNA (Lambert, 2005). Resistance 
to fluorquinolones can result from chromosomal mutations in DNA gyrase and/or 
topoisomerase IV enzymes (Lambert, 2005).  
Nosocomial MRSA is remarkable for its clonal pattern of spread. A recent study 
looking at 359 MRSA isolates collected from 20 countries from 1961 to 1999 identified 
11 major MRSA clones within 5 groups of related genotypes (Enright et al., 2002; Rice, 
2006). Similarly, Oliveira and colleagues (2002) used molecular typing techniques to 
identify 5 major MRSA clones that accounted for approximately 70% of more than 3000 
MRSA isolates obtained primarily from hospitals in the United States, South America, 
and Europe. The major reason for this sort of clonal spread is thought to be infection 
control lapses by healthcare practitioners or other persons who become colonized with S.
aureus and then have contact with hospitalized patients (Lowy, 1998).  
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There is, now, an increase of MRSA in the community among people without 
typical hospital-associated risk factors for MRSA acquisition (Chambers, 2001). 
Community-associated MRSA infections are prevalent among young and healthy 
individuals who do not have a history of recent hospitalization, residence in health care 
facilities, surgery, or dialysis (Salgado et al., 2003). Community-associated MRSA 
infections are usually observed in children and young adults. Clusters of CA-MRSA 
infections have also been reported in prisoners and athletes (Rice, 2006). In addition, 
crowded living conditions and poor access to sanitation facilities by street and shelter 
dwellers place them at a high risk for CA-MRSA (Charlebois et al., 2002). Intravenous 
drug users are also on the list of populations at risk for CA-MRSA. In addition, there 
have been several reports that show that CA-MRSA has been occurring in closed 
populations such as the Canadian and Australian aboriginal communities and the Pacific 
Islanders (Salgado et al., 2003). 
Unlike nosocomial strains which are resistant to multiple antibiotics, CA-MRSA 
strains tend to be susceptible to other antibacterial drugs and are only resistant to J-
lactam antibiotics (Chambers, 2001). They tend to be more susceptible than hospital 
strains to tetracycline and trimethoprim-sulfamethoxazole (Rice, 2006). The lack of 
resistance to multiple antibiotics suggests a community origin because antibiotic selective 
pressure is much lower within the community than in hospitals and the survival 
advantage of multiple drug resistance is lower (Chambers, 2001).  
Community-associated MRSA strains are different from hospital strains in that 
they tend to cause infections at a higher rate and some of these infections can be severe 
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(Rice, 2006). Skin and soft tissue infections and furunculosis are the most common 
manifestations of CA-MRSA. Community-associated MRSA may also be associated with 
life-threatening infections such as necrotizing pneumonia (Rice, 2006). The high rates of 
CA-MRSA may be associated with risk factors for spread in the community, such as 
overcrowding, high rates of skin infections, and the frequent use of antibiotics (Salgado 
et al., 2003).  
A high percentage of CA-MRSA strains carry genes for PVL, the cytotoxin that 
causes leukocyte destruction and tissue necrosis (Rice, 2006). Lina et al., (1999) screened 
isolates from patients in France with S. aureus infections and identified PVL in 93% of 
the cases of furunculosis and 85% of the cases of necrotic hemorrhagic pneumonia. More 
recently, Francis and colleagues (2005) described 4 cases of previously healthy adult 
patients in the United States who developed severe necrotizing pneumonia caused by 
MRSA-carrying PVL genes. One patient died after 2 days, while the other three survived. 
All of the survivors experienced very prolonged hospitalizations. According to a study 
conducted by Dufour and colleagues (2002), PVL genes were detected in 93% of strains 
associated with furunculosis, 55% of strains associated with cellulitis, 50% of strains 
associated with cutaneous abscess, and 13% of strains associated with finger-pulp 
infection, but these genes were absent in strains associated with superficial folliculitis and 
impetigo. Therefore, the PVL genes may be responsible for causing more disease in 
people infected with CA-MRSA than HA-MRSA.  
Besides being acquired in the community there are a number of other differences 
between HA-MRSA and CA-MRSA. Both HA-MRSA and CA-MRSA are resistant to 
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methicillin and other J-lactams due to the presence of the mecA gene (Rice, 2006). 
However, the genetic environment of the mecA gene differs in hospital-acquired and 
community-acquired isolates (Rice, 2006). The mecA gene which is carried on the mobile 
genetic element known as SCCmec is divided into 4 types designated I to IV, which 
differ in size and the presence of additional resistance genes. Types I, II, and III of 
SCCmec are relatively large, about 34kb to 67kb in size, and contain significant 
quantities of DNA in addition to the basic components of mecA, its regulators, and the 
ccrAB genes that confer mobility. In some cases, the functions encoded by the additional 
DNA are unknown; in other instances, further antimicrobial resistance determinants are 
included through the insertion of small plasmids or transposons. Types I, II, and III in 
SCCmec are common in HA-MRSA strains (Rice, 2006). In contrast, type IV SCCmec is 
relatively small containing only the basic components of SCCmec. Type IV SCCmec is 
estimated to be 20kb long and is a typical feature of the CA-MRSA strains (Rice, 2006).  
The small size and lack of resistance genes besides mecA have been connected in 
the non-MDR nature of CA-MRSA, whose drug-susceptibility profile is characterized by 
resistance to methicillin and by susceptibility to non-J-lactam drugs (Rice, 2006). 
However, there are exceptions, some CA-MRSA strains exhibit resistance to a few non-
J-lactam drugs, probably due to the acquisition of resistance via other mechanisms (Rice, 
2006). 
The rapid spread and polyclonal nature of CA-MRSA has raised the intriguing 
question of whether methicillin resistance is transferable from these strains (Rice, 2006). 
The small size of SCCmec type IV would allow its incorporation into a bacteriophage 
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head (an option not available to the larger types of SCCmec), implying that transduction 
could be responsible for the spread of the determinant between strains. Studies have 
shown that the presence of type IV SCCmec in CA-MRSA is the only thing that 
distinguishes it from methicillin-susceptible S. aureus (MSSA), suggesting that CA-
MRSA may have spread into the community when type IV SCCmec was transferred into 
MSSA strains (Rice, 2006).  
 
1.2.3.4 Current Approach for the Treatment of Methicillin-Resistant            
Staphylococcus aureus 
For many years, vancomycin, a glycopeptide, was the only effective treatment for 
MRSA infections. Glycopeptides (Table 1) are drugs that exhibit antibacterial effects by 
combining with cell wall substrates (Bohach et al., 1999). Vancomycin (Figure 12)
prevents the NAM/NAG peptide subunits from being incorporated into the peptidoglycan 
matrix (Neu et al., 2004). The large hydrophilic molecule is able to form hydrogen bonds 
with terminal D-alanyl-D-alanine moieties of the NAM/NAG peptides. This binding of 
vancomycin to the D-alanyl-D-alanine moieties prevents the incorporation of the peptide 
subunits into the peptidoglycan matrix, and thus, prevents cell wall synthesis (Neu et al.,
2004).  
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Figure 12: Structure of the Vancomycin Glycopeptide (Neu et al., 2004)
S. aureus strains with intermediate resistance to vancomycin were eventually 
observed in 1997. The first case occurred in a hospitalized patient in Japan (Hiramatsu et 
al., 1997; Rice, 2006). In the United States, the first 4 cases of vancomycin intermediate-
resistant S. aureus (VISA) were reported between 1997 and 1999. In each instance, 
emergence of VISA was associated with extensive exposure to vancomycin, ranging from 
25 days to 18 weeks. These were patients, often on dialysis, who were exposed to large 
amounts of vancomycin to treat MRSA infections (Rice, 2006; Sieradzki et al., 1999;
Smith et al., 1999).  
The mechanism of resistance in VISA has been linked to cell wall thickening, 
which may cause vancomycin molecules to become trapped in the outer layers of the cell 
wall, thereby limiting access to the cytoplasmic membrane where the functional 
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transglycosylate targets of vancomycin are located (Cui et al., 2003; Lambert, 2005; 
Rice, 2006). Recently, vancomycin-resistant S. aureus (VRSA) strains were isolated from 
3 patients in the United States. The mechanism for the high level of vancomycin 
resistance involves the horizontal transfer of a transposon containing vanA and associated 
genes from vancomycin-resistant Enterococcus (Chang et al., 2003; Rice, 2006; Tenover 
et al., 2004; Weigel et al., 2003). Certain transposable genetic elements also encode 
special cell wall synthesizing enzymes which change the structure of the normal D-
alanyl-D-alanine side chains in the peptidoglycan assembly pathway (Neu et al., 1999). 
The altered side chain does not bind vancomycin and allows normal peptidoglycan 
polymerization to occur in the presence of the drug (Neu et al., 1999).  
Thus, in the past few years, new agents with anti-MRSA activity have been 
introduced such as linezolid, quinupristin-dalfopristin, daptomycin, rifampin, and 
tigecycline (Drew, 2007). Due to the rapid emergence of resistance to rifampin, it can 
never be used as a single agent to treat MRSA infections (Drew, 2007). At OMH, HA-
MRSA is usually treated with vancomycin or linezolid. On the other hand, CA-MRSA is 
usually treated with trimethoprim-sulfamethoxazole or rifampin. Of note is that these 
drugs affect MRSA via different mechanisms (Table 1). In addition, at OMH, HA-
MRSA is always treated using multiple drug therapy due to the high rates of resistance to 
multiple antibiotics while CA-MRSA is treated using monotherapy.  
There are several ways to reduce the incidence of S. aureus infections and to treat 
infections caused by MRSA, especially the ones that are caused by strains that are 
resistant to other antibiotics (Archer, 1998). The first way is to establish more effective 
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infection control and prevention practices. This includes improving hygiene practices 
among people who are colonized and susceptible to MRSA. The second method is by the 
development of S. aureus vaccines (Archer, 1998). Although there has been little success 
with vaccination for preventing human infections, a conjugate vaccine with S. aureus 
types 5 and 8 capsular polysaccharide coupled to Pseudomonas exotoxin A has been 
shown to be immunogenic in humans and provides some protection. Studies of additional 
antigens, including toxoids, are needed (Archer, 1998). The third option is the 
development of new or improved antimicrobial agents (Archer, 1998). With the increase 
in the prevalence of MDR isolates, the pharmaceutical industry is responding by 
modifying existing compounds to broaden their spectra of novel compounds. Therefore, 
the synthesis of unique compounds that attack new targets may work against MRSA 
(Archer, 1998).  
 
1.3 Nanotechnology as a Treatment Modality 
Nanotechnology is an emerging field of research which consists of the study of 
functional structures with dimensions in the 1-100nm range (Jianrong et al., 2004). 
Nanotechnology impacts a wide variety of disciplines, from materials science to 
engineering to biology, and has a wide variety of effects in every industry, from 
aerospace to medicine to agriculture.  
A nanometer is one-billionth of a meter, which is the width of about three to five 
atoms. Nanotechnology provides the ability to engineer the properties of materials by 
controlling their size. In the nanoscale range, bulk materials exhibit specific physical, 
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chemical, and biological properties such as changes in conductivity and changes in 
surface-to-weight ratios (Ebbesen et al., 2007; Luo et al., 2007, In Press).  
For years, chemists have designed and fabricated nanomaterials via chemical 
synthesis. Indeed, during the last decade, developments in the areas of nanotechnology 
have evolved to provide outstanding capabilities for understanding, fabricating, and 
manipulating structures at the atomic level. The US Business Weekly listed 
nanotechnology as one of the key areas of focus in the 21st century. In addition, in 1999, 
the government of the United States classified nanometer technology as one of the eleven 
important research areas in the 21st century (Markoff, 2000). In February 2000, Bill 
Clinton, former president of the United States, announced that the government would 
invest and allocate funds to promote research in nanometer technology (Markoff, 2000). 
Currently, nanotechnology is utilized in a range of applications from water and air 
purification using nanofilters to clothing with stain-resistant nanofibers treated with 
fluorinated nanopolymers to food storage incorporating the antibacterial effects of 
nanoparticles (Luo et al., 2007, In Press). In addition, nanoscience and nanotechnology 
also has a broad range of applications in the fields of biomedicine and biotechnology. 
Among these are drug delivery, cancer detection and diagnosis, labeling, biosensors, and 
several others. One of the most studied aspects of nanotechnology nowadays is their 
ability to offer the opportunity to fight microbial infections via the synthesis of 
nanoparticles (Luo et al., 2007, In Press).  
As described earlier, antibiotic resistance is rampant. Due to the clinical misuse, 
the administration of low doses of antibiotics, and the changes in the target receptors of 
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drugs, antibiotic resistance is a major problem (Luo et al., 2007, In Press). The 
mechanisms by which antibiotics prevent bacterial growth vary from the mechanisms by 
which nanoparticles inhibit microbial growth. Therefore, nanoparticles have the potential 
to serve as an alternative to antibiotics and to control microbial infections such as those 
caused by MRSA (Luo et al., 2007, In Press).  
In the review paper by Luo and colleagues (2007), various applications of 
nanoparticles as antibacterial agents are listed. These include the usage of sugar 
nanoparticles for anti-adhesion therapy, the usage of metallic nanoparticles to produce 
modified antibiotics, and the utilization of silver and gold nanoparticles, chitosan 
polysaccharides, and metal oxide nanoparticles such as magnesium oxide, zinc oxide, and 
titanium dioxide for antimicrobial therapy (Luo et al., 2007, In Press). 
 
1.4 Titanium Dioxide 
1.4.1 Structure and Characteristics 
William Gregor discovered titanium as a mineral in 1791 while he was studying 
mineralogy in England and named it menachanite. Martin Klaproth later recognized that 
there was a new chemical element in this mineral and he later renamed it titanium after 
the Titans. However, Klaporth was only able to produce titanium dioxide (TiO2) rather 
than the pure element, titanium.  
Titanium dioxide, also known as titanium (IV) oxide or titania, is the naturally 
occurring oxide of titanium. There are several different crystalline and amorphous forms 
of TiO2 (Bokhimi et al., 2004). Titanium dioxide mainly exists in three crystalline 
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polymorphs, namely rutile, anatase, and brookite forms. These three polymorphs are 
expressed using the same chemical formula, but have different crystalline structures 
(Watson et al., 2004). All the phases contain a TiO62- (Figure 13) octahedra (Bhave, 
2007). The octahedral structure has titanium as the center atom and is surrounded by six 
oxygen atoms (Figure 13). 
 
Figure 13: Structure of the TiO62- Octahedra (Bhave, 2007) 
 
During the formation of a TiO2 crystal (Figure 14A), two octahedrons condense 
to form a bond and the orientation of a third octahedron determines the phase of TiO2 that 
will be formed (Bhave, 2007). Rutile phase has a tetragonal structure (Three Bond 
Technical News, 2004; Watson et al., 2004). In rutile structures, two of the twelve edges 
of the octahedron are shared forming a linear chain (Figure 14B). The linear chains are 
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joined by the sharing of corner oxygen atoms to form the overall structure of rutile 
particles. The linear arrangement in the rutile structure is the most stable since the 
electrostatic repulsive energy is minimized thus, thermodynamically this structure is most 
favored (Watson et al., 2004). When materials are thermodynamically stable, their phase, 
structure, and physical and chemical properties are not altered when exposed to 
extremely high temperatures. Anatase phase of TiO2 also has a tetragonal structure 
(Three Bond Technical News, 2004; Watson et al., 2004). Anatase phase has no corner 
oxygen sharing and has four edges shared per octahedron (Figure 14C).  In contrast to 
rutile and anatase, brookite phase has an orthorhombic structure (Three Bond Technical 
News, 2004; Watson et al., 2004). In brookite particles, three edges are shared per 
octahedron (Figure 14D). Although brookite particles are less stable than rutile and 
anatase particles, the phase and structure of brookite particles does remain the same at 
room temperature conditions, which indicates that brookite particles may still be used in 
practical applications.  
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Figure 14: Condensation of (A) Titanium Dioxide Crystal; (B) Rutile Titanium Dioxide;         
(C) Anatase Titanium Dioxide; and (D) Brookite Titanium Dioxide (Watson et al., 2004)
The three forms of TiO2 can be synthesized by various techniques such as dry 
methods like flame synthesis, chemical vapor deposition and wet chemistry methods such 
as the chloride method, hydrothermal processing, and the alkoxide method also known as 
the sol-gel process (Watson et al., 2004). Rutile, anatase, and brookite forms can be 
formed at room temperature conditions; however, anatase and brookite phases are 
transformed into thermodynamically stable rutile phases at higher temperatures (Jagtap et 
al., 2005). The properties of pure brookite phase particles are scarcely known, because of 
the difficulty in preparing samples in pure brookite phases at low temperatures. It is, 
however, often synthesized as a second phase, when other phases of TiO2 are produced. 
For example, during the synthesis of anatase particles, brookite particles frequently 
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appear as a secondary minority phase (Bokhimi et al., 2004). An exact explanation for its 
appearance has not been elucidated. Studies have shown that brookite phase TiO2 can be 
carefully prepared at low temperatures by thermolysis of strongly acidic solutions or by 
the hydrothermal treatment of basic solutions. However, care has to be exercised to make 
sure that the phases formed are not mixtures of brookite and anatase types (Bokhimi et 
al., 2004). Studies have shown that heat treatment of amorphous TiO2 suggests a closer 
relation to the brookite phase than to the other phases of TiO2 (Zallen et al., 2006). 
However, the exact relationship is yet to be determined.  
When amorphous TiO2 is crystallized, the original bonding in the amorphous 
particles is modified to form new bonding for the various phases. During crystallization 
these bonds are broken, resulting in the deformation of particles and fine crystal forms 
into the interstices among the original amorphous structure. Depending on the 
temperature of synthesis, various phases and corresponding crystalline structures (Figure 
15) are formed. At low reaction temperatures, brookite phase is produced while at high 
reaction temperatures anatase and rutile phases are formed (Bhave, 2007; Jagtap et al., 
2005; Three Bond Technical News, 2004; Watson et al., 2004).  
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A B C
Figure 15: Crystalline Structures of (A) Rutile; (B) Anatase; and (C) Brookite Particles  
(Bhave, 2007) 
 
The band gap values are almost the same for each crystalline structure. At room 
temperature, the band gap values for anatase and rutile phases are approximately 3.3eV 
and 3.06eV, respectively (Degussa Corporation, 2005; Zallen et al., 2006). The exact 
band gap for brookite particles is unknown. However, studies have shown that the band 
gap for brookite phase is similar to anatase and rutile forms at about 3eV. According to 
Li et al., (2004), the density of rutile, anatase, and brookite TiO2 structures is 4.26g/cm3,
3.84g/cm3, and 4.11g/cm3, respectively. Therefore, it can be deduced that the physical 
properties of rutile, anatase, and brookite forms of TiO2 are similar.  
Due to their band gap, the TiO2 phases mentioned can only absorb light in the 
ultraviolet (UV) range. For rutile structures, the absorption band is less than 415nm and 
for anatase types, the absorption band is less than 385nm (Degussa Corporation, 2005). 
Rutile phases may absorb rays that are slightly closer to visible light rays. Since the rutile 
type can absorb light in a wider range, it would be hypothesized that the rutile type is 
most suitable for use as a photocatalyst. However, studies have demonstrated that the 
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anatase form exhibits higher photocatalytic activity and stability than the rutile phase 
(Jagtap et al., 2005; Three Bond Technical News, 2004). 
Several theories have been suggested for the better photocatalytic activity and 
stability of anatase phases of TiO2. In both rutile and anatase types of TiO2, the position 
of the valence band and the resulting positive holes exhibit sufficient oxidative power. 
However, the conduction band is positioned near the oxidation-reduction potential of the 
hydrogen, indicating that both types are relatively weak in terms of reducing power. The 
conduction band in anatase forms is closer to the negative position than in rutile phases. 
The difference in the positions of the conduction band allows anatase structures of TiO2
to exhibit stronger photocatalytic activity than rutile phases (Three Bond Technical 
News, 2004). The stronger photoactivity of anatase particles can also be explained by the 
longer lifetime of the excited state in anatase phases and the better adsorption of oxygen 
in anionic form at the anatase structure surface (Degussa Corporation, 2005). 
 
1.4.2 Properties as a Nanoparticle 
Typical TiO2 pigments are characterized by a primary particle size of between 
200nm and 250nm. In contrast to TiO2 pigments, nanoscaled TiO2 products can be 
produced at a size of less than 50nm.  
It is well known that the average size of TiO2 nanoparticles increases with the 
increase of synthesis temperatures. A key difference between the brookite phase from 
rutile and anatase phases is the particle size and surface area. Rutile and anatase phases 
are synthesized at higher temperatures and result in the production of slightly larger 
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particles than brookite phase nanoparticles that are synthesized at lower temperatures. An 
advantage for brookite phase is that the decreased size of the particles and the increased 
surface area which make up a given weight will lead to the increase in the number of 
particles represented by the same weight. This means a larger amount of brookite 
nanoparticles will occupy the same volume than a smaller amount of rutile and anatase 
particles will occupy and therefore it is hypothesized that the smaller particle size results 
in an increase in the rate of reaction because the surface area of the brookite catalysts 
have been increased.  
Titanium dioxide nanoparticles are widely studied as semiconductor 
photocatalysts due to their chemical stability, availability at a reasonable cost, and 
capability of repeated usage without substantial loss of catalytic activity. Also, TiO2 does 
not produce hazardous waste neither does it require the addition of consumable chemicals 
during photocatalysis (Srinivasan et al., 2003).  
 
1.4.3 Properties as a Semiconductor 
The path that an electron travels in the atoms is referred to as an orbit. The 
number of electrons that can occupy one orbit is limited. Electrons in the outermost orbit 
are referred to as valence electrons (Three Bond Technical News, 2004). Valence 
electrons are responsible for bonding between elements. When there are a few atoms, the 
energy values of electrons in orbits are scattered. However, when the number of atoms 
increases, the values become consistent within a certain range. This range is referred to as 
an energy band. There is an area between the two energy bands, valence and conduction 
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bands, where there is no electron energy and this is referred to as the forbidden band. In 
the bands filled with electrons, the one with the lowest energy level is found in the 
electron orbit farthest from the nucleus and is referred to as the valence band and the 
band outside this valence band is the conduction band (Three Bond Technical News, 
2004). 
The energy width of the forbidden band, between the valence band and the 
conduction band is referred to as the band gap. The band gap acts as a wall that electrons 
must leap over in order to become free. The amount of energy required to leap over the 
wall is referred to as the band gap energy (Three Bond Technical News, 2004). Only 
electrons that can leap over the wall and enter the conduction band can move freely. As 
the electrons jump to the conduction band positive holes are created in their place (Three 
Bond Technical News, 2004). 
 The valence band of TiO2 is comprised of the 2p orbital of oxygen, while the 
conduction band is comprised of the 3d orbital of titanium. In a semiconductor with a 
large band gap, electrons in the valence band cannot jump up to the conduction band 
unless energy is applied externally which causes the electrons in the valence band to leap 
to the conduction band. As a result, electron holes are created in the place of the electrons 
that move up to the conduction band. This is similar to the concept of movement of 
electrons from the bonding orbital to the antibonding orbital (Three Bond Technical 
News, 2004). 
The creation of the positive holes affects the photoexcited state of a 
semiconductor and makes it unstable. However, TiO2 remains stable even when it is 
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photoexcited thus, making it an excellent semiconductor (Three Bond Technical News, 
2004). 
 
1.4.4 Properties as a Photocatalyst 
Since the discovery of photocatalytic cleavage of water on TiO2 electrodes by 
Fujishima and Honda (1972), interest in the photocatalytic properties of TiO2 has 
increased. Photocatalysis is a reaction that uses light to activate a substance in order to 
improve the rate of a reaction without being degraded (Three Bond Technical News, 
2004). 
When light is absorbed by TiO2, two carriers, electrons (e-) and positive holes (h+)
are formed. The positive holes exhibit greater decomposing power than the electrons 
excited to the conduction band (Three Bond Technical News, 2004). The surface of a 
photocatalyst contains water known as adsorbed water. When the adsorbed water is 
oxidized by positive holes, hydroxyl radicals (·OH) (Figure 16) are formed which have 
strong oxidizing power and can damage organic material (Srinivasan et al., 2003; Three 
Bond Technical News, 2004). 
If oxygen is present when photocatalysis takes place, the intermediate radicals in 
the organic compounds and oxygen molecules can undergo chain reactions with the 
radicals and consume oxygen in some cases. If oxygen is consumed, the organic matter 
eventually decomposes and releases carbon dioxide and water.   
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Figure 16: Phenomenon of Photocatalysis (Gerrity, 2005) 
 
Additionally, the electrons promoted from the valence band to the conduction 
band are available for transfer and causes the reduction of oxygen in the air. This occurs 
as a pairing reaction which results in the formation of superoxide anions (O2-) (Srinivasan 
et al., 2003; Three Bond Technical News, 2004). Superoxide anions (Figure 16) attach to 
the intermediate product in the oxidative reactions, forming peroxide or changing to 
hydrogen peroxide and then to water (Three Bond Technical News, 2004). 
The e- and h+ in TiO2 nanoparticles do not recombine as quickly as they do in 
other substances. This low percentage of recombination has a major effect on the 
efficiency of the photocatalytic surface reactions of TiO2 (Three Bond Technical News, 
2004).  
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1.4.5 Ultraviolet Light Activation 
 In photocatalytic reactions, the band gap energy determines which wavelength of 
light is most effective (Three Bond Technical News, 2004). The band gap energy of 
anatase TiO2 particles is equivalent to a wavelength of 388nm, which implies that anatase 
phase TiO2 is a photocatalyst under UV light (Three Bond Technical News, 2004). 
Ultraviolet light (Figure 17) is electromagnetic radiation with a wavelength 
shorter than that of visible light, but longer than soft x-rays. It can be subdivided into near 
UV (400nm to 200nm) wavelength, far or vacuum UV (200nm to 10nm) wavelength, and 
extreme or deep UV (31nm to 1nm) wavelength. When considering the effect of UV light 
radiation on human health and the environment, the range of UV wavelengths is often 
subdivided into UVA (400nm to 320nm), also called long wave or black light; UVB 
(320nm to 280nm), also called medium wave light, and UVC (less than 280nm), also 
called short wave or germicidal light.  
 
Figure 17: Electromagnetic Spectrum (Gerrity, 2005) 
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Shorter wavelengths of light have a greater frequency and more energy than 
longer wavelengths. This means that they release more energy in a shorter time and that 
their energy is likely to meet or exceed the required activation energy for molecules. 
Thus, they cause photochemical deterioration to occur more quickly and they are 
extremely damaging. As wavelengths become longer, toward the red end of the spectrum, 
they have less energy, lower frequency, and a reduced capacity to excite molecules.  
An advantage of TiO2 photocatalysts is that they do not require UV light that has 
a high energy level such as 254nm which is used in germicidal lamps. This wavelength of 
UV light is often used to inhibit bacterial growth and disinfect materials. This wavelength 
of UV light is utilized because it damages the DNA of living organisms and is thus, also 
proven to be hazardous to humans. Fortunately, TiO2 initiates reactions when exposed to 
near UV light of greater than 350nm with relatively long wavelengths emitted from 
fluorescent lamps (Srinivasan et al., 2003; Three Bond Technical News, 2004). 
 
1.4.6 Visible Light Activation 
The activation of TiO2 nanoparticles utilizing UV light exposure is not practical 
for daily usage. Since TiO2 nanoparticles require UV light exposure to effectively release 
radicals and anions to destruct organic substances, using TiO2 nanoparticles without UV 
light is not effective. Therefore, the utilization of TiO2 nanoparticles under visible light 
would allow the nanoparticles to be used for practical applications as coatings on surfaces 
such as walls and tables or even doorknobs and computer keyboards in hospitals, clinics, 
or household settings where visible light is already available.  
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The development of a visible light photocatalyst may be highly desired as an 
alternative to using UV light, but no substance superior to TiO2 has yet been discovered. 
One of the reasons is that a semiconductor with a smaller band gap than that of TiO2
results in autolysis if it receives light in the presence of water (Three Bond Technical 
News, 2004).  
 However, it is believed that under conditions where the positive holes are 
sufficiently consumed, electrons transferring to oxygen molecules on the reduction side 
of the photocatalytic reaction determine the outcome of the entire reaction (Three Bond 
Technical News, 2004). Therefore, by enabling easier transfer of electrons to oxygen 
molecules, the efficiency of photocatalytic reactions can be improved. This can be done 
by the addition of metals such as silver, iron, and copper and non-metals such as nitrogen 
and carbon, which would increase the absorption edge to the visible light region by 
forming a donor or an acceptor level in the forbidden band (Pan et al., 2006; Umebayashi 
et al., 2002). Sometimes, the addition of these substances inhibits the recombination of 
carriers and improves their photocatalytic efficiency by ensuring the stable formation of 
radicals (Three Bond Technical News, 2004). 
According to Machida and colleagues (2005), metal ions such as silver, copper, 
and zinc have antibacterial capabilities, a phenomenon known as oligodynamic effect. If 
such metals are coupled with TiO2, the metal ions would exhibit antibacterial properties 
in the dark and the TiO2 photocatalyst would exhibit antibacterial properties under UV 
light (Machida et al., 2005). Anpo et al., (2001) substituted transition metals such as 
chromium (Cr3+) and vanadium into the lattice of TiO2 by the ion implantation method. 
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This shifted the absorption band of Cr3+-TiO2 to the visible light region of greater than 
450 nm. Chromium doped into the TiO2 lattice was responsible for the visible light 
photocatalytic activity because of the isolated narrow bands formed in the band gap thus, 
lowering the photon energy required to excite the electrons (Pan et al., 2006). In most 
cases, with increased dopant concentration, the absorption edge shifts to a longer 
wavelength and the band gap energy is reduced. Another research study showed that 
gold-capped TiO2 nanocomposites and vanadium-doped TiO2 nanoparticles exhibit 
antibacterial activity against Escherichia coli (E. coli) and Bacillus megaterium under 
indoor ambient light. According to the researcher, this may be due to the increased 
amount of active sites for catalytic reactions to occur (Fu et al., 2005). Finally, another 
study released last year indicated that InVO4-TiO2 thin films extended the edge of 
radiation absorption towards the visible light region (Ge et al., 2006). 
 
1.4.7 Applications 
1.4.7.1 White Pigment Properties 
Due to its brightness, high refractive index, and white color, TiO2 provides an 
excellent reflective optical coating for dielectric mirrors. Titanium dioxide is also an 
effective opacifier in powder form, where it is employed as a pigment to provide 
whiteness and opacity to products such as paints, coatings, papers, inks, foods, and most 
toothpastes (Chen et al., 2006). The pigment is also used in plastics for its UV light-
resistant properties where it acts as a UV light absorber (Chen et al., 2006). 
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Titanium dioxide is also currently being used as a pigment and thickener in skin 
care products and cosmetics. In many sunscreen lotions with a physical blocker, TiO2 is 
found because of its refractive index and its resistance to discoloration under UV light. 
This advantage increases its stability and ability to protect the skin from harmful UV 
light. 
1.4.7.2 Photomineralization 
Activation of TiO2 with UV light causes the complete decomposition of phenol, 
cholorophenols, nitroaromates, aromatic amines, agricultural effluents, and crude oil in 
water. Due to this TiO2 nanoparticles have been used for outdoor and indoor air and 
water purification (Chen et al., 2006).  
The purification of water by TiO2 is attracting attention from water purification 
companies because the minerals it produces are harmless to the environment, the process 
of photomineralization can be turned on and off by activating or not activating with UV 
light, and there is a possibility that this technology can be incorporated into existing UV 
light water purification systems (Mill et al., 1993).  
 
1.4.7.3 Photoinduced Hydrophilicity 
Various glass products, such as mirrors and glasses, can now be imparted with 
anti-fogging, self-cleaning, and stain-proof capabilities with TiO2 thin films (Chen et al., 
2006). After enough UV light exposure, the TiO2 surface reaches super hydrophilicity, 
due to the adsorption of water and the occurrence of hydroxylation. In other words, it 
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ceases to repel water so that the water spreads flat on the surface of the photocatalyst 
rather than forming a drop. Water contact angles of less than 5º can be measured and such 
surfaces are considered as being super hydrophilic. This process is reversed in the dark 
with the surface turning hydrophobic (Degussa Corporation, 2005). The hydrophilic 
property of TiO2 also makes it hard for mold to stay on surfaces treated with TiO2
coatings so surfaces sanitize themselves (Chen et al., 2006). 
 
1.4.7.4 Photoelectrode Properties 
Titanium dioxide has the potential for use in energy production. Titanium dioxide 
is also used as a hydrolysis catalyst in the Graetzel cell, a type of chemical solar cell. 
When TiO2 absorbs light, it can convert solar energy into electrical energy which can be 
used for various energy applications (Chen et al., 2006). As a photocatalyst it carries out 
hydrolysis to produce hydrogen and oxygen and if the hydrogen were collected, it could 
be used as a source of fuel. Using TiO2 nanomaterials as active photoelectrode materials 
for the production of electricity and/or hydrogen is one of the most important research 
areas for future clean energy applications (Chen et al., 2006).  
 
1.4.7.5 Photosterilization 
The photocatalytic properties can be useful for self-sterilizing materials. Titanium 
dioxide can also be added to paints, cements, windows, tiles, and other similar products 
for sterilizing, deodorizing, and anti-fouling purposes (Chen et al., 2006). The hydroxyl 
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radicals produced kill and decompose bacteria and odor-causing organic compounds as 
can be concluded from the following studies.  
In 1985, Matsunaga et al., reported that Lactobacillus acidophilus, 
Saccharomyces cerevisiae, and E. coli were sterilized when incubated with platinum-
loaded 1mg/mL concentrations of TiO2 nanoparticles under a metal halide lamp 
irradiated for 60 to 120 minutes. In another study on solar-assisted water disinfection 
systems, Wei and colleagues (1994) established that irradiation of suspensions of E. coli 
and TiO2 with UV light of about 380nm resulted in the complete killing of cells within 
minutes. In another study the survival of E. coli in a liquid film decreased when exposed 
to UV light (Srinivasan et al., 2003). These studies demonstrate the adverse effects of 
free radicals on bacterial viability.  
Another study proved that the antibacterial effects of TiO2-coated materials were 
not a simple bacteriostatic action, but rather a bactericidal action that involves the 
decomposition of the cell wall (Srinivasan et al., 2003). Regardless of the initial cell 
concentration, the damage of cells involved two steps, an initial lower rate photokilling 
step followed by a higher rate photokilling step (Srinivasan et al., 2003). The mechanism 
of photokilling involves decomposition of the outer membrane by the reactive species 
and the decomposition of the membrane allows the permeability of reactive species to 
easily reach the cytoplasmic membrane. When the cytoplasmic membrane is attacked, it 
leads to the peroxidation of lipids in the membrane. Lipid peroxidation causes structural 
and functional disorders of the cytoplasmic membrane that causes cell wall 
decomposition and thus, the loss of cell viability (Srinivasan et al., 2003). 
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CHAPTER 2 
CURRENT RESEARCH RATIONALE 
 
2.1 Overview 
 In spite of the various antibiotics currently used to treat MRSA infections, 
antimicrobial resistance is an unavoidable consequence due to the selective pressure of 
antibiotic exposure. Although the epidemiology of the various MRSA strains may differ, 
the ability to develop resistance to the antibiotics is the same. Due to the mechanisms by 
which bacteria develop resistance to antibiotics, other prevention methods such as TiO2
nanoparticles that inhibit viable cell counts by different means than antibiotics, may be 
used to prevent MRSA infections.  
 Previous research has been conducted on commercially produced anatase phase 
TiO2 nanoparticles due to their ease of production, high stability, and small particle size 
(Kim et al., 2003; Kuhn et al., 2003; Maness et al., 1999). The studies have concluded 
that UV light activated anatase nanoparticles can successfully inhibit bacterial growth. 
However, for several studies, there is a lack of appropriate controls and thus, a need for 
an experimental methodology with appropriate controls.  
 Due to the difficulty in brookite production, brookite nanoparticles are not 
commercially available and consequently, there is a lack of research on brookite 
nanoparticles as antimicrobial agents. However, when produced, brookite nanoparticles 
are smaller in size than anatase nanoparticles which promote a larger number of brookite 
nanoparticles to contact the surface of bacterial cells, than anatase nanoparticles. The 
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primary objective of this study was to evaluate the effects of brookite nanoparticles on 
various S. aureus strains and to compare the lethality of UV light activated brookite 
nanoparticles with that of UV light activated anatase nanoparticles, by implementing 
appropriate controls.  
 
2.2 Research Objectives 
Objective I:  Evaluate the Antibacterial Effects of Activated Anatase and Brookite Phase 
Nanoparticles on MRSA 
Hypothesis: Due to their larger surface area, brookite phase nanoparticles (diameter = 
10nm to 15nm) when compared to anatase phase nanoparticles (diameter = 40nm) 
provide a higher surface area and approximately three to four times the number of 
particles per weight than anatase phase nanoparticles, causing an increase in the 
production of radicals which attack bacterial cells. This difference in surface area implies 
that brookite phase nanoparticles may inhibit MRSA growth within a lesser amount of 
time than larger anatase phase nanoparticles at similar concentrations.  
Experimental Plan: A free suspension and drop-coated slide bioassay will be utilized to 
test the antibacterial properties of anatase versus brookite phase nanoparticles at specific 
time intervals under UV light activation. Appropriate controls that show the effects of 
UV light alone and nanoparticles alone will also be utilized.  
 
Objective II: Determine the Optimum Concentration of UV Light Irradiated Brookite 
Phase Nanoparticles that Effectively Reduces Viable Cell Counts within 30 Minutes 
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Hypothesis: Previous studies have indicated that 1mg/mL concentration of anatase phase 
nanoparticles successfully inhibit bacterial growth within 30 minutes (Maneerat et al., 
2005). Therefore, brookite phase nanoparticles may exhibit such antibacterial activities at 
similar concentrations. Furthermore, brookite phase nanoparticles may be ineffective at 
extremely high or low concentrations, as are anatase phase nanoparticles (Zhang et al., 
2004).  
Experimental Plan: Various concentrations of brookite phase nanoparticles will be 
tested via the free suspension and the drop-coated slide bioassays to determine the 
optimum concentration that will reduce MRSA cell viability when activated with UV 
light.  
 
Objective III: Evaluate the Toxicity of Brookite Phase Nanoparticle Coatings without 
UV Light Irradiation 
Hypothesis: When activated under UV light, TiO2 nanoparticles release hydroxyl 
radicals which have strong oxidizing power and cause the destruction of organic 
compounds. Since TiO2 nanoparticles are photocatalysts, brookite nanoparticles should 
not exhibit antibacterial effects in the absence of UV light activation.  
Experimental Plan: To study the activities of non-activated nanoparticles, the free-
suspension bioassay will be used without any source of light. Various concentrations of 
brookite phase nanoparticles will be tested to determine the degree of toxicity as 
concentrations change.  
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Objective IV: Investigate whether TiO2 nanoparticles need to Undergo Continuous UV 
Light Activation to Prevent MRSA Cell Growth 
Hypothesis: Researchers have indicated that TiO2 nanoparticles result in damage to 
organic compounds due to the active formation and constant release of ·OH radicals and 
O2- ions under UV light exposure (Srinivasan et al., 2003; Three Bond Technical News, 
2004). These nanoparticles must be under continuous UV light exposure while in 
concurrent contact with the object of killing, such as bacterial cells, in order to exhibit a 
significant amount of reduction in viable cell counts. Thus, the extent of the 
nanoparticles’ antibacterial effects may not persist without steady UV light exposure.  
Experimental Plan: The drop-coated slide bioassay will be utilized to ascertain the 
effects of pre-exposed nanoparticle-coated slides on MRSA cell growth. Post exposure, 
slides will be incubated for various time periods in order to recover undamaged cells.  
 
Objective V: Qualitatively Examine the Morphological Changes in Bacterial Cells Post 
Treatment with Activated TiO2 Nanoparticles 
Hypothesis: Past studies have indicated that exposure to UV light activated nanoparticles 
cause cells to develop abnormal and irregular shaped cells (Amezaga-Madrid et al., 2003; 
Kuhn et al., 2003). In contrast, untreated cells have uniform composition without any 
defects. Hence, brookite phase nanoparticles may cause similar damages to bacteria at an 
optimum concentration and time when activated by UV light.  
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Experimental Plan: Scanning Electron Microscopy (SEM) will be utilized to determine 
the changes in bacteria shape, structure, and size. Higher magnifications will provide 
details such as the extent of interactions between bacterial cells and nanoparticles.  
 
Objective VI:  Determine the Antibacterial Effects of Visible Light Activated TiO2
Nanoparticles on MRSA Viable Cell Counts 
Hypothesis: In order to exhibit antibacterial properties under visible light (400nm to 
700nm), TiO2 nanoparticles must be doped with another element. Since these TiO2
nanoparticles do not contain other elements, visible light activation may not cause any 
significant changes in the viable cell counts of MRSA.  
Experimental Plan: A free suspension bioassay will be utilized to test the antibacterial 
properties of anatase and brookite phase nanoparticles under visible light activation for 8 
hours. Appropriate controls that show the effects of visible light activation alone and 
nanoparticles alone will be utilized.  
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CHAPTER 3 
MATERIALS AND METHODS 
 
3.1 Bacterial Strains 
Two gram-negative bacterial strains were utilized to establish the protocols 
utilized in this study. The wild-type strain, E. coli B, was purchased from the American 
Tissue Culture Collection (ATCC) and is referred to as E. coli ATCC 23848. E. coli 
DH10B/pK21 is a mutant strain that was graciously provided by Dr. Glenn Kaatz from 
Wayne State University School of Medicine. E. coli DH10B/pK21 contains the plasmid, 
pK21, which encodes the S. aureus norA1199 gene that is responsible for the efflux of 
fluoroquinolones from E. coli cells (Kaatz et al., 1993).  
Three gram-positive bacterial strains, S. aureus ATCC 25923, S. aureus 1199, and 
S. aureus 1199B, were utilized in the experiments to obtain a brief understanding of the 
overall effects on MRSA. S. aureus ATCC 25923 is a clinical isolate. Staphylococcus 
aureus 1199 is a methicillin- and fluoroquinolone-susceptible isolate, and S. aureus 
1199B is its methicillin- and ciprofloxacin-resistant derivative (Dickson et al., 2007; 
Gibbons et al., 2003; Huang et al., 2004, Kaatz et al., 1997). S. aureus 1199B has shown 
resistance to multiple drugs while S. aureus 1199 is not an MDR strain. The two strains, 
S. aureus 1199 and S. aureus 1199B, were also courteously provided by Dr. Kaatz and 
were recovered from the blood and cardiac vegetations of rabbits that had experimental 
endocarditis (Kaatz et al., 1997). 
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3.2 Culture Media 
 Stock cultures were stored at -80ºC in trypticase soy broth (TSB) (CASO Broth, 
VWR Scientific International) with 10% glycerol. Media was sterilized by autoclaving at 
121ºC. Tryptic soy agar (TSA) (CASO Agar, VWR Scientific International) was poured 
into 100mm X 15mm polystyrene Petri dishes and refrigerated at 4ºC until ready for use.  
Stock cultures were thawed, isolated on TSA plates using sterile techniques, and 
incubated at 37ºC for 24 hours. When preparing for experiments, a single colony was 
used to inoculate 10mL of TSB and incubated at 37ºC for 24 hours in a shaking 
incubator. Overnight cultures were utilized for all experiments.  
Antibiotic solutions of ampicillin (Sigma-Aldrich) at 25>g/mL concentrations 
were filter sterilized by a 0.45>m filter and added to autoclaved media after cooling to 
45ºC. This antibiotic was utilized for the isolation of the mutant, MDR E. coli 
DH10B/pK21.  
 
3.3 Free Suspensions of Nanoparticles 
 Two various types of TiO2 photocatalysts were utilized in this study, namely P25 
and Br200. Free suspensions of P25 nanoparticles consist of 79% anatase phase and 21% 
rutile phase and was the commercial source of TiO2 from Degussa Corporation (Coleman 
et al., 2005; Degussa Corporation, 2005). Degussa’s TiO2 samples are produced by the 
Aerosil fumed silica process by utilizing TiO2 as a raw material and by utilizing titanium 
tetrachloride (TiCl4), a high-purity liquid, which is vaporized and mixed with air and 
hydrogen (Degussa Corporation, 2005). Immediately thereafter, the gases are reacted at 
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temperatures between 1000ºC and 2400 ºC in a burner leading to the formation of pure 
and nanoscaled TiO2 according to the following reaction: 
TiCl4 + 2H2 + O2 X TiO2 + 4HCl 
 The P25 nanoparticles have a mean diameter of approximately 40nm. The small 
particle size and high density of approximately 3.71g/cm3 lead to a specific surface area 
of approximately 56.3m2/g. (Degussa Corporation, 2005). The P25 sample was utilized as 
a reference for all the experiments performed.  
Free suspensions of the Br200 brookite nanoparticles, which consist of 10% rutile 
phase and 90% brookite phase nanoparticles, were synthesized and also graciously 
supplied by Dr. Lee’s Lab. The particles were prepared under ambient condition sol 
(Figure 18) process (Bhave, 2007). Titanium tetrachloride (Sigma Aldrich) was used as 
the precursor in water with the co-solvent, isopropanol (Alfa Aesar), in high 
concentrations of hydrochloric acid (HCl) (Alfa Aesar) which was employed as the 
reaction catalyst. The formed gel mass was peptized and crystallized under refluxing 
conditions. A refluxing temperature of 83°C with a refluxing time period of 15 hours led 
to the formation of brookite phase nanoparticles. In the last step, the sample was dried at 
100°C, in a vacuum oven (Napco, Model 5831) for a maximum of 20 hours, to remove 
excess water (Bhave, 2007). 
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Figure 18: Synthesis of Brookite Phase Titanium Dioxide Nanoparticles (Bhave, 2007) 
 
The synthesized brookite nanoparticles have a mean diameter of approximately 
10nm to 15nm. The particles have a density of 3.85g/cm3 and a surface area of 156m2/g 
(Bhave, 2007). Finally, both the P25 and the Br200 samples were calcined in a 
calcination oven (Thermolyne Oven) at high temperatures of 200°C for 2 hours in order 
to remove any impurities from the sample and to increase the physical stability and 
absorbent properties of the sample.  
The densities and surface area of the calcined samples were calculated to obtain 
slightly different values than the uncalcined nanoparticles. The Brunauer-Emmett-Teller 
surface area and density were determined by nitrogen physisorption at -196 and 200°C 
(Micromeritics Automated System, Model ASAP 2020). The density and surface area of 
the calcined P25 sample was 3.63g/cm3 and 57.1m2/g, respectively while the density and 
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surface area of the calcined Br200 was 3.68g/cm3 and 163m2/g, respectively. Synthesized 
nanoparticles were stored in sterile plastic vials at room temperature in the dark.  
 
3.4 Free Suspension Bioassay 
A free suspension bioassay was established in order to evaluate the antibacterial 
properties of the TiO2 nanoparticles via cell viability calculations. Bacterial cells were 
harvested overnight, centrifuged at 7,000xg in a microcentrifuge (Eppendorf Centrifuge, 
Model 5417R), washed with phosphate buffered saline (PBS) (MP Biomedicals) three 
times, and resuspended in distilled water. The cells were standardized to 108 colony 
forming units (CFU) by spectrophototometrical (UV Visible Reading SmartSpec, Model 
3000) examination. Preliminary experiments and calculations indicated that an optical 
density of approximately 0.2 at 600nm equals to roughly 108CFU/mL. Titanium dioxide 
suspensions in distilled water at concentrations of 100, 10, 1, 0.1, 0.01, and 0.001mg/mL 
were prepared while exercising sterile techniques.  
Six-well polystyrene plates were utilized for the experiments and each well 
contained a mixture of 6mL TiO2 suspensions or distilled water plus 108 total cells. 
Distilled water was used as a medium for exposure with cells in order to observe the 
effects of UV light alone or visible light alone, without TiO2 nanoparticles.  
The bioassay apparatus (Figure 19) consisted of a microplate mixer (Microplate 
Genie, Model SI-0400), which exerts an orbit of motion and speed to allow consistent 
mixing within all microplate wells. The plates were always placed on the mixer during 
experimentation for constant mixing of nanoparticles and cells.  
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The experimental apparatus also consisted of a multiple ray lamp (MRL, Model 
58; Fisher Scientific) (Figure 19) with various tubes consisting of shortwave germicidal 
UV light (254nm), longwave unfiltered UV light (365nm), or a cool white light. The 
energy intensity of the light source utilized was measured and stabilized with a 
photoradiometer (UVX Digital Radiometer, Model 97-0015-02; Fisher Scientific).  
 
Figure 19: Free Suspension Bioassay Apparatus (A) Light Source; (B) Six-well 
Polystyrene Plate; and (C) Microplate Mixer  
In the samples incubated in the dark, the light source was absent and the sample was covered with 
aluminum foil. Distance between the light source and the six-well polystyrene plate was based on the 
energy intensity of the light source utilized for each experiment.  
 
The mixtures were exposed vertically to the various sources of light as well as 
incubated in the dark without any light source as a control. Appropriate dilutions of the 
sample mixtures (Table 2) were plated uniformly on TSA plates using a spiral plater 
(Spiral Biotech Autoplate, Model 4000). For UV light activation, appropriate dilutions of 
the sample mixtures were plated at time intervals of 0, 30, 75, and 120 minutes. For 
visible light activation, appropriate dilutions of the sample mixtures were plated 
C
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uniformly on TSA plates after 4 and 8 hours post activation. Samples were plated in 
triplicates. 
 
Table 2: Treatments via Free Suspension Bioassay 
 
The TSA plates were incubated at 37ºC for 24 hours. Viable cell counts at various 
time intervals were obtained by quantifying the number of colonies on TSA plates post 
24 hours of incubation. Cell viability calculations were based on respective dilution 
factors. The experiments were duplicated at least four times to confirm that the results are 
consistent. Results were plotted in line graphs of time versus cell viability to compare the 
effects of various treatments at various concentrations. Changes in viable cell counts at 
various time points were calculated as percentages by the following formula: 
 
Control represents cells incubated in the dark, without UV light exposure, UVLA represents cells under 
UV light exposure without nanoparticles, UVLA-P25 represents cells exposed to UV light activated P25 
nanoparticles, UVLA-Br200 represents cells exposed to UV light activated Br200 nanoparticles, P25 
represents cells with nanoparticles incubated in the dark, without UV light exposure, and Br200 
represents cells with nanoparticles incubated in the dark, without UV light exposure. All samples were 
tested at all time points. For Control and UVLA samples, distilled water was utilized as the medium of 
treatment, instead of nanoparticle suspensions.  
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3.5 Drop-Coated Slides of Nanoparticles 
Apart from their usage as nanoparticles, TiO2 photocatalysts can be utilized for 
coatings on inanimate objects. Studies have shown that TiO2 coatings are important for 
microbiologically sensitive environments such as medical and sanitary facilities that have 
to be kept clean from contamination (Fu et al., 2005; Machida et al., 2005). Therefore, 
TiO2 coatings could be utilized on hospital and clinic walls to combat the high rates of 
MRSA and other bacterial cells. A variety of coating techniques have been developed to 
produce photocatalytic TiO2 surfaces. In this study, the drop-coating technique was 
employed.  
Glass slides of size 25mm X 75mm and 1mm in thickness were coated with P25 
anatase and Br200 brookite nanoparticles. An inorganic binder was produced with 3 mol 
of 3-glycidoxypropyl-trimethoxysilane (Gelest) and 5 mol of Tetramethyl orthosilicate 
(Alfa Aesar). The two solutions were prehydrolyzed with ethanol (Alfa Aesar) at room 
temperature for 3 hours under continuous stirring. After 5 minutes, acetic acid was added 
to maintain the pH at 4. The nanoparticles were added to the inorganic solution which 
was then ultrasonicated for 1 hour and later stirred with a magnetic rod for at least 12 
hours. The P25 and Br200 nanoparticle solutions were drop-coated on glass slides in 
concentrations of 0.0125g/5mL of binder, 0.0375g/5mL of binder, and 0.075g/5mL of 
binder. These concentrations correspond to 2.5, 7.5, and 15mg/mL. Slides coated with 
plain binder at similar concentrations were employed as controls. The coatings were then 
cured at 110°C for 4 hours in a constant temperature drying oven (Baxter Scientific 
Products, Model DN43). The process of creating drop-coated slides (Figure 20) is 
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summarized below. Prepared slides were stored at room temperature in the dark until 
ready to use.  
 
Figure 20: Titanium Dioxide Slide Coating Process (Bhave, 2007) 
 
3.6 Drop-Coated Slide Bioassay 
A film analysis bioassay was established in order to evaluate the antibacterial 
properties of the TiO2-coated slides. Bacterial cells were harvested overnight, centrifuged 
at 7,000xg in a microcentrifuge, washed with PBS three times, and resuspended in 
distilled water. The cells were standardized to 108 CFU by spectrophototometrical 
examination. Preliminary experiments indicated that an optical density of approximately 
0.2 at 600nm equals to roughly 108 CFU/mL. 
Sterile polystyrene 150mm X 15mm Petri dishes were utilized to hold slides 
during UV light exposure. The energy intensity of the UV light utilized was measured 
and stabilized with a photoradiometer.  
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Various treatments were conducted on the slides that were exposed. Slides were 
either initially or continuously exposed to UV light for 30 and 60 minutes. An amount of 
2 X 105 cells from the bacterial culture was placed on each slide. The effects of TiO2
nanoparticles alone were determined by placing the slides in the dark without any UV 
light exposure. All cells were recovered by incubating the slides for 30 minutes in 35mL 
of PBS. Appropriate dilutions of the sample mixtures (Table 3) were plated uniformly on 
TSA plates using a spiral plater. Samples were plated in triplicates.  
 
Table 3: Treatments via Drop-Coated Slide Bioassay 
 
The TSA plates were incubated at 37ºC for 24 hours. Viable cell counts at various 
time intervals were obtained by quantifying the number of colonies on TSA plates post 
24 hours of incubation. Cell viability calculations were based on respective dilution 
factors. The experiments were replicated at least three times to confirm that the results 
are consistent. Results were plotted in bar graphs to determine the cell viability at various 
Control slide represents plain, uncoated slides, Binder slide represents slides coated with the 
inorganic binder, P25 slide represents slides coated with P25 nanoparticles, and Br200 slide 
represents slides coated with Br200 nanoparticles. All samples were tested at all time points. 
Initial exposure indicates that the slides were pre-exposed to UV light before contact with 
bacterial cells. Constant exposure indicates that the slides were continuously exposed to UV light 
while in contact with bacterial cells. 
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concentrations and at various time points. Changes in viable cell counts at various time 
points were calculated as percentages by the following formula: 
 
3.7 Scanning Electron Microscopy 
Scanning electron microscopy was used to evaluate the interactions of TiO2
nanoparticles with the various cells. Bacterial cells were harvested, centrifuged at 
7,000xg in a microcentrifuge, washed with PBS three times, and resuspended in distilled 
water. The cells were standardized to 109CFU/mL as described previously. To prepare 
the cells for imaging, 10mL of the 109CFU/mL bacterial samples were utilized. In 
addition, the concentration of TiO2 nanoparticles varied according to the imaging needs 
of the samples.  
Samples of the untreated cells and treated cells were obtained at various time 
points (0, 30, and 180 minutes) during the free suspension bioassay. Titanium dioxide 
nanoparticle suspensions were sonicated at maximum setting for 4 minutes (Banson 
Ultrasonicator Bath, Model 200) in order to disperse them. The mixtures were 
centrifuged and after the removal of the supernatants, the samples were fixed with 1mL 
of Karnowsky’s fixative for 4 hours at 4ºC. Karnowsky’s fixative at a pH of 7.2 was 
prepared by mixing 10mL of 25% glutaraldehyde (Electron Microscopy Sciences), 20mL 
of 16% formaldehyde (Electron Microscopy Sciences), 50mL of Gomori phosphate 
buffer (VWR International), and 2.4g of sucrose (VWR International). After 4 hours, the 
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samples were rinsed three times with PBS. Thereafter, the samples were post fixed with 
1mL of 1% osmium tetroxide (Electron Microscopy Sciences) at 4ºC. After 6 hours, the 
samples were dehydrated using an ascending series of 30%, 75%, and 100% ethanol. 
Following the last wash, the sample was resuspended in 1mL of fresh 100% ethanol. A 
100>l droplet of each sample was mounted on 200mesh, formvar coated, carbon 
stabilized copper grids (Electron Microscopy Sciences). After air drying the grids for 10 
minutes the samples were ready for imaging.  
High resolution images at various magnifications were derived from the scanning 
mode of a Hitachi HD2000 Scanning Transmission Electron Microscope System to 
observe the surface morphology of the bacterial cells and the destruction due to the action 
of radicals released by activated TiO2 nanoparticles. It is pertinent to note that images in 
the same treatment group may not be of the same scale. The images have been presented 
in order to observe the differences between the damaged and the undamaged cells. 
 
3.8 Statistical Analysis 
All subsequent data, for a specified group size (n), are expressed as mean ±
standard error. Most graphs are plotted in logarithmic scale to determine the changes in 
CFU/mL over time. The changes in CFU/ml over time were compared to the original 
CFU/ml obtained at the beginning of the study. In general, standard errors were too small 
to be witnessed on logarithmic scale graphs. Statistical analyses of the data were 
performed by analysis of variance (single factor) and probability values (P) for 
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significance were calculated using the two-tailed student’s t-test.  P values of less than 
0.05 were considered statistically significant.  
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CHAPTER 4 
RESULTS 
 
4.1 Preliminary Experiments 
Previous studies have indicated that a wavelength of 365nm and an energy 
intensity of 400>w/cm2 effectively activates anatase phase TiO2 nanoparticles (Kim et 
al., 2003). Preliminary studies were conducted to determine the optimum wavelength and 
energy of UV light required for the activation of nanoparticles with non-drug-resistant E. 
coli 23848. At wavelengths of 254nm, viable cell counts were completely reduced within 
5 minutes in the absence of TiO2 nanoparticles. Hence, a longer wavelength of 365nm 
was utilized for the activation of TiO2 nanoparticles under UV light, which caused a 
minimal reduction in the number of viable cells without the usage of TiO2 nanoparticles. 
Various experiments were conducted to determine the optimum energy output required to 
activate nanoparticles. Finally, UV light at an intensity of 370>w/cm2 was utilized to 
establish relevant bioassay protocols. At this energy, UV light alone caused a minimal 
decrease in viable cell counts during 120 minutes of exposure.  
In addition, visible light activation (VLA) of nanoparticles was performed using a 
cool white light at a wavelength of between 400nm and 700nm. The energy intensity was 
stabilized at 140>w/cm2. At that energy level, visible light activation alone caused a 
minimal decrease in viable cell counts.  
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4.2 Antibacterial Effects of Ultraviolet Light Activated Anatase versus Brookite 
Nanoparticles 
4.2.1 Escherichia coli ATCC 23848
To compare the effects of UV light activated P25 and Br200 nanoparticles on 
non-drug-resistant E. coli ATCC 23848, various concentrations of 10, 1, and 0.1mg/mL 
P25 and Br200 nanoparticles were tested via the free suspension bioassay. Ultraviolet 
light (Figure 21 and 22) alone (UVLA) caused a steady decline in viable cell counts over 
time. It is important to note that UV light alone caused an approximate one log reduction 
after 120 minutes of exposure. The decrease from 0 to 30 minutes was not statistically 
significant (P = 0.4321). However, the decrease from 0 to 75 minutes was statistically 
significant at concentrations of 10mg/mL (P = 0.00002068), 1mg/mL (P = 0.00004249), 
and 0.1mg/mL (P = 0.0008669). Cells (control) incubated at similar experimental 
conditions in the dark, away from any light source, did not show any significant increase 
or decrease in the number of viable cells.  
The figure below (Figure 21) is a representation of the Petri dishes that illustrates 
the difference in colony growth over time in various samples, including the appropriate 
controls and various concentrations of TiO2 nanoparticles, containing non-drug-resistant 
E. coli ATCC 23848.   
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Figure 21: Viable Cell Counts of Escherichia coli ATCC 23848 on Petri Dishes at                              
(A) 10mg/mL; (B) 1mg/mL; and (C) 0.1mg/mL                                                   
Concentrations of Nanoparticle Suspensions 
Samples were plated at 0, 30, 75, and 120 minutes. The following samples were plated: (a) Control: Cells 
incubated in the dark, without UV light exposure; (b) UVLA: Cells under UV light exposure without 
nanoparticles; (c) UVLA-P25: Cells exposed to UV light activated P25 nanoparticles; (d) UVLA-Br200:
Cells exposed to UV light activated Br200 nanoparticles; (e) P25: Cells with nanoparticles incubated in the 
dark, without UV light exposure; and (f) Br200: Cells with nanoparticles incubated in the dark, without UV 
light exposure. For Control and UVLA samples, distilled water was utilized as the medium of treatment 
instead of nanoparticle suspensions.  
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Figure 22: Antibacterial Effects of Ultraviolet Light Activated Anatase versus Brookite 
Nanoparticles on Escherichia coli ATCC 23848 at concentrations of                                              
(A) 10mg/mL; (B) 1mg/mL; and (C) 0.1mg/mL 
Samples were plated at 0, 30, 75, and 120 minutes. Control represents cells incubated in the dark, without 
UV light exposure; UVLA represents cells under UV light exposure without nanoparticles; UVLA-P25 
represents cells exposed to UV light activated P25 nanoparticles; UVLA-Br200 represents cells exposed to 
UV light activated Br200 nanoparticles; P25 represents cells with nanoparticles incubated in the dark, 
without UV light exposure; and Br200 represents cells with nanoparticles incubated in the dark, without 
UV light exposure. For Control and UVLA samples, distilled water was utilized as the medium of 
treatment instead of nanoparticle suspensions. The data represents the mean + standard error of 3 
experiments.  
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At the concentration of 10mg/mL (Figure 22A), there was a seven log 
statistically significant reduction in viable cell counts within 30 minutes of contact with 
UV light activated P25 and Br200 nanoparticles (P = 0.0001281 and P = 0.0001402,
respectively). Similarly, at the concentration of 1mg/mL (Figure 22B), there was a seven 
log statistically significant reduction in viable cell counts within 30 minutes of contact 
with UV light activated P25 and Br200 nanoparticles (P = 0.0002352 and P =
0.0006764, respectively).  
However, at the 0.1mg/mL concentration (Figure 22C), it was evident that P25 
and Br200 nanoparticles showed different antibacterial effects than at 10 and 1mg/mL 
concentrations. Within 120 minutes P25 nanoparticles only caused a four log reduction 
while activated Br200 nanoparticles resulted in a seven log reduction. The activated P25 
nanoparticles did not result in a seven log reduction at any time point. However, after 30 
minutes activated P25 nanoparticles did show a statistically significant difference in 
growth (P = 0.0001574) as did Br200 nanoparticles after 30 minutes (P = 0.0003308).   
Appropriate controls were established which represented the action of TiO2
nanoparticles on the cells incubated in the dark (Figure 22) without UV light. At the 
concentration of 10mg/mL (Figure 22A), non-activated P25 nanoparticles exhibited a 
one log statistically significant decrease (P = 0.00006130) in cell growth after 120 
minutes while non-activated Br200 nanoparticles exhibited a two log statistically 
significant decrease (P = 0.0006105) in cell growth after 120 minutes. It was evident that 
non-activated Br200 nanoparticles caused a much larger decrease in viable cell counts 
than non-activated P25 nanoparticles. Within 30 minutes non-activated Br200 
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nanoparticles caused a half log statistically significant reduction (P = 0.001589) while 
P25 nanoparticles did not cause a statistically significant reduction within 30 minutes (P
= 0.4993). In fact, non-activated P25 nanoparticles did not cause a statistically significant 
reduction until after 120 minutes (P = 0.00006129) of incubation.  
The trends observed at the 10mg/mL concentration were also observed at the 
1mg/mL concentration (Figure 22B). Non-activated P25 nanoparticles exhibited a one 
log statistically significant decrease (P = 0.0001294) in cell growth after 120 minutes 
while non-activated Br200 nanoparticles exhibited a two log statistically significant 
decrease (P = 0.001040) in cell growth after 120 minutes. It was evident that non-
activated Br200 nanoparticles caused a much larger decrease in viable cell counts than 
non-activated P25 nanoparticles. Within 30 minutes non-activated Br200 nanoparticles 
caused a half log statistically significant reduction (P = 0.0009927) while while P25 
nanoparticles did not cause a statistically significant reduction within 30 minutes (P =
0.6290). In fact, non-activated P25 nanoparticles did not cause a statistically significant 
reduction until after 120 minutes (P = 0.0001294) of incubation.  
Non-activated nanoparticles exhibited similar effects at the concentration of 
0.1mg/mL (Figure 22C). Non-activated P25 nanoparticles exhibited a one log 
statistically significant decrease (P = 0.0001085) in cell growth after 120 minutes while 
non-activated Br200 nanoparticles exhibited a two log statistically significant decrease (P
= 0.00004256) in cell growth after 120 minutes. It was evident that non-activated Br200 
nanoparticles caused a much larger decrease in viable cell counts than non-activated P25 
nanoparticles. Within 30 minutes non-activated Br200 nanoparticles caused a half log 
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statistically significant reduction (P = 0.001906) while P25 nanoparticles did not cause a 
statistically significant reduction within 30 minutes (P = 0.2907). In fact, non-activated 
P25 nanoparticles did not cause a statistically significant reduction until after 120 minutes 
(P = 0.0001084) of incubation. 
 
4.2.2 Escherichia coli DH10B/pK21 
To compare the effects of UV light activated P25 and Br200 nanoparticles on 
MDR E. coli DH10B/pK21, various concentrations of 10, 1, and 0.1mg/mL P25 and 
Br200 nanoparticles were tested via the free suspension bioassay. Ultraviolet light 
(Figure 23 and 24) alone (UVLA) caused a steady decline in viable cell counts over 
time. It is important to note that UV light alone caused an approximate one log reduction 
after 120 minutes of exposure. The decrease from 0 to 30 minutes was not statistically 
significant (P = 0.2101). However, the decrease from 0 to 75 minutes was statistically 
significant at concentrations of 10mg/mL (P = 0.004075), 1mg/mL (P = 0.0005914), and 
0.1mg/mL (P = 0.001189). Cells (control) incubated at similar experimental conditions 
in the dark, away from any light source, did not show any significant increase or decrease 
in viable cell counts.  
The figure below (Figure 23) is a representation of the Petri dishes that illustrates 
the difference in colony growth over time in various samples, including the appropriate 
controls and various concentrations of TiO2 nanoparticles, containing MDR E. coli 
DH10B/pK21.  
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Figure 23: Viable Cell Counts of Escherichia coli DH10B/pK21 on Petri Dishes at           
(A) 10mg/mL; (B) 1mg/mL; and (C) 0.1mg/mL                                                     
Concentrations of Nanoparticle Suspensions 
Samples were plated at 0, 30, 75, and 120 minutes. The following samples were plated: (a) Control: Cells 
incubated in the dark, without UV light exposure; (b) UVLA: Cells under UV light exposure without 
nanoparticles; (c) UVLA-P25: Cells exposed to UV light activated P25 nanoparticles; (d) UVLA-Br200:
Cells exposed to UV light activated Br200 nanoparticles; (e) P25: Cells with nanoparticles incubated in the 
dark, without UV light exposure; and (f) Br200: Cells with nanoparticles incubated in the dark, without UV 
light exposure. For Control and UVLA samples, distilled water was utilized as the medium of treatment 
instead of nanoparticle suspensions.  
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Figure 24: Antibacterial Effects of Ultraviolet Light Activated Anatase versus Brookite 
Nanoparticles on Escherichia coli DH10B/pK21 at Concentrations of                             
(A) 10mg/mL; (B) 1mg/mL; and (C) 0.1mg/mL 
Samples were plated at 0, 30, 75, and 120 minutes. Control represents cells incubated in the dark, without 
UV light exposure; UVLA represents cells under UV light exposure without nanoparticles; UVLA-P25 
represents cells exposed to UV light activated P25 nanoparticles; UVLA-Br200 represents cells exposed to 
UV light activated Br200 nanoparticles; P25 represents cells with nanoparticles incubated in the dark, 
without UV light exposure; and Br200 represents cells with nanoparticles incubated in the dark, without 
UV light exposure. For Control and UVLA samples, distilled water was utilized as the medium of 
treatment instead of nanoparticle suspensions. The data represents the mean + standard error of 3 
experiments.  
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At the concentration of 10mg/mL (Figure 24A), there was a seven log 
statistically significant reduction in viable cell counts within 30 minutes of contact with 
UV light activated P25 and Br200 nanoparticles (P = 0.0009050 and P = 0.0004853,
respectively). Similarly, at the concentration of 1mg/mL (Figure 24B), there was a seven 
log statistically significant reduction in viable cell counts within 30 minutes of contact 
with UV light activated P25 and Br200 nanoparticles (P = 0.0003140 and P =
0.0001999, respectively).  
However, at the 0.1mg/mL concentration (Figure 24C), it was evident that P25 
and Br200 nanoparticles showed different antibacterial effects than at 10 and 1mg/mL 
concentrations. Within 120 minutes P25 nanoparticles only caused a four log reduction 
while activated Br200 nanoparticles resulted in a seven log reduction. The activated P25 
nanoparticles did not result in a seven log reduction at any time point. However, after 30 
minutes activated P25 nanoparticles did show a statistically significant difference in 
growth (P = 0.001175) as did Br200 nanoparticles after 30 minutes (P = 0.0001222).   
Appropriate controls were established which represented the action of TiO2
nanoparticles on the cells incubated in the dark (Figure 24) without UV light. At the 
concentration of 10mg/mL (Figure 24A), non-activated P25 nanoparticles exhibited a 
one log statistically significant decrease (P = 0.00009869) in cell growth after 120 
minutes while non-activated Br200 nanoparticles exhibited a two log statistically 
significant decrease (P = 0.0006506) in cell growth after 120 minutes. It was evident that 
non-activated Br200 nanoparticles caused a much larger decrease in viable cell counts 
than non-activated P25 nanoparticles. Within 30 minutes non-activated Br200 
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nanoparticles caused a half log statistically significant reduction (P = 0.0001567) while 
P25 nanoparticles did not cause a statistically significant reduction within 30 minutes (P
= 0.2622). In fact, non-activated P25 nanoparticles did not cause a statistically significant 
reduction until after 120 minutes (P = 0.0001083) of incubation. 
The trends observed at the 10mg/mL concentration were also observed at the 
1mg/mL concentration (Figure 24B). Non-activated P25 nanoparticles exhibited a one 
log statistically significant decrease (P = 0.00005695) in cell growth after 120 minutes 
while non-activated Br200 nanoparticles exhibited a two log statistically significant 
decrease (P = 0.0006207) in cell growth after 120 minutes. It was evident that non-
activated Br200 nanoparticles caused a much larger decrease in viable cell counts than 
non-activated P25 nanoparticles. Within 30 minutes non-activated Br200 nanoparticles 
caused a half log statistically significant reduction (P = 0.005259) while P25 
nanoparticles P25 nanoparticles did not cause a statistically significant reduction within 
30 minutes (P = 0.1728). In fact, non-activated P25 nanoparticles did not cause a 
statistically significant reduction until after 120 minutes (P = 0.00005695) of incubation. 
Non-activated nanoparticles exhibited similar effects at the concentration of 
0.1mg/mL (Figure 24C). Non-activated P25 nanoparticles exhibited a one log 
statistically significant decrease (P = 0.00005695) in cell growth after 120 minutes while 
non-activated Br200 nanoparticles exhibited a two log statistically significant decrease (P
= 0.002439) in cell growth after 120 minutes. It was evident that non-activated Br200 
nanoparticles caused a much larger decrease in viable cell counts than non-activated P25 
nanoparticles. Within 30 minutes non-activated Br200 nanoparticles caused a half log 
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statistically significant reduction (P = 0.03314) while P25 nanoparticles did not cause a 
statistically significant reduction within 30 minutes (P = 0.2186). In fact, non-activated 
P25 nanoparticles did not cause a statistically significant reduction until after 120 minutes 
(P = 0.0008739) of incubation. 
 
4.2.3 Staphylococcus aureus ATCC 25923 
To compare the effects of UV light activated P25 and Br200 nanoparticles on 
non-drug-resistant S. aureus ATCC 25923, various concentrations of 10, 1, and 
0.1mg/mL P25 and Br200 nanoparticles were tested via the free suspension bioassay. 
Ultraviolet light (Figure 25 and 26) alone (UVLA) caused a steady decline in viable cell 
counts over time. It is important to note that UV light alone caused an approximate one 
log reduction after 120 minutes of exposure. The decrease from 0 to 30 minutes was not 
statistically significant (0.07621). However, the decrease from 0 to 75 minutes was 
statistically significant at concentrations of 10mg/mL (P = 0.005428), 1mg/mL (P =
0.03766), and 0.1mg/mL (P = 0.002150). Cells (control) incubated at similar 
experimental conditions in the dark, away from any light source, did not show any 
significant increase or decrease in viable cell counts.  
The figure below (Figure 25) is a representation of the Petri dishes that illustrates 
the difference in colony growth over time in various samples, including the appropriate 
controls and various concentrations of TiO2 nanoparticles, containing non-drug-resistant 
S. aureus ATCC 25923.   
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Figure 25: Viable Cell Counts of Staphylococcus aureus ATCC 25923 on Petri Dishes                   
(A) 10mg/mL; (B) 1mg/mL; and (C) 0.1mg/mL                                            
Concentrations of Nanoparticle Suspensions 
Samples were plated at 0, 30, 75, and 120 minutes. The following samples were plated: (a) Control: Cells 
incubated in the dark, without UV light exposure; (b) UVLA: Cells under UV light exposure without 
nanoparticles; (c) UVLA-P25: Cells exposed to UV light activated P25 nanoparticles; (d) UVLA-Br200:
Cells exposed to UV light activated Br200 nanoparticles; (e) P25: Cells with nanoparticles incubated in the 
dark, without UV light exposure; and (f) Br200: Cells with nanoparticles incubated in the dark, without UV 
light exposure. For Control and UVLA samples, distilled water was utilized as the medium of treatment 
instead of nanoparticle suspensions.  
a
b
c
d
e
f A B C
a
b
c
d
e
f
87
Figure 26: Antibacterial Effects of Ultraviolet Light Activated Anatase versus Brookite 
Nanoparticles on Staphylococcus aureus ATCC 25923 at Concentrations of                                 
(A) 10mg/mL; (B) 1mg/mL; and (C) 0.1mg/mL 
Samples were plated at 0, 30, 75, and 120 minutes. Control represents cells incubated in the dark, without 
UV light exposure; UVLA represents cells under UV light exposure without nanoparticles; UVLA-P25 
represents cells exposed to UV light activated P25 nanoparticles; UVLA-Br200 represents cells exposed to 
UV light activated Br200 nanoparticles; P25 represents cells with nanoparticles incubated in the dark, 
without UV light exposure; and Br200 represents cells with nanoparticles incubated in the dark, without 
UV light exposure. For Control and UVLA samples, distilled water was utilized as the medium of 
treatment instead of nanoparticle suspensions. The data represents the mean + standard error of 3 
experiments.  
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At the concentration of 10mg/mL (Figure 26A), there was a three log statistically 
significant reduction (P = 0.0001156) in viable cell counts within 30 minutes of contact 
with UV light activated P25 which led to a statistically significant seven log reduction (P
= 0.0001154) post 75 minutes of exposure. In contrast, Br200 nanoparticles caused a 
seven log reduction within 30 minutes of exposure which was statistically significant (P
= 0.0002023).  
At the concentration of 1mg/mL (Figure 26B), there was a statistically significant 
two log reduction (P = 0.0008179) in viable cell counts within 30 minutes of contact 
with UV light activated P25 which led to a seven log reduction after 75 minutes of 
exposure. Br200 nanoparticles caused a seven log reduction within 30 minutes of 
exposure which was statistically significant (P = 0.0003792) when compared to the 
original sample.  
At the 0.1mg/mL concentration (Figure 26C), it was evident that P25 and Br200 
nanoparticles showed different antibacterial effects than at 10 and 1mg/mL 
concentrations. Within 120 minutes P25 nanoparticles only caused a two log reduction 
while activated Br200 nanoparticles resulted in a three log reduction. The activated P25 
and Br200 nanoparticles did not result in a seven log reduction at any time point. 
However, after 30 minutes activated P25 nanoparticles did show a statistically significant 
difference in growth (P = 0.0004298) as did Br200 nanoparticles after 30 minutes (P =
0.0004094).   
Appropriate controls were established which represented the action of TiO2
nanoparticles on the cells incubated in the dark (Figure 26) without UV light. At the 
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concentration of 10mg/mL (Figure 26A), non-activated P25 nanoparticles exhibited a 
one log statistically significant decrease (P = 0.0002713) in cell growth after 120 minutes 
while non-activated Br200 nanoparticles exhibited a two log statistically significant 
decrease (P = 0.0006540) in cell growth after 120 minutes. It was evident that non-
activated Br200 nanoparticles caused a much larger decrease in viable cell counts than 
non-activated P25 nanoparticles. Within 30 minutes non-activated Br200 nanoparticles 
caused a half log statistically significant reduction (P = 0.02206) while P25 nanoparticles 
P25 nanoparticles did not cause a statistically significant reduction within 30 minutes (P
= 0.5122). In fact, non-activated P25 nanoparticles did not cause a statistically significant 
reduction until after 120 minutes (P = 0.0001336) of incubation. 
The trends observed at the 10mg/mL concentration were also observed at the 
1mg/mL concentration (Figure 26B). Non-activated P25 nanoparticles exhibited a one 
log statistically significant decrease (P = 0.00005384) in cell growth after 120 minutes 
while Non-activated Br200 nanoparticles exhibited a two log statistically significant 
decrease (P = 0.0001252) in cell growth after 120 minutes. It was evident that non-
activated Br200 nanoparticles caused a much larger decrease in viable cell counts than 
non-activated P25 nanoparticles. Within 30 minutes non-activated Br200 nanoparticles 
caused a half log statistically significant reduction (P = 0.001706) while P25 
nanoparticles P25 nanoparticles did not cause a statistically significant reduction within 
30 minutes (P = 0.06228). In fact, non-activated P25 nanoparticles did not cause a 
statistically significant reduction until after 120 minutes (P = 0.0005429) of incubation. 
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Non-activated nanoparticles exhibited similar effects at the concentration of 
0.1mg/mL (Figure 26C). Non-activated P25 nanoparticles exhibited a one log 
statistically significant decrease (P = 0.001013) in cell growth after 120 minutes while 
non-activated Br200 nanoparticles exhibited a two log statistically significant decrease (P
= 0.0007249) in cell growth after 120 minutes. It was evident that non-activated Br200 
nanoparticles caused a much larger decrease in viable cell counts than non-activated P25 
nanoparticles. Within 30 minutes non-activated Br200 nanoparticles caused a half log 
statistically significant reduction (P = 0.01354) while P25 nanoparticles did not cause a 
statistically significant reduction within 30 minutes (P = 0.3295). In fact, non-activated 
P25 nanoparticles did not cause a statistically significant reduction until after 120 minutes 
(P = 0.0005564) of incubation. 
 
4.2.4 Staphylococcus aureus 1199 
To compare the effects of UV light activated P25 and Br200 nanoparticles on 
non-drug-resistant S. aureus 1199, various concentrations of 10, 1, and 0.1mg/mL  P25 
and Br200 nanoparticles were tested via the free suspension bioassay. Ultraviolet light 
(Figure 27 and 28) alone (UVLA) caused a steady decline in viable cell counts over 
time. It is important to note that UV light alone caused an approximate one log reduction 
after 120 minutes of exposure. The decrease from 0 to 30 minutes was not statistically 
significant (0.07706). However, the decrease from 0 to 75 minutes was statistically 
significant at concentrations of 10mg/mL (P = 0.002199), 1mg/mL (P = 0.03044), and 
0.1mg/mL (P = 0.0003151). Cells (control) incubated at similar experimental conditions 
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in the dark, away from any light source, did not show any significant increase or decrease 
in viable cell counts.  
The figure below (Figure 27) is a representation of the Petri dishes that illustrates 
the difference in colony growth over time in various samples, including the appropriate 
controls and various concentrations of TiO2 nanoparticles, containing non-drug-resistant 
S. aureus 1199.
Figure 27: Viable Cell Counts of Staphylococcus aureus 1199 on Petri Dishes at                      
(A) 10mg/mL; (B) 1mg/mL; and (C) 0.1mg/mL                                                  
Concentrations of Nanoparticle Suspensions 
Samples were plated at 0, 30 75, and 120 minutes. The following samples were plated: (a) Control: Cells 
incubated in the dark, without UV light exposure; (b) UVLA: Cells under UV light exposure without 
nanoparticles; (c) UVLA-P25: Cells exposed to UV light activated P25 nanoparticles; (d) UVLA-Br200:
Cells exposed to UV light activated Br200 nanoparticles; (e) P25: Cells with nanoparticles incubated in the 
dark, without UV light exposure; and (f) Br200: Cells with nanoparticles incubated in the dark, without UV 
light exposure. For Control and UVLA samples, distilled water was utilized as the medium of treatment 
instead of nanoparticle suspensions.  
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Figure 28: Antibacterial Effects of Ultraviolet Light Activated Anatase versus Brookite 
Nanoparticles on Staphylococcus aureus 1199 at Concentrations of                                 
(A) 10mg/mL; (B) 1mg/mL; and (C) 0.1mg/mL 
Samples were plated at 0, 30, 75, and 120 minutes. Control represents cells incubated in the dark, without 
UV light exposure; UVLA represents cells under UV light exposure without nanoparticles; UVLA-P25 
represents cells exposed to UV light activated P25 nanoparticles; UVLA-Br200 represents cells exposed to 
UV light activated Br200 nanoparticles; P25 represents cells with nanoparticles incubated in the dark, 
without UV light exposure; and Br200 represents cells with nanoparticles incubated in the dark, without 
UV light exposure. For Control and UVLA samples, distilled water was utilized as the medium of 
treatment instead of nanoparticle suspensions. The data represents the mean + standard error of 3 
experiments.  
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At the concentration of 10mg/mL (Figure 28A), there was a three log statistically 
significant reduction (P = 0.0004186) in viable cell counts within 30 minutes of contact 
with UV light activated P25 which led to a statistically significant seven log reduction (P
= 0.0004178) post 75 minutes of exposure. In contrast, Br200 nanoparticles caused a 
seven log reduction within 30 minutes of exposure which was statistically significant (P
= 0.0001877).  
At the concentration of 1mg/mL (Figure 28B), there was a statistically significant 
two log reduction (P = 0.0006872) in viable cell counts within 30 minutes of contact 
with UV light activated P25 which led to a seven log reduction after 75 minutes of 
exposure. Br200 nanoparticles caused a seven log reduction within 30 minutes of 
exposure which was statistically significant (P = 0.001402).  
At the 0.1mg/mL concentration (Figure 28C), it was evident that P25 and Br200 
nanoparticles showed different antibacterial effects than at 10 and 1mg/mL 
concentrations. Within 120 minutes P25 nanoparticles only caused a two log reduction 
while activated Br200 nanoparticles resulted in a three log reduction. The activated P25 
and Br200 nanoparticles did not result in a seven log reduction at any time point. 
However, after 30 minutes activated P25 nanoparticles did show a statistically significant 
difference in growth (P = 0.00004064) as did Br200 nanoparticles after 30 minutes (P =
0.0004960).   
Appropriate controls were established which represented the action of TiO2
nanoparticles on the cells incubated in the dark (Figure 28) without UV light. At the 
concentration of 10mg/mL (Figure 28A), non-activated P25 nanoparticles exhibited a 
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one log statistically significant decrease (P = 0.0007937) in cell growth after 120 minutes 
while non-activated Br200 nanoparticles exhibited a two log statistically significant 
decrease (P = 0.0001077) in cell growth after 120 minutes. It was evident that non-
activated Br200 nanoparticles caused a much larger decrease in viable cell counts than 
non-activated P25 nanoparticles. Within 30 minutes non-activated Br200 nanoparticles 
caused a half log statistically significant reduction (P = 0.003927) while P25 
nanoparticles did not cause a statistically significant reduction within 30 minutes (P =
0.8632). In fact, non-activated P25 nanoparticles did not cause a statistically significant 
reduction until after 120 minutes (P = 0.0002654) of incubation. 
The trends observed at the 10mg/mL concentration were also observed at the 
1mg/mL concentration (Figure 28B). Non-activated P25 nanoparticles exhibited a one 
log statistically significant decrease (P = 0.0002840) in cell growth after 120 minutes 
while non-activated Br200 nanoparticles exhibited a two log statistically significant 
decrease (P = 0.001269) in cell growth after 120 minutes. It was evident that non-
activated Br200 nanoparticles caused a much larger decrease in viable cell counts than 
non-activated P25 nanoparticles. Within 30 minutes non-activated Br200 nanoparticles 
caused a half log statistically significant reduction (P = 0.008369) while P25 
nanoparticles did not cause a statistically significant reduction within 30 minutes (P =
0.7331). In fact, non-activated P25 nanoparticles did not cause a statistically significant 
reduction until after 120 minutes (P = 0.0002961) of incubation. 
Non-activated nanoparticles exhibited similar effects at the concentration of 
0.1mg/mL (Figure 28C). Non-activated P25 nanoparticles exhibited a one log 
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statistically significant decrease (P = 0.0004390) in cell growth after 120 minutes while 
non-activated Br200 nanoparticles exhibited a two log statistically significant decrease (P
= 0.0000004798) in cell growth after 120 minutes. It was evident that non-activated 
Br200 nanoparticles caused a much larger decrease in viable cell counts than non-
activated P25 nanoparticles. Within 30 minutes non-activated Br200 nanoparticles caused 
a half log statistically significant reduction (P = 0.00006649) while P25 nanoparticles did 
not cause a statistically significant reduction within 30 minutes (P = 0.8521). In fact, 
non-activated P25 nanoparticles did not cause a statistically significant reduction until 
after 120 minutes (p =0.0003256) of incubation. 
 
4.2.5 Staphylococcus aureus 1199B
To compare the effects of UV light activated P25 and Br200 nanoparticles on 
MDR S. aureus 1199B, various concentrations of 10, 1, and 0.1mg/mL P25 and Br200 
nanoparticles were tested via the free suspension bioassay. Ultraviolet light (Figure 29 
and 30) alone (UVLA) caused a steady decline in viable cell counts over time. It is 
important to note that UV light alone caused an approximate one log reduction after 120 
minutes of exposure. The decrease from 0 to 30 minutes was not statistically significant 
(P = 0.07823). However, the decrease from 0 to 75 minutes was statistically significant at 
concentrations of 10mg/mL (P = 0.004927), 1mg/mL (P = 0.04845), and 0.1mg/mL (P =
0.001755). Cells (control) incubated at similar experimental conditions in the dark, away 
from any light source, did not show any significant increase or decrease in viable cell 
counts.  
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The figure below (Figure 29) is a representation of the Petri dishes that illustrates 
the difference in colony growth over time in various samples, including the appropriate 
controls and various concentrations of TiO2 nanoparticles, containing MDR S. aureus 
1199B.   
 
Figure 29: Viable Cell Counts of Staphylococcus aureus 1199B on Petri Dishes                    
(A) 10mg/mL; (B) 1mg/mL; and (C) 0.1mg/mL                                                   
Concentrations of Nanoparticle Suspensions 
Samples were plated at 0, 30, 75, and 120 minutes. The following samples were plated: (a) Control: Cells 
incubated in the dark, without UV light exposure; (b) UVLA: Cells under UV light exposure without 
nanoparticles; (c) UVLA-P25: Cells exposed to UV light activated P25 nanoparticles; (d) UVLA-Br200:
Cells exposed to UV light activated Br200 nanoparticles; (e) P25: Cells with nanoparticles incubated in the 
dark, without UV light exposure; and (f) Br200: Cells with nanoparticles incubated in the dark, without UV 
light exposure. For Control and UVLA samples, distilled water was utilized as the medium of treatment 
instead of nanoparticle suspensions.  
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Figure 30: Antibacterial Effects of Ultraviolet Light Activated Anatase versus Brookite 
Nanoparticles on Staphylococcus aureus 1199B at Concentrations of                                  
(A) 10mg/mL; (B) 1mg/mL; and (C) 0.1mg/mL 
Samples were plated at 0, 30, 75, and 120 minutes. Control represents cells incubated in the dark, without 
UV light exposure; UVLA represents cells under UV light exposure without nanoparticles; UVLA-P25 
represents cells exposed to UV light activated P25 nanoparticles; UVLA-Br200 represents cells exposed to 
UV light activated Br200 nanoparticles; P25 represents cells with nanoparticles incubated in the dark, 
without UV light exposure; and Br200 represents cells with nanoparticles incubated in the dark, without 
UV light exposure. For Control and UVLA samples, distilled water was utilized as the medium of 
treatment instead of nanoparticle suspensions. The data represents the mean + standard error of 3 
experiments.  
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At the concentration of 10mg/mL (Figure 30A), there was a three log statistically 
significant reduction (P = 0.0001250) in viable cell counts within 30 minutes of contact 
with UV light activated P25 which led to a statistically significant four log reduction (P =
0.0001248) post 75 minutes of exposure and finally caused a seven log reduction in 120 
minutes, which was also statistically significant (P = 0.0001248). In contrast, Br200 
nanoparticles caused a seven log reduction within 30 minutes of exposure which was 
statistically significant (P = 0.0003557).  
At the concentration of 1mg/mL (Figure 30B), there was a statistically significant 
two log reduction (P = 0.00003103) in viable cell counts within 30 minutes of contact 
with UV light activated P25 which led to a statistically significant three log reduction (P
= 0.00003076) after 75 minutes of exposure, and finally a complete seven log reduction 
in viable cell counts, which was statistically significant (P = 0.00003071). Br200 
nanoparticles caused a seven log reduction within 30 minutes of exposure which was 
statistically significant (P = 0.001040).  
At the 0.1mg/mL concentration (Figure 30C), it was evident that P25 and Br200 
nanoparticles showed different antibacterial effects than at 10 and 1mg/mL 
concentrations. Within 120 minutes P25 nanoparticles only caused a two log reduction 
while activated Br200 nanoparticles resulted in a three log reduction. The activated P25 
and Br200 nanoparticles did not result in a seven log reduction at any time point. 
However, after 30 minutes activated P25 nanoparticles did show a statistically significant 
difference in growth (P = 0.007128) as did Br200 nanoparticles after 30 minutes (P =
0.001520).   
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Appropriate controls were established which represented the action of TiO2
nanoparticles on the cells incubated in the dark (Figure 30) without UV light. At the 
concentration of 10mg/mL (Figure 30A), non-activated P25 nanoparticles exhibited a 
one log statistically significant decrease (P = 0.00001734) in cell growth after 120 
minutes while non-activated Br200 nanoparticles exhibited a two log statistically 
significant decrease (P = 0.0003354) in cell growth after 120 minutes. It was evident that 
non-activated Br200 nanoparticles caused a much larger decrease in viable cell counts 
than non-activated P25 nanoparticles. Within 30 minutes non-activated Br200 
nanoparticles caused a half log statistically significant reduction (P = 0.01079) while P25 
nanoparticles did not cause a statistically significant reduction within 30 minutes (P =
0.6439). In fact, non-activated P25 nanoparticles did not cause a statistically significant 
reduction until after 120 minutes (P = 0.0002375) of incubation. 
The trends observed at the 10mg/mL concentration were also observed at the 
1mg/mL concentration (Figure 30B). Non-activated P25 nanoparticles exhibited a one 
log statistically significant decrease (P = 0.0001991) in cell growth after 120 minutes 
while non-activated Br200 nanoparticles exhibited a two log statistically significant 
decrease (P = 0.0002318) in cell growth after 120 minutes. It was evident that non-
activated Br200 nanoparticles caused a much larger decrease in viable cell counts than 
non-activated P25 nanoparticles. Within 30 minutes non-activated Br200 nanoparticles 
caused a half log statistically significant reduction (P = 0.008171) while P25 
nanoparticles did not cause a statistically significant reduction within 30 minutes (P =
100
0.5399). In fact, non-activated P25 nanoparticles did not cause a statistically significant 
reduction until after 120 minutes (P = 0.00007632) of incubation. 
Non-activated nanoparticles exhibited similar effects at the concentration of 
0.1mg/mL (Figure 30C). Non-activated P25 nanoparticles exhibited a one log 
statistically significant decrease (P = 0.0001250) in cell growth after 120 minutes while 
non-activated Br200 nanoparticles exhibited a two log statistically significant decrease (P
= 0.00005513) in cell growth after 120 minutes. It was evident that non-activated Br200 
nanoparticles caused a much larger decrease in viable cell counts than non-activated P25 
nanoparticles. Within 30 minutes non-activated Br200 nanoparticles caused a half log 
statistically significant reduction (P = 0.04477) while P25 nanoparticles did not cause a 
statistically significant reduction within 30 minutes (P = 0.7762). In fact, non-activated 
P25 nanoparticles did not cause a statistically significant reduction until after 120 minutes 
(P = 0.0000963) of incubation. 
 
4.3 Antibacterial Effects of Ultraviolet Light Activated Anatase versus Brookite 
Coatings  
4.3.1 Escherichia coli ATCC 23848 
The effects of UV light activated P25 and Br200 nanoparticles on non-drug-
resistant E. coli ATCC 23848 were tested via the drop-coated slide bioassay, utilizing 
slides of 15, 7.5, and 2.5mg/mL concentrations (Figure 31). Uncoated (plain) slides 
containing cells when exposed to UV light (Figure 31) alone, caused a steady decline in 
viable cell counts over time. Evidently, UV light alone caused an approximate one log 
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reduction after 30 minutes of exposure and an approximate two log reduction after 60 
minutes of exposure. Both decreases were statistically significant at all concentrations of 
15mg/mL (P = 0.002054 and P = 0.001723, respectively), 7.5mg/mL (P = 0.0003591 
and P = 0.0004189, respectively), and 2.5mg/mL (P = 0.0006596 and P = 0.0006352,
respectively).  
Binder slides (Figure 31) containing cells when exposed to UV light did not 
cause a statistically significant reduction in cell growth after 30 minutes of exposure (P =
0.43354) but resulted in almost a one log reduction after 60 minutes of exposure, which 
was statistically significant at slide concentrations of 15mg/mL (P = 0.00009274), 
7.5mg/mL (P = 0.0002270), and 2.5mg/mL (P = 0.0002925). Slides incubated at similar 
experimental conditions in the dark (Figure 31), away from any light source, did not 
show any significant increase or decrease in viable cell counts after 30 and 60 minutes.  
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Figure 31: Antibacterial Effects of Ultraviolet Light Activated Anatase versus Brookite 
Coatings on Escherichia coli ATCC 23848 at Concentrations of                                                  
(A) 15mg/mL; (B) 7.5mg/mL; and (C) 2.5mg/mL 
Samples were plated at 0, 30, and 60 minutes. Control slide represents plain, uncoated slides; Binder slide 
represents slides coated with the inorganic binder; P25 slide represents slides coated with P25 
nanoparticles; and Br200 slide represents slides coated with Br200 nanoparticles. The first 3 time intervals 
of 0, 30, and 60 minutes represent controls, without UV light activation. The next 2 time intervals of 30 and 
60 minutes (UV LIGHT) represent samples that were treated under UV light activation. The data 
represents the mean + standard error of 3 experiments.  
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At the concentration of 15mg/mL (Figure 31A), activated P25 and Br200 slides 
showed the same decrease in viable cell counts as seen at the 7.5 and 2.5mg/mL 
concentrations. Activated P25 slides caused a one log reduction after 30 minutes of 
exposure which was statistically significant (P = 0.0009152) and a two log reduction 
after 60 minutes of exposure which was statistically significant (P = 0.0009782). In 
contrast, activated Br200 slides caused a two log reduction after 30 minutes of exposure 
which was statistically significant (P = 0.001266) and a three log reduction after 60 
minutes of exposure which was statistically significant (P = 0.001258). 
At the concentration of 7.5mg/mL (Figure 31B), activated P25 slides caused a 
one log reduction after 30 minutes of exposure which was statistically significant (P =
0.001364) and a two log reduction after 60 minutes of exposure which was statistically 
significant (P = 0.001308). In contrast, activated Br200 slides caused a two log reduction 
after 30 minutes of exposure which was statistically significant (P = 0.0009901) and a 
three log reduction after 60 minutes of exposure which was statistically significant (P =
0.0009841).  
At the concentration of 2.5mg/mL (Figure 31C), activated P25 slides caused a 
one log reduction after 30 minutes of exposure which was statistically significant (P =
0.001094) and a two log reduction after 60 minutes of exposure which was statistically 
significant (P = 0.001156). In contrast, activated Br200 slides caused a two log reduction 
after 30 minutes of exposure which was statistically significant (P = 0.0005331) and a 
three log reduction after 60 minutes of exposure which was statistically significant (P =
0.0005289).  
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4.3.2 Escherichia coli DH10B/pK21 
The effects of UV light activated P25 and Br200 nanoparticles on MDR E. coli 
DH10B/pK21 were tested via the drop-coated slide bioassay, utilizing slides of 15, 7.5, 
and 2.5mg/mL concentrations (Figure 32). Uncoated (plain) slides containing cells when 
exposed to UV light (Figure 32) alone, caused a steady decline in viable cell counts over 
time. Evidently, UV light alone caused an approximate one log reduction after 30 
minutes of exposure and an approximate two log reduction after 60 minutes of exposure. 
Both decreases were statistically significant at all concentrations of 15mg/mL (P =
0.001873 and P = 0.001630, respectively), 7.5mg/mL (P = 0.0003867 and P =
0.0003943, respectively), and 2.5mg/mL (P = 0.002558 and P = 0.002302, respectively).  
Binder slides (Figure 32) containing cells when exposed to UV light did not 
cause a statistically significant reduction in cell growth after 30 minutes of exposure (P =
0.5321) but resulted in almost a one log reduction after 60 minutes of exposure, which 
was statistically significant at slide concentrations of 15mg/mL (P = 0.001028), 
7.5mg/mL (P = 0.002275), and 2.5mg/mL (P = 0.0004695). Slides incubated at similar 
experimental conditions in the dark (Figure 32), away from any light source, did not 
show any significant increase or decrease in viable cell counts after 30 and 60 minutes.  
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Figure 32: Antibacterial Effects of Ultraviolet Light Activated Anatase versus Brookite 
Coatings on Escherichia coli DH10B/pK21 at Concentrations of                                      
(A) 15mg/mL; (B) 7.5mg/mL; and (C) 2.5mg/mL 
Samples were plated at 0, 30, and 60 minutes. Control slide represents plain, uncoated slides; Binder slide 
represents slides coated with the inorganic binder; P25 slide represents slides coated with P25 
nanoparticles; and Br200 slide represents slides coated with Br200 nanoparticles. The first 3 time intervals 
of 0, 30, and 60 minutes represent controls, without UV light activation. The next 2 time intervals of 30 and 
60 minutes (UV LIGHT) represent samples that were treated under UV light activation. The data 
represents the mean + standard error of 3 experiments.  
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At the concentration of 15mg/mL (Figure 32A), activated P25 and Br200 slides 
showed the same decrease in viable cell counts as seen at the 7.5 and 2.5mg/mL 
concentration. Activated P25 slides caused a one log reduction after 30 minutes of 
exposure which was statistically significant (P = 0.0001738) and a two log reduction 
after 60 minutes of exposure which was statistically significant (P = 0.0002975). In 
contrast, activated Br200 slides caused a two log reduction after 30 minutes of exposure 
which was statistically significant (P = 0.000004830) and a three log reduction after 60 
minutes of exposure which was statistically significant (P = 0.000007178). 
At the concentration of 7.5mg/mL (Figure 32B), activated P25 slides caused a 
one log reduction after 30 minutes of exposure which was statistically significant (P =
0.0002310) and a two log reduction after 60 minutes of exposure which was statistically 
significant (P = 0.0002342). In contrast, activated Br200 slides caused a two log 
reduction after 30 minutes of exposure which was statistically significant (P =
0.0002191) and a three log reduction after 60 minutes of exposure which was statistically 
significant (P = 0.0002174). 
At the concentration of 2.5mg/mL (Figure 32C), activated P25 slides caused a 
one log reduction after 30 minutes of exposure which was statistically significant (P =
0.001672) and a two log reduction after 60 minutes of exposure which was statistically 
significant (P = 0.001672). In contrast, activated Br200 slides caused a two log reduction 
after 30 minutes of exposure which was statistically significant (P = 0.0004261) and a 
three log reduction after 60 minutes of exposure which was statistically significant (P =
0.0004222).  
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4.3.3 Staphylococcus aureus ATCC 25923 
The effects of UV light activated P25 and Br200 nanoparticles on non-drug-
resistant S. aureus ATCC 25923 were tested via the drop-coated slide bioassay, utilizing 
slides of 15, 7.5, and 2.5mg/mL concentrations (Figure 33). Uncoated (plain) slides 
containing cells when exposed to UV light (Figure 33) alone caused a steady decline in 
viable cell counts over time. Evidently, UV light alone caused an approximate one log 
reduction after 30 minutes of exposure and an approximate two log reduction after 60 
minutes of exposure. Both decreases were statistically significant at all concentrations of 
15mg/mL (P = 0.0001026 and P = 0.0001737, respectively), 7.5mg/mL (P = 0.0009727
and P = 0.0009671, respectively), and 2.5mg/mL (P = 0.00001842 and P = 0.0001238,
respectively).  
Binder slides (Figure 33) containing cells when exposed to UV light did not 
cause a statistically significant reduction in cell growth after 30 minutes of exposure 
(p=0.3577) but resulted in almost a one log reduction after 60 minutes of exposure, which 
was statistically significant at slide concentrations of 15mg/mL (P = 0.0001408), 
7.5mg/mL (P = 0.0007286), and 2.5mg/mL (P = 0.0002857). Slides incubated at similar 
experimental conditions in the dark (Figure 33), away from any light source, did not 
show any significant increase or decrease in viable cell counts after 30 minutes and 60 
minutes.  
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Figure 33: Antibacterial Effects of Ultraviolet Light Activated Anatase versus Brookite 
Coatings on Staphylococcus aureus ATCC 25923 at Concentrations of                                          
(A) 15mg/mL; (B) 7.5mg/mL; and (C) 2.5mg/mL 
Samples were plated at 0, 30, and 60 minutes. Control slide represents plain, uncoated slides; Binder slide 
represents slides coated with the inorganic binder; P25 slide represents slides coated with P25 
nanoparticles; and Br200 slide represents slides coated with Br200 nanoparticles. The first 3 time intervals 
of 0, 30, and 60 minutes represent controls, without UV light activation. The next 2 time intervals of 30 and 
60 minutes (UV LIGHT) represent samples that were treated under UV light activation. The data 
represents the mean + standard error of 3 experiments. 
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At the concentration of 15mg/mL (Figure 33A), activated P25 and Br200 slides 
showed the same decrease in viable cell counts as seen at the 7.5 and 2.5mg/mL 
concentration. Activated P25 slides caused a one log reduction after 30 minutes of 
exposure which was statistically significant (P = 0.00003285) and a two log reduction 
after 60 minutes of exposure which was statistically significant (P = 0.00004834). In 
contrast, activated Br200 slides caused a two log reduction after 30 minutes of exposure 
which was statistically significant (P = 0.0004397) and a three log reduction after 60 
minutes of exposure which was statistically significant (P = 0.0004365). 
At the concentration of 7.5mg/mL (Figure 33B), activated P25 slides caused a 
one log reduction after 30 minutes of exposure which was statistically significant (P =
0.0005458) and a two log reduction after 60 minutes of exposure which was statistically 
significant (P = 0.0005384). In contrast, activated Br200 slides caused a two log 
reduction after 30 minutes of exposure which was statistically significant (P =
0.0004468) and a three log reduction after 60 minutes of exposure which was statistically 
significant (P = 0.0004432). 
At the concentration of 2.5mg/mL (Figure 33C), activated P25 slides caused a 
one log reduction after 30 minutes of exposure which was statistically significant (P =
0.0008246) and a two log reduction after 60 minutes of exposure which was statistically 
significant (P = 0.0007964). In contrast, activated Br200 slides caused a two log 
reduction after 30 minutes of exposure which was statistically significant (P =
0.0006490) and a three log reduction after 60 minutes of exposure which was statistically 
significant (P = 0.0006397).  
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4.3.4 Staphylococcus aureus 1199 
The effects of UV light activated P25 and Br200 nanoparticles on non-drug-
resistant S. aureus 1199 were tested via the drop-coated slide bioassay, utilizing slides of 
15, 7.5, and 2.5mg/mL concentrations (Figure 34). Uncoated (plain) slides containing 
cells when exposed to UV light (Figure 34) alone caused a steady decline in viable cell 
counts over time. Evidently, UV light alone caused an approximate one log reduction 
after 30 minutes of exposure and an approximate two log reduction after 60 minutes of 
exposure. Both decreases were statistically significant at all concentrations of 15mg/mL 
(P = 0.0005566 and P = 0.0004861, respectively), 7.5mg/mL (P = 0.0003396 and P =
0.0004600, respectively), and 2.5mg/mL (P = 0.0005357 and P = 0.0005555,
respectively).  
Binder slides (Figure 34) containing cells when exposed to UV light did not 
cause a statistically significant reduction in cell growth after 30 minutes of exposure (P =
05672) but resulted in almost a one log reduction after 60 minutes of exposure, which 
was statistically significant at slide concentrations of 15mg/mL (P = 0.001276), 
7.5mg/mL (P = 0.0001494), and 2.5mg/mL (P = 0.0003594). Slides incubated at similar 
experimental conditions in the dark (Figure 34), away from any light source, did not 
show any significant increase or decrease in viable cell counts after 30 and 60 minutes.  
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Figure 34: Antibacterial Effects of Ultraviolet Light Activated Anatase versus Brookite 
Coatings on Staphylococcus aureus 1199 at Concentrations of                                              
(A) 15mg/mL; (B) 7.5mg/mL; and (C) 2.5mg/mL 
Samples were plated at 0, 30, and 60 minutes. Control slide represents plain, uncoated slides; Binder slide 
represents slides coated with the inorganic binder; P25 slide represents slides coated with P25 
nanoparticles; and Br200 slide represents slides coated with Br200 nanoparticles. The first 3 time intervals 
of 0, 30, and 60 minutes represent controls, without UV light activation. The next 2 time intervals of 30 and 
60 minutes (UV LIGHT) represent samples that were treated under UV light activation. The data 
represents the mean + standard error of 3 experiments. 
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At the concentration of 15mg/mL (Figure 34A), activated P25 and Br200 slides 
showed the same decrease in viable cell counts as seen at the 7.5 and 2.5mg/mL 
concentration. Activated P25 slides caused a one log reduction after 30 minutes of 
exposure which was statistically significant (P = 0.0006371) and a two log reduction 
after 60 minutes of exposure which was statistically significant (P = 0.0006910). In 
contrast, activated Br200 slides caused a two log reduction after 30 minutes of exposure 
which was statistically significant (P = 0.001127) and a three log reduction after 60 
minutes of exposure which was statistically significant (P = 0.001114).  
At the concentration of 7.5mg/mL (Figure 34B), activated P25 slides caused a 
one log reduction after 30 minutes of exposure which was statistically significant (P =
0.001561) and a two log reduction after 60 minutes of exposure which was statistically 
significant (p =0.001393). In contrast, activated Br200 slides caused a two log reduction 
after 30 minutes of exposure which was statistically significant (P = 0.001231) and a 
three log reduction after 60 minutes of exposure which was statistically significant (P =
0.001216).  
At the concentration of 2.5mg/mL (Figure 34C), activated P25 slides caused a 
one log reduction after 30 minutes of exposure which was statistically significant (P =
0.003555) and a two log reduction after 60 minutes of exposure which was statistically 
significant (P = 0.003093). In contrast, activated Br200 slides caused a two log reduction 
after 30 minutes of exposure which was statistically significant (P = 0.0001229) and a 
three log reduction after 60 minutes of exposure which was statistically significant (P =
0.0001225). 
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4.3.5 Staphylococcus aureus 1199B
The effects of UV light activated P25 and Br200 nanoparticles on MDR S. aureus 
1199B were tested via the drop-coated slide bioassay, utilizing slides of 15, 7.5, and 
2.5mg/mL concentrations (Figure 35). Uncoated (plain) slides containing cells when 
exposed to UV light (Figure 35) alone caused a steady decline in viable cell counts over 
time. Evidently, UV light alone caused an approximate one log reduction after 30 
minutes of exposure and an approximate two log reduction after 60 minutes of exposure. 
Both decreases were statistically significant at all concentrations of 15mg/mL (P =
0.0007823 and P = 0.0007012 respectively), 7.5mg/mL (P = 0.001168 and P =
0.001048, respectively), and 2.5mg/mL (P = 0.002536 and P = 0.002180, respectively).  
Binder slides (Figure 35) containing cells when exposed to UV light did not 
cause a statistically significant reduction in cell growth after 30 minutes of exposure (P =
0.6520) but resulted in almost a one log reduction after 60 minutes of exposure, which 
was statistically significant at slide concentrations of 15mg/mL (P = 0.001811), 
7.5mg/mL (P = 0.00007400), and 2.5mg/mL (P = 0.0003291). Slides incubated at 
similar experimental conditions in the dark (Figure 35), away from any light source, did 
not show any significant increase or decrease in viable cell counts after 30 and 60 
minutes.  
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Figure 35: Antibacterial Effects of Ultraviolet Light Activated Anatase versus Brookite 
Coatings on Staphylococcus aureus 1199B at Concentrations of 
(A) 15mg/mL; (B) 7.5mg/mL; and (C) 2.5mg/mL 
Samples were plated at 0, 30, and 60 minutes. Control slide represents plain, uncoated slides; Binder slide 
represents slides coated with the inorganic binder; P25 slide represents slides coated with P25 
nanoparticles; and Br200 slide represents slides coated with Br200 nanoparticles. The first 3 time intervals 
of 0, 30, and 60 minutes represent controls, without UV light activation. The next 2 time intervals of 30 and 
60 minutes (UV LIGHT) represent samples that were treated under UV light activation. The data 
represents the mean + standard error of 3 experiments. 
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At the concentration of 15mg/mL (Figure 35A), activated P25 and Br200 slides 
showed the same decrease in viable cell counts as seen at the 7.5 and 2.5mg/mL 
concentration. Activated P25 slides caused a one log reduction after 30 minutes of 
exposure which was statistically significant (P = 0.0002560) and a two log reduction 
after 60 minutes of exposure which was statistically significant (P = 0.0002553). In 
contrast, activated Br200 slides caused a two log reduction after 30 minutes of exposure 
which was statistically significant (P = 0.001609) and a three log reduction after 60 
minutes of exposure which was statistically significant (P = 0.001590).  
At the concentration of 7.5mg/mL (Figure 35B), activated P25 slides caused a 
one log reduction after 30 minutes of exposure which was statistically significant (P =
0.0006068) and a two log reduction after 60 minutes of exposure which was statistically 
significant (P = 0.0006297). In contrast, activated Br200 slides caused a two log 
reduction after 30 minutes of exposure which was statistically significant (P =
0.0001142) and a three log reduction after 60 minutes of exposure which was statistically 
significant (P = 0.0001147).  
At the concentration of 2.5mg/mL (Figure 35C), activated P25 slides caused a 
one log reduction after 30 minutes of exposure which was statistically significant (P =
0.0001292) and a two log reduction after 60 minutes of exposure which was statistically 
significant (P = 0.0001243). In contrast, activated Br200 slides caused a two log 
reduction after 30 minutes of exposure which was statistically significant (P =
0.00005662) and a three log reduction after 60 minutes of exposure which was 
statistically significant (P = 0.00005735).  
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4.4 Antibacterial Effects of Various Concentrations of Ultraviolet Light Activated 
Brookite Nanoparticles 
4.4.1 Escherichia coli ATCC 23848 
To determine the minimum concentration at which activated Br200 nanoparticles 
exhibit antibacterial properties 100, 10, 1, 0.1, 0.01, and 0.001mg/mL concentrations 
(Figure 36) of Br200 nanoparticles were tested against non-drug-resistant E. coli ATCC 
23848 under UV light via the free suspension bioassay.  These concentrations were tested 
against a control sample of bacterial cells under UV light without Br200 nanoparticles. 
Under UV light alone (Figure 36) without Br200 nanoparticles, there was an 8.59% 
reduction within 30 minutes of exposure which was not statistically significant (P =
0.06721). However, at 75 minutes there was a statistically significant reduction of 
21.41% (P = 0.04075) which led to a statistically significant 91.82% decrease (P =
0.0002954) after 120 minutes of exposure.  
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Figure 36: Antibacterial Effects of Various Concentrations of Ultraviolet Light Activated 
Brookite Nanoparticles on Escherichia coli ATCC 23848 
Samples were plated at 0, 30, 75, and 120 minutes. Various concentrations of UV light activated Br200 
nanoparticles were tested and compared with one another and with the effects of UV light exposure 
(distilled water) alone. The data represents the mean + standard error of 3 experiments. 
 
At the 100mg/mL concentration (Figure 36), activated Br200 nanoparticles 
caused a statistically significant 72.87% reduction (P = 0.0002970) after 30 minutes of 
exposure, a statistically significant 97.28% reduction (P = 0.001326) after 75 minutes of 
exposure, and a statistically significant 99.71% reduction (P = 0.001415) after 120 
minutes of exposure. At 10 and 1mg/mL concentrations (Figure 36), activated Br200 
nanoparticles caused a larger reduction of 100% within 30 minutes of exposure.  
At the 0.1mg/mL concentration (Figure 36), there was a gradual decrease of 
99.00% within 30 minutes of exposure and 100% within 75 minutes of exposure and 120 
minutes of exposure. Even though there wasn’t a complete 100% reduction until 75 
minutes, the difference after 30 minutes was statistically significant (P = 0.001784). At 
0.01 and 0.001mg/mL concentrations (Figure 36), there was no statistically significant 
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reduction at any time point. The number of cells remained consistent throughout the 
experiment for 120 minutes. 
 
4.4.2 Escherichia coli DH10B/pK21 
To determine the minimum concentration at which activated Br200 nanoparticles 
exhibit antibacterial properties 100, 10, 1, 0.1, 0.01, and 0.001mg/mL concentrations 
(Figure 37) of Br200 nanoparticles were tested against MDR E. coli DH10B/pK21 under 
UV light via the free suspension bioassay. These concentrations were tested against a 
control sample of bacterial cells under UV light without Br200 nanoparticles. Under UV 
light alone (Figure 37) without Br200 nanoparticles, there was an 8.22% reduction 
within 30 minutes of exposure which was not statistically significant (P = 0.06554). 
However, at 75 minutes there was a statistically significant reduction of 17.40% (P =
0.005914) which led to a statistically significant 91.81% decrease (P = 0.0003775) after 
120 minutes of exposure.  
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Figure 37: Antibacterial Effects of Various Concentrations of Ultraviolet Light Activated 
Brookite Nanoparticles on Escherichia coli DH10B/pK21 
Samples were plated at 0, 30, 75, and 120 minutes. Various concentrations of UV light activated Br200 
nanoparticles were tested and compared with one another and with the effects of UV light exposure 
(distilled water) alone. The data represents the mean + standard error of 3 experiments. 
 
At the 100mg/mL concentration (Figure 37), activated Br200 nanoparticles 
caused a statistically significant 78.10% reduction (P = 0.0001249) after 30 minutes of 
exposure, a statistically significant 96.96% reduction (P = 0.001308) after 75 minutes of 
exposure, and a statistically significant 99.72% reduction (P = 0.001415) after 120 
minutes of exposure. At 10 and 1mg/mL concentrations (Figure 37), activated Br200 
nanoparticles caused a larger reduction of 100% within 30 minutes of exposure.  
At the 0.1mg/mL concentration (Figure 37), there was a gradual decrease of 
98.97% within 30 minutes of exposure and 100% within 75 minutes of exposure and 120 
minutes of exposure. Even though there wasn’t a complete 100% reduction until 75 
minutes, the difference after 30 minutes was statistically significant (P = 0.001786). At 
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0.01 and 0.001mg/mL concentrations (Figure 37), there was no statistically significant 
reduction at any time point. The number of cells remained consistent throughout the 
experiment for 120 minutes. 
 
4.4.3 Staphylococcus aureus ATCC 25923 
To determine the minimum concentration at which activated Br200 nanoparticles 
exhibit antibacterial properties 100, 10, 1, 0.1, 0.01, and 0.001mg/mL concentrations 
(Figure 38) of Br200 nanoparticles were tested against non-drug-resistant S. aureus 
ATCC 25923 under UV light via the free suspension bioassay. These concentrations were 
tested against a control sample of bacterial cells under UV light without Br200 
nanoparticles. Under UV light alone (Figure 38) without Br200 nanoparticles, there was 
an 8.22% reduction within 30 minutes of exposure which was not statistically significant 
(P = 0.08621). However, at 75 minutes there was a statistically significant reduction of 
17.16% (P = 0.01037) which led to a statistically significant 92.23% decrease (P =
0.0003500) after 120 minutes of exposure.  
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Figure 38: Antibacterial Effects of Various Concentrations of Ultraviolet Light Activated 
Brookite Nanoparticles on Staphylococcus aureus ATCC 25923 
Samples were plated at 0, 30, 75, and 120 minutes. Various concentrations of UV light activated Br200 
nanoparticles were tested and compared with one another and with the effects of UV light exposure 
(distilled water) alone. The data represents the mean + standard error of 3 experiments. 
 
At the 100mg/mL concentration (Figure 38), activated Br200 nanoparticles 
caused a statistically significant 70.46% reduction (P = 0.0001631) after 30 minutes of 
exposure, a statistically significant 96.88% reduction (P = 0.001416) after 75 minutes of 
exposure, and a statistically significant 98.37% reduction (P = 0.001448) after 120 
minutes of exposure. At 10 and 1mg/mL concentrations (Figure 38), activated Br200 
nanoparticles caused a larger reduction of 100% within 30 minutes of exposure.  
At the 0.1mg/mL concentration (Figure 38), there was a gradual decrease of 
96.89% within 30 minutes of exposure, 99.03% within 75 minutes of exposure, and 
99.92% within 120 minutes of exposure. Even though there wasn’t a complete 100% 
reduction, the difference after 30 minutes was statistically significant (P = 0.001821). At 
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0.01 and 0.001mg/mL concentrations (Figure 38), there was no statistically significant 
reduction at any time point. The number of cells remained consistent throughout the 
experiment for 120 minutes. 
 
4.4.4 Staphylococcus aureus 1199 
To determine the minimum concentration at which activated Br200 nanoparticles 
exhibit antibacterial properties, 100, 10, 1, 0.1, 0.01, and 0.001mg/mL concentrations 
(Figure 39) of Br200 nanoparticles were tested against non-drug-resistant S. aureus 1199 
under UV light via the free suspension bioassay. These concentrations were tested against 
a control sample of bacterial cells under UV light without Br200 nanoparticles. Under 
UV light alone (Figure 39) without Br200 nanoparticles, there was an 8.46% reduction 
within 30 minutes of exposure which was not statistically significant (P = 0.06512). 
However, at 75 minutes there was a statistically significant reduction of 20.54% (P =
0.01348) which led to a statistically significant 92.12% decrease (P = 0.0002832) after 
120 minutes of exposure.  
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Figure 39: Antibacterial Effects of Various Concentrations of Ultraviolet Light Activated 
Brookite Nanoparticles on Staphylococcus aureus 1199 
Samples were plated at 0, 30, 75, and 120 minutes. Various concentrations of UV light activated Br200 
nanoparticles were tested and compared with one another and with the effects of UV light exposure 
(distilled water) alone. The data represents the mean + standard error of 3 experiments. 
 
At the 100mg/mL concentration (Figure 39), activated Br200 nanoparticles 
caused a statistically significant 69.31% reduction (P = 0.0002580) after 30 minutes of 
exposure, a statistically significant 97.09% reduction (P = 0.001457) after 75 minutes of 
exposure, and a statistically significant 98.40% reduction (P = 0.001443) after 120 
minutes of exposure. At 10 and 1mg/mL concentrations (Figure 39), activated Br200 
nanoparticles caused a larger reduction of 100% within 30 minutes of exposure.  
At the 0.1mg/mL concentration (Figure 39), there was a gradual decrease of 
97.19% within 30 minutes of exposure, 99.09% within 75 minutes of exposure, and 
99.91% within 120 minutes of exposure. Even though there wasn’t a complete 100% 
reduction, the difference after 30 minutes was statistically significant (P = 0.001848). At 
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0.01 and 0.001mg/mL concentrations (Figure 39), there was no statistically significant 
reduction at any time point. The number of cells remained consistent throughout the 
experiment for 120 minutes. 
 
4.4.5 Staphylococcus aureus 1199B
To determine the minimum concentration at which activated Br200 nanoparticles 
exhibit antibacterial properties, 100, 10, 1, 0.1, 0.01, and 0.001mg/mL concentrations 
(Figure 40) of Br200 nanoparticles were tested against MDR S. aureus 1199B under UV 
light via the free suspension bioassay. These concentrations were tested against a control 
sample of bacterial cells under UV light without Br200 nanoparticles. Under UV light 
alone (Figure 40) without Br200 nanoparticles, there was a 7.92% reduction within 30 
minutes of exposure which was not statistically significant (P = 0.07231). However, at 
75 minutes there was a statistically significant reduction of 17.40% (P = 0.005914) 
which led to a statistically significant 92.54% decrease (P = 0.0004464) after 120 
minutes of exposure.  
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Figure 40: Antibacterial Effects of Various Concentrations of Ultraviolet Light Activated 
Brookite Nanoparticles on Staphylococcus aureus 1199B 
Samples were plated at 0, 30, 75, and 120 minutes. Various concentrations of UV light activated Br200 
nanoparticles were tested and compared with one another and with the effects of UV light exposure 
(distilled water) alone. The data represents the mean + standard error of 3 experiments. 
 
At the 100mg/mL concentration (Figure 40), activated Br200 nanoparticles 
caused a statistically significant 74.31% reduction (P = 0.0001328) after 30 minutes of 
exposure, a statistically significant 97.09% reduction (P = 0.001420) after 75 minutes of 
exposure, and a statistically significant 98.50% reduction (P = 0.001448) after 120 
minutes of exposure. At 10 and 1mg/mL concentrations (Figure 40), activated Br200 
nanoparticles caused a larger reduction of 100% within 30 minutes of exposure.  
At the 0.1mg/mL concentration (Figure 40), there was a gradual decrease of 
96.73% within 30 minutes of exposure, 99.13% within 75 minutes of exposure, and 
99.92% within 120 minutes of exposure. Even though there wasn’t a complete 100% 
reduction, the difference after 30 minutes was statistically significant (P = 0.001844). At 
0.01 and 0.001mg/mL concentrations (Figure 40), there was no statistically significant 
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reduction at any time point. The number of cells remained consistent throughout the 
experiment for 120 minutes. 
 
4.5 Antibacterial Effects of Various Concentrations of Ultraviolet Light Activated 
Brookite Coatings 
 4.5.1 Escherichia coli ATCC 23848 
To determine the minimum concentration at which activated Br200 nanoparticles 
exhibit antibacterial properties, 15, 7.5, and 2.5mg/mL concentrations (Figure 41) of 
Br200 slides were also tested against non-drug-resistant E. coli ATCC 23848 under UV 
light via the drop-coated slide bioassay. These concentrations were tested against a 
control slide of bacterial cells under UV light without any Br200 nanoparticle coatings. 
On the uncoated slides, under UV light alone (Figure 41), there was a 90.65% reduction 
after 30 minutes and a 99.06% reduction after 60 minutes, both of which were 
statistically significant (P = 0.0003591 and P = 0.0004189, respectively).  
 
127
Figure 41: Antibacterial Effects of Various Concentrations of  
Ultraviolet Light Activated Brookite Coatings on Escherichia coli ATCC 23848 
Samples were plated at 0, 30, and 60 minutes. Various concentrations of Br200 nanoparticle slide coatings 
were tested and compared with one another and with the effects of the plain control slides under UV light 
activation without any coatings. The data represents the mean + standard error of 3 experiments. 
 
As noted on the slides, there was a similar cell growth reduction in the 15 and 
7.5mg/mL concentration slides. On the 15mg/mL concentration slide (Figure 41), there 
was a 99.62% reduction after 30 minutes of exposure and a 99.96% reduction after 60 
minutes of exposure. Both of which were statistically significant reductions (P =
0.001266 and P = 0.001258, respectively). Similarly, on the 7.5mg/mL concentration 
slide (Figure 41), there was a 99.54% reduction after 30 minutes of exposure and a 
99.96% reduction after 60 minutes of exposure. Both of these values were also 
statistically significant (P = 0.0009900 and P = 0.0009841, respectively). 
On the 2.5mg/mL concentration slide (Figure 41), there was a slightly lower 
decrease noted than in the 15 and 7.5mg/mL concentration slides. However, the decrease 
was still statistically significant. Within 30 minutes of exposure, there was a 99.35% 
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decrease (P = 0.0005331) and within 60 minutes of exposure, there was a 99.94% 
decrease (P = 0.0005289) in viable cell counts.  
 
4.5.2 Escherichia coli DH10B/pK21 
To determine the minimum concentration at which activated Br200 nanoparticles 
exhibit antibacterial properties, 15, 7.5, and 2.5mg/mL concentrations (Figure 42) of 
Br200 slides were also tested against MDR E. coli DH10B/pK21 under UV light via the 
drop-coated slide bioassay. These concentrations were tested against a control slide of 
bacterial cells under UV light without any Br200 nanoparticle coatings. On the uncoated 
slides, under UV light alone (Figure 42), there was a 90.66% reduction after 30 minutes 
and a 99.08% reduction after 60 minutes, both of which were statistically significant (P =
0.0003791 and P = 0.0004189, respectively).  
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Figure 42: Antibacterial Effects of Various Concentrations of  
Ultraviolet Light Activated Brookite Coatings on Escherichia coli DH10B/pK21 
Samples were plated at 0, 30, and 60 minutes. Various concentrations of Br200 nanoparticle slide coatings 
were tested and compared with one another and with the effects of the plain control slides under UV light 
activation without any coatings. The data represents the mean + standard error of 3 experiments. 
 
As noted on the slides, there was a similar cell growth reduction in the 15 and 
7.5mg/mL concentration slides. On the 15mg/mL concentration slide (Figure 42), there 
was a 99.56% reduction after 30 minutes of exposure and a 99.95% reduction after 60 
minutes of exposure. Both of which were statistically significant reductions (P =
0.000004830 and P = 0.000007178, respectively). Similarly, on the 7.5mg/mL 
concentration slide (Figure 42), there was a 99.54% reduction after 30 minutes of 
exposure and a 99.96% reduction after 60 minutes of exposure. Both of these values were 
also statistically significant (P = 0.0002191 and P = 0.0002174, respectively). 
On the 2.5mg/mL concentration slide (Figure 42), there was a slightly lower 
decrease noted than in the 15 and 7.5mg/mL concentration slides. However, the decrease 
was still statistically significant. Within 30 minutes of exposure, there was a 99.35% 
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decrease (P = 0.0004261) and within 60 minutes of exposure, there was a 99.94% 
decrease (P = 0.0004222) in viable cell counts.  
 
4.5.3 Staphylococcus aureus ATCC 25923 
To determine the minimum concentration at which activated Br200 nanoparticles 
exhibit antibacterial properties, 15, 7.5, and 2.5mg/mL concentrations (Figure 43) of 
Br200 slides were also tested against non-drug-resistant S. aureus ATCC 25923 under 
UV light via the drop-coated slide bioassay. These concentrations were tested against a 
control slide of bacterial cells under UV light without any Br200 nanoparticle coatings. 
On the uncoated slides, under UV light alone (Figure 43), there was a 91.06% reduction 
after 30 minutes and a 99.05% reduction after 60 minutes, both of which were 
statistically significant (P = 0.0004763 and P = 0.0004197, respectively).  
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Figure 43: Antibacterial Effects of Various Concentrations of  
Ultraviolet Activated Light Brookite Coatings on Staphylococcus aureus ATCC 25923 
Samples were plated at 0, 30, and 60 minutes. Various concentrations of Br200 nanoparticle slide coatings 
were tested and compared with one another and with the effects of the plain control slides under UV light 
activation without any coatings. The data represents the mean + standard error of 3 experiments. 
 
As noted on the slides, there was a similar cell growth reduction in the 15 and 
7.5mg/mL concentration slides. On the 15mg/mL concentration slide (Figure 43), there 
was a 99.34% reduction after 30 minutes of exposure and a 99.94% reduction after 60 
minutes of exposure. Both of which were statistically significant reductions (P =
0.0004397 and P = 0.0004365, respectively). Similarly, on the 7.5mg/mL concentration 
slide (Figure 43), there was a 99.37% reduction after 30 minutes of exposure and a 
99.94% reduction after 60 minutes of exposure. Both of these values were also 
statistically significant (P = 0.0004468 and P = 0.0004433, respectively). 
On the 2.5mg/mL concentration slide (Figure 43), there was a slightly lower 
decrease noted than in the 15 and 7.5mg/mL concentration slides. However, the decrease 
was still statistically significant. Within 30 minutes of exposure, there was a 99.17% 
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decrease (P = 0.0006490) and within 60 minutes of exposure, there was a 99.92% 
decrease (P = 0.0006397) in viable cell counts.  
 
4.5.4 Staphylococcus aureus 1199 
To determine the minimum concentration at which activated Br200 nanoparticles 
exhibit antibacterial properties, 15, 7.5, and 2.5mg/mL concentrations (Figure 44) of 
Br200 slides were also tested against non-drug-resistant S. aureus 1199 under UV light 
via the drop-coated slide bioassay. These concentrations were tested against a control 
slide of bacterial cells under UV light without any Br200 nanoparticle coatings. On the 
uncoated slides, under UV light alone (Figure 44), there was a 90.12% reduction after 30 
minutes and a 99.06% reduction after 60 minutes, both of which were statistically 
significant (P = 0.0003544 and P = 0.0004182, respectively).  
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Figure 44: Antibacterial Effects of Various Concentrations of  
Ultraviolet Light Activated Brookite Coatings on Staphylococcus aureus 1199 
Samples were plated at 0, 30, and 60 minutes. Various concentrations of Br200 nanoparticle slide coatings 
were tested and compared with one another and with the effects of the plain control slides under UV light 
activation without any coatings. The data represents the mean + standard error of 3 experiments. 
 
As noted on the slides, there was a similar cell growth reduction in the 15 and 
7.5mg/mL concentration slides. On the 15mg/mL concentration slide (Figure 44), there 
was a 99.32% reduction after 30 minutes of exposure and a 99.93% reduction after 60 
minutes of exposure. Both of which were statistically significant reductions (P =
0.001127 and P = 0.001114, respectively). Similarly, on the 7.5mg/mL concentration 
slide (Figure 44), there was a 99.32% reduction after 30 minutes of exposure and a 
99.94% reduction after 60 minutes of exposure. Both of these values were also 
statistically significant (P = 0.001231 and P = 0.001216, respectively).  
On the 2.5mg/mL concentration slide (Figure 44), there was a slightly lower 
decrease noted than in the 15 and 7.5mg/mL concentration slides. However, the decrease 
was still statistically significant. Within 30 minutes of exposure, there was a 99.11% 
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decrease (P = 0.0001229) and within 60 minutes of exposure, there was a 99.92% 
decrease (P = 0.0001225) in viable cell counts.  
 
4.5.5 Staphylococcus aureus 1199B
To determine the minimum concentration at which activated Br200 nanoparticles 
exhibit antibacterial properties, 15, 7.5, and 2.5mg/mL concentrations (Figure 45) of 
Br200 slides were also tested against MDR S. aureus 1199B under UV light via the drop-
coated slide bioassay. These concentrations were tested against a control slide of bacterial 
cells under UV light without any Br200 nanoparticle coatings. On the uncoated slides, 
under UV light alone (Figure 45), there was a 90.66% reduction after 30 minutes and a 
99.06% reduction after 60 minutes, both of which were statistically significant (P =
0.0003590 and P = 0.0004288, respectively).  
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Figure 45: Antibacterial Effects of Various Concentrations of  
Ultraviolet Light Activated Brookite Coatings on Staphylococcus aureus 1199B 
Samples were plated at 0, 30, and 60 minutes. Various concentrations of Br200 nanoparticle slide coatings 
were tested and compared with one another and with the effects of the plain control slides under UV light 
activation without any coatings. The data represents the mean + standard error of 3 experiments. 
 
As noted on the slides, there was a similar cell growth reduction in the 15 and 
7.5mg/mL concentration slides. On the 15mg/mL concentration slide (Figure 45), there 
was a 99.32% reduction after 30 minutes of exposure and a 99.94% reduction after 60 
minutes of exposure. Both of which were statistically significant reductions (P =
0.001609 and P = 0.001590, respectively). Similarly, on the 7.5mg/mL concentration 
slide (Figure 45), there was a 99.35% reduction after 30 minutes of exposure and a 
99.94% reduction after 60 minutes of exposure. Both of these values were also 
statistically significant (P = 0.0001142 and P = 0.0001147, respectively). 
On the 2.5mg/mL concentration slide (Figure 45), there was a slightly lower 
decrease noted than in the 15 and 7.5mg/mL concentration slides. However, the decrease 
was still statistically significant. Within 30 minutes of exposure, there was a 99.23% 
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decrease (P = 0.00005662) and within 60 minutes of exposure, there was a 99.92% 
decrease (P = 0.00005735) in viable cell counts.  
 
4.6 Toxic Effects of Non-Activated Brookite Nanoparticles  
4.6.1 Escherichia coli ATCC 23848 
 To examine the potency of non-activated Br200 nanoparticles at various 
concentrations of 100, 10, 1, 0.1, 0.01, and 0.001mg/mL (Figure 46), the free suspension 
bioassay was utilized against non-drug-resistant E. coli ATCC 23848. The various 
concentrations of nanoparticles were tested against a control sample of bacterial cells in 
the dark, without any light source, by substituting nanoparticles with distilled water. In 
the dark (Figure 46), without Br200 nanoparticles, there was no statistically significant 
reduction at any time point. The number of cells remained constant throughout the 
experiment for 120 minutes.  
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Figure 46: Toxic Effects of Non-Activated Brookite Nanoparticles on  
Escherichia coli ATCC 23848 
Samples were plated at 0, 30, 75, and 120 minutes. Various concentrations of non-activated Br200 
nanoparticles were tested and compared with one another and with the effects of cells incubated in the dark 
(distilled water) without any UV light exposure. The data represents the mean + standard error of 3 
experiments. 
 
At the 100mg/mL concentration (Figure 46), non-activated Br200 nanoparticles 
caused a statistically significant reduction of 70.76% (P = 0.0001913) within 30 minutes, 
a statistically significant reduction of 97.15% (P = 0.001472) within 75 minutes, and a 
statistically significant reduction of 99.73% (P = 0.001415) within 120 minutes. At the 
10mg/mL concentration (Figure 46), non-activated Br200 nanoparticles demonstrated 
lower death rates but similar trends. Within 30 minutes there was a statistically 
significant reduction of 56.07% (P = 0.0007662) in cell growth, within 75 minutes there 
was a statistically significant reduction of 79.20% (P = 0.0009387) in cell growth, and 
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within 120 minutes there was a statistically significant reduction of 99.08% (P =
0.001406) in cell growth.  
 At the 1mg/mL concentration (Figure 46), non-activated Br200 nanoparticles 
presented an even lower death rate but similar trends. After 30 minutes, there was a 
statistically significant reduction of 39.80% (P = 0.001522), after 75 minutes, there was a 
statistically significant reduction of 52.45% (P = 0.001224), and after120 minutes, there 
was a statistically significant reduction of 98.66% (P = 0.001309).  
 At the 0.1mg/mL concentration (Figure 46), non-activated Br200 nanoparticles 
resulted in a statistically significant decrease of 24.77% (P = 0.01346) post 30 minutes of 
contact, a statistically significant decrease of 43.64% (P = 0.003478) post 75 minutes of 
contact, and a statistically significant decrease of 97.55% (P = 0.001696) post 120 
minutes of contact. At 0.01 and 0.001mg/mL concentrations (Figure 46), non-activated 
Br200 nanoparticles did not cause any significant changes in viable cell counts over time.  
 
4.6.2 Escherichia coli DH10B/pK21 
 To examine the potency of non-activated Br200 nanoparticles at various 
concentrations of 100, 10, 1, 0.1, 0.01, and 0.001mg/mL (Figure 47), the free suspension 
bioassay was utilized against MDR E. coli DH10B/pK21. The various concentrations of 
nanoparticles were tested against a control sample of bacterial cells incubated in the dark, 
without any light source, by substituting nanoparticles with distilled water. In the dark 
(Figure 47), without Br200 nanoparticles, there was no statistically significant reduction 
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at any time point. The number of cells remained constant throughout the experiment for 
120 minutes.  
 
Figure 47: Toxic Effects of Non-Activated Brookite Nanoparticles on                         
Escherichia coli DH10B/pK21 
Samples were plated at 0, 30, 75, and 120 minutes. Various concentrations of non-activated Br200 
nanoparticles were tested and compared with one another and with the effects of cells incubated in the dark 
(distilled water) without any UV light exposure. The data represents the mean + standard error of 3 
experiments. 
 
At the 100mg/mL concentration (Figure 47), non-activated Br200 nanoparticles 
caused a statistically significant reduction of 72.14% (P = 0.0002688) within 30 minutes, 
a statistically significant reduction of 97.61% (P = 0.001358) within 75 minutes, and a 
statistically significant reduction of 99.76% (P = 0.001414) within 120 minutes. At the 
10mg/mL concentration (Figure 47), non-activated Br200 nanoparticles demonstrated 
lower death rates but similar trends. Within 30 minutes there was a statistically 
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significant reduction of 55.47% (P = 0.0009584) in cell growth, within 75 minutes there 
was a statistically significant reduction of 76.99% (P = 0.0003103) in cell growth, and 
within 120 minutes there was a statistically significant reduction of 98.90% (P =
0.001395) in cell growth.  
 At the 1mg/mL concentration (Figure 47), non-activated Br200 nanoparticles 
presented an even lower death rate but similar trends. After 30 minutes, there was a 
statistically significant reduction of 35.59% (P = 0.003285), after 75 minutes, there was a 
statistically significant reduction of 56.30% (P = 0.0003380), and after120 minutes, there 
was a statistically significant reduction of 98.79% (P = 0.001303).  
 At the 0.1mg/mL concentration (Figure 47), non-activated Br200 nanoparticles 
resulted in a statistically significant decrease of 25.38% (P = 0.02178) post 30 minutes of 
contact, a statistically significant decrease of 37.34% (P = 0.008181) post 75 minutes of 
contact, and a statistically significant decrease of 97.84% (P = 0.001807) post 120 
minutes of contact. At 0.01 and 0.001mg/mL concentrations (Figure 47), non-activated 
Br200 nanoparticles did not cause any significant changes in viable cell counts over time.  
 
4.6.3 Staphylococcus aureus ATCC 25923 
 To examine the potency of non-activated Br200 nanoparticles at various 
concentrations of 100, 10, 1, 0.1, 0.01, and 0.001mg/mL (Figure 48), the free suspension 
bioassay was utilized against non-drug-resistant S. aureus ATCC 25923. The various 
concentrations of nanoparticles were tested against a control sample of bacterial cells 
incubated in the dark, without any light source, by substituting nanoparticles with 
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distilled water. In the dark (Figure 48), without Br200 nanoparticles, there was no 
statistically significant reduction at any time point. The number of cells remained 
constant throughout the experiment for 120 minutes.  
 
Figure 48: Toxic Effects of Non-Activated Brookite Nanoparticles on                          
Staphylococcus aureus ATCC 25923 
Samples were plated at 0, 30, 75, and 120 minutes. Various concentrations of non-activated Br200 
nanoparticles were tested and compared with one another and with the effects of cells incubated in the dark 
(distilled water) without any UV light exposure. The data represents the mean + standard error of 3 
experiments. 
 
At the 100mg/mL concentration (Figure 48), non-activated Br200 nanoparticles 
caused a statistically significant reduction of 72.86% (P = 0.0001934) within 30 minutes, 
a statistically significant reduction of 97.38% (P = 0.001451) within 75 minutes, and a 
statistically significant reduction of 98.36% (P = 0.001445) within 120 minutes. At the 
10mg/mL concentration (Figure 48), non-activated Br200 nanoparticles demonstrated 
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lower death rates but similar trends. Within 30 minutes there was a statistically 
significant reduction of 21.64% (P = 0.0231) in cell growth, within 75 minutes there was 
a statistically significant reduction of 36.40% (P = 0.006410) in cell growth, and within 
120 minutes there was a statistically significant reduction of 97.94% (P = 0.001448) in 
cell growth.  
 At the 1mg/mL concentration (Figure 48), non-activated Br200 nanoparticles 
presented an even lower death rate but similar trends. After 30 minutes, there was a 
statistically significant reduction of 19.16% (P = 0.01790), after 75 minutes, there was a 
statistically significant reduction of 36.52% (P = 0.006462), and after120 minutes, there 
was a statistically significant reduction of 97.30% (P = 0.001303).  
 At the 0.1mg/mL concentration (Figure 48), non-activated Br200 nanoparticles 
resulted in a statistically significant decrease of 17.80% (P = 0.03178) post 30 minutes of 
contact, a statistically significant decrease of 32.00% (P = 0.007193) post 75 minutes of 
contact, and a statistically significant decrease of 97.26% (P = 0.001783) post 120 
minutes of contact. At 0.01 and 0.001mg/mL concentrations (Figure 48), non-activated 
Br200 nanoparticles did not cause any significant changes in viable cell counts over time.  
 
4.6.4 Staphylococcus aureus 1199 
 To examine the potency of non-activated Br200 nanoparticles at various 
concentrations of 100, 10, 1, 0.1, 0.01, and 0.001mg/mL (Figure 49), the free suspension 
bioassay was utilized against non-drug-resistant S. aureus 1199. The various 
concentrations of nanoparticles were tested against a control sample of bacterial cells 
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incubated in the dark, without any light source, by substituting nanoparticles with 
distilled water. In the dark (Figure 49), without Br200 nanoparticles, there was no 
statistically significant reduction at any time point. The number of cells remained 
constant throughout the experiment for 120 minutes.  
 
Figure 49: Toxic Effects of Non-Activated Brookite Nanoparticles on                       
Staphylococcus aureus 1199 
Samples were plated at 0, 30, 75, and 120 minutes. Various concentrations of non-activated Br200 
nanoparticles were tested and compared with one another and with the effects of cells incubated in the dark 
(distilled water) without any UV light exposure. The data represents the mean + standard error of 3 
experiments. 
 
At the 100mg/mL concentration (Figure 49), non-activated Br200 nanoparticles 
caused a statistically significant reduction of 70.22% (P = 0.0001789) within 30 minutes, 
a statistically significant reduction of 97.09% (P = 0.001485) within 75 minutes, and a 
statistically significant reduction of 98.42% (P = 0.001446) within 120 minutes. At the 
144
10mg/mL concentration (Figure 49), non-activated Br200 nanoparticles demonstrated 
lower death rates but similar trends. Within 30 minutes there was a statistically 
significant reduction of 23.85% (P = 0.008689) in cell growth, within 75 minutes there 
was a statistically significant reduction of 38.43% (P = 0.002238) in cell growth, and 
within 120 minutes there was a statistically significant reduction of 97.61% (P =
0.001426) in cell growth.  
 At the 1mg/mL concentration (Figure 49), non-activated Br200 nanoparticles 
presented an even lower death rate but similar trends. After 30 minutes, there was a 
statistically significant reduction of 19.65% (P = 0.01450), after 75 minutes, there was a 
statistically significant reduction of 37.26% (P = 0.001660), and after120 minutes, there 
was a statistically significant reduction of 97.71% (P = 0.001301).  
 At the 0.1mg/mL concentration (Figure 49), non-activated Br200 nanoparticles 
resulted in a statistically significant decrease of 19.24% (P = 0.04026) post 30 minutes of 
contact, a statistically significant decrease of 38.30% (P = 0.007884) post 75 minutes of 
contact, and a statistically significant decrease of 97.34% (P = 0.001845) post 120 
minutes of contact. At 0.01 and 0.001mg/mL concentrations (Figure 49), non-activated 
Br200 nanoparticles did not cause any significant changes in viable cell counts over time.  
 
4.6.5 Staphylococcus aureus 1199B
To examine the potency of non-activated Br200 nanoparticles at various 
concentrations of 100, 10, 1, 0.1, 0.01, and 0.001mg/mL (Figure 50), the free suspension 
bioassay was utilized against MDR S. aureus 1199B. The various concentrations of 
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nanoparticles were tested against a control sample of bacterial cells incubated in the dark, 
without any light source, by substituting nanoparticles with distilled water. In the dark 
(Figure 50), without Br200 nanoparticles, there was no statistically significant reduction 
at any time point. The number of cells remained constant throughout the experiment for 
120 minutes.  
 
Figure 50: Toxic Effects of Non-Activated Brookite Nanoparticles on                      
Staphylococcus aureus 1199B 
Samples were plated at 0, 30, 75, and 120 minutes. Various concentrations of non-activated Br200 
nanoparticles were tested and compared with one another and with the effects of cells incubated in the dark 
(distilled water) without any UV light exposure. The data represents the mean + standard error of 3 
experiments. 
 
At the 100mg/mL concentration (Figure 50), non-activated Br200 nanoparticles 
caused a statistically significant reduction of 70.10% (P = 0.0001938) within 30 minutes, 
a statistically significant reduction of 96.85% (P = 0.001441) within 75 minutes, and a 
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statistically significant reduction of 98.43% (P = 0.001448) within 120 minutes. At the 
10mg/mL concentration (Figure 50), non-activated Br200 nanoparticles demonstrated 
lower death rates but similar trends. Within 30 minutes there was a statistically 
significant reduction of 21.88% (P = 0.01492) in cell growth, within 75 minutes there 
was a statistically significant reduction of 39.21% (P = 0.001859) in cell growth, and 
within 120 minutes there was a statistically significant reduction of 97.21% (P =
0.001287) in cell growth.  
 At the 1mg/mL concentration (Figure 50), non-activated Br200 nanoparticles 
presented an even lower death rate but similar trends. After 30 minutes, there was a 
statistically significant reduction of 15.87% (P = 0.02847), after 75 minutes, there was a 
statistically significant reduction of 37.63% (P = 0.001744), and after120 minutes, there 
was a statistically significant reduction of 97.60% (P = 0.001340).  
 At the 0.1mg/mL concentration (Figure 50), non-activated Br200 nanoparticles 
resulted in a statistically significant decrease of 18.52% (P = 0.03277) post 30 minutes of 
contact, a statistically significant decrease of 35.06% (P = 0.003346) post 75 minutes of 
contact, and a statistically significant decrease of 97.40% (P = 0.001836) post 120 
minutes of contact. At 0.01 and 0.001mg/mL concentrations (Figure 50), non-activated 
Br200 nanoparticles did not cause any significant changes in viable cell counts over time.  
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4.7. Antibacterial Effects of Pre-Ultraviolet Light Exposed Coatings 
4.7.1 Escherichia coli ATCC 23848 
To ascertain the effects of UV light on nanoparticles and whether continuous 
activation with UV light is required in order for nanoparticles to exhibit antibacterial 
properties, the drop-coated slide bioassay was employed. Various concentrations of drop-
coated slides were tested, namely 15, 7.5, and 2.5mg/mL (Figure 51) against non-drug-
resistant E. coli ATCC 23848.  
As controls, various slides containing bacterial samples were incubated in the 
dark, without any UV light activation for 0, 30, and 60 minutes. The viable cell counts 
did not change on the unexposed slides (Figure 51) as there was no significant increase 
or decrease noted after recovery. In addition, as observed (Figure 51) there was no 
significant change on the control and binder when they were pre-exposed to UV light for 
30 minutes. When exposed for a longer amount of time for 60 minutes (Figure 51) there 
was still no difference on the control and binder slides. 
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Figure 51: Antibacterial Effects of Pre-Ultraviolet Light Exposed Coatings on 
Escherichia coli ATCC 23848 at Concentrations of  
(A) 15mg/mL; (B) 7.5mg/mL; and (C) 2.5mg/mL 
Samples were plated at 0, 30, and 60 minutes. Control slide represents plain, uncoated slides; Binder slide 
represents slides coated with the inorganic binder P25 slide represents slides coated with P25 nanoparticles; 
and Br200 slide represents slides coated with Br200 nanoparticles. The first 3 time intervals of 0, 30, and 
60 minutes represent controls, without UV light activation. The next 2 time intervals of 30 and 60 minutes 
(UV LIGHT) represent samples that were pre-treated under UV light activation. The data represents the 
mean + standard error of 3 experiments. 
A
B
C
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At the concentration of 15mg/mL (Figure 51A), there was no statistically 
significant decrease in the P25 drop-coated slides when pre-exposed to UV light for 30 
minutes (P = 0.3662) and 60 minutes (P = 0.5650). Likewise, there was no statistically 
significant decrease in the Br200 drop-coated slides when pre-exposed to UV light for 30 
minutes (P = 0.9265) and 60 minutes (P = 0.4803).  
In addition, the amount of bacterial cells remained the same even when cells were 
exposed to slides with lower concentrations of nanoparticle coatings. At the concentration 
of 7.5mg/mL (Figure 51B), there was no statistically significant reduction in the P25 
drop-coated slides when pre-exposed to UV light for 30 minutes (P = 0.5562) and 60 
minutes (P = 0.9680). Comparably, there was no statistically significant reduction in the 
Br200 drop-coated slides when pre-exposed to UV light for 30 minutes (P = 0.7168) and 
60 minutes (P = 0.5565).  
Furthermore, at the concentration of 2.5mg/mL (Figure 51C), there was no 
statistically significant difference in the P25 drop-coated slides when pre-exposed to UV 
light for 30 minutes (P = 0.8476) and 60 minutes (P = 0.5586). Similarly, there was no 
statistically significant difference in the Br200 drop-coated slides when pre-exposed to 
UV light for 30 minutes (P = 0.2620) and 60 minutes (P = 0.1118).  
 
4.7.2 Escherichia coli DH10B/pK21 
To ascertain the effects of UV light on nanoparticles and whether continuous 
activation with UV light is required in order for nanoparticles to exhibit antibacterial 
properties, the drop-coated slide bioassay was employed. Various concentrations of drop-
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coated slides were tested, namely 15, 7.5, and 2.5mg/mL (Figure 52) against MDR E. 
coli DH10B/pK21.  
As controls, various slides containing bacterial samples were incubated in the 
dark, without any UV light activation, for 0, 30, and 60 minutes. The viable cell counts 
did not change on the unexposed slides (Figure 52) as there was no significant increase 
or decrease noted after recovery. In addition, as observed (Figure 52) there was no 
significant change on the control and binder when they were pre-exposed to UV light for 
30 minutes. When exposed for a longer amount of time for 60 minutes (Figure 52) there 
was still no difference on the control and binder slides.  
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Figure 52: Antibacterial Effects of Pre-Ultraviolet Light Exposed Coatings on 
Escherichia coli DH10B/pK21 at Concentrations of  
(A) 15mg/mL; (B) 7.5mg/mL; and (C) 2.5mg/mL 
Samples were plated at 0, 30, and 60 minutes. Control slide represents plain, uncoated slides; Binder slide 
represents slides coated with the inorganic binder; P25 slide represents slides coated with P25 
nanoparticles; and Br200 slide represents slides coated with Br200 nanoparticles. The first 3 time intervals 
of 0, 30, and 60 minutes represent controls, without UV light activation. The next 2 time intervals of 30 and 
60 minutes (UV LIGHT) represent samples that were pre-treated under UV light activation. The data 
represents the mean + standard error of 3 experiments. 
C
B
A
152
At the concentration of 15mg/mL (Figure 52A), there was no statistically 
significant decrease in the P25 drop-coated slides when pre-exposed to UV light for 30 
minutes (P = 0.3768) and 60 minutes (P = 0.2222). Likewise, there was no statistically 
significant decrease in the Br200 drop-coated slides when pre-exposed to UV light for 30 
minutes (P = 0.05183) and 60 minutes (P = 0.9306). 
In addition, the amount of bacterial cells remained the same even when cells were 
exposed to slides with lower concentrations of nanoparticle coatings. At the concentration 
of 7.5mg/mL (Figure 52B), there was no statistically significant reduction in the P25 
drop-coated slides when pre-exposed to UV light for 30 minutes (P = 0.6176) and 60 
minutes (P = 0.7476). Comparably, there was no statistically significant reduction in the 
Br200 drop-coated slides when pre-exposed to UV light for 30 minutes (P = 0.5345) and 
60 minutes (P = 0.7399).  
Furthermore, at the concentration of 2.5mg/mL (Figure 52C), there was no 
statistically significant difference in the P25 drop-coated slides when pre-exposed to UV 
light for 30 minutes (P = 0.8825) and 60 minutes (P = 0.4947). Similarly, there was no 
statistically significant difference in the Br200 drop-coated slides when pre-exposed to 
UV light for 30 minutes (P = 0.2506) and 60 minutes (P = 0.3466).  
 
4.7.3 Staphylococcus aureus ATCC 25923 
To ascertain the effects of UV light on nanoparticles and whether continuous 
activation with UV light is required in order for nanoparticles to exhibit antibacterial 
properties, the drop-coated slide bioassay was employed. Various concentrations of drop-
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coated slides were tested, namely 15, 7.5, and 2.5mg/mL (Figure 53) against non-drug-
resistant S. aureus ATCC 25923. 
As controls, various slides containing bacterial samples were incubated in the 
dark, without any UV light activation, for 0, 30, and 60 minutes. The viable cell counts 
did not change on the unexposed slides (Figure 53) as there was no significant increase 
or decrease noted after recovery. In addition, as observed (Figure 53) there was no 
significant change on the control and binder when they were pre-exposed to UV light for 
30 minutes. When exposed for a longer amount of time for 60 minutes (Figure 53) there 
was still no difference on the control and binder slides.  
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Figure 53: Antibacterial Effects of Pre-Ultraviolet Light Exposed Coatings on 
Staphylococcus aureus ATCC 25923 at Concentrations of  
(A) 15mg/mL; (B) 7.5mg/mL; and (C) 2.5mg/mL 
Samples were plated at 0, 30, and 60 minutes. Control slide represents plain, uncoated slides; Binder slide 
represents slides coated with the inorganic binder; P25 slide represents slides coated with P25 
nanoparticles; and Br200 slide represents slides coated with Br200 nanoparticles. The first 3 time intervals 
of 0, 30, and 60 minutes represent controls, without UV light activation. The next 2 time intervals of 30 and 
60 minutes (UV LIGHT) represent samples that were pre-treated under UV light activation. The data 
represents the mean + standard error of 3 experiments. 
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At the concentration of 15mg/mL (Figure 53A), there was no statistically 
significant decrease in the P25 drop-coated slides when pre-exposed to UV light for 30 
minutes (P = 0.4386) and 60 minutes (P = 0.4240). Likewise, there was no statistically 
significant decrease in the Br200 drop-coated slides when pre-exposed to UV light for 30 
minutes (P = 0.2103) and 60 minutes (P = 0.6232).  
In addition, the amount of bacterial cells remained the same even when cells were 
exposed to slides with lower concentrations of nanoparticle coatings. At the concentration 
of 7.5mg/mL (Figure 53B), there was no statistically significant reduction in the P25 
drop-coated slides when pre-exposed to UV light for 30 minutes (P = 0.8040) and 60 
minutes (P = 0.5866). Comparably, there was no statistically significant reduction in the 
Br200 drop-coated slides when pre-exposed to UV light for 30 minutes (P = 0.6160) and 
60 minutes (P = 0.2592).  
Furthermore, at the concentration of 2.5mg/mL (Figure 53C), there was no 
statistically significant difference in the P25 drop-coated slides when pre-exposed to UV 
light for 30 minutes (P = 0.9229) and 60 minutes (P = 0.1448). Similarly, there was no 
statistically significant difference in the Br200 drop-coated slides when pre-exposed to 
UV light for 30 minutes (P = 0.4332) and 60 minutes (P = 0.6613).  
 
4.7.4 Staphylococcus aureus 1199 
To ascertain the effects of UV light on nanoparticles and whether continuous 
activation with UV light is required in order for nanoparticles to exhibit antibacterial 
properties, the drop-coated slide bioassay was employed. Various concentrations of drop-
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coated slides were tested, namely 15, 7.5, and 2.5mg/mL (Figure 54) against non-drug-
resistant S. aureus 1199. 
As controls, various slides containing bacterial samples were incubated in the 
dark, without any UV light activation, for 0, 30, and 60 minutes. The viable cell counts 
did not change on the unexposed slides (Figure 54) as there was no significant increase 
or decrease noted after recovery. In addition, as observed (Figure 54) there was no 
significant change on the control and binder when they were pre-exposed to UV light for 
30 minutes. When exposed for a longer amount of time for 60 minutes (Figure 54) there 
was still no difference on the control and binder slides.  
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Figure 54: Antibacterial Effects of Pre-Ultraviolet Light Exposed Coatings on 
Staphylococcus aureus 1199 at Concentrations of  
(A) 15mg/mL; (B) 7.5mg/mL; and (C) 2.5mg/mL 
Samples were plated at 0, 30, and 60 minutes. Control slide represents plain, uncoated slides; Binder slide 
represents slides coated with the inorganic binder; P25 slide represents slides coated with P25 
nanoparticles; and Br200 slide represents slides coated with Br200 nanoparticles. The first 3 time intervals 
of 0, 30, and 60 minutes represent controls, without UV light activation. The next 2 time intervals of 30 and 
60 minutes (UV LIGHT) represent samples that were pre-treated under UV light activation. The data 
represents the mean + standard error of 3 experiments. 
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At the concentration of 15mg/mL (Figure 54A), there was no statistically 
significant decrease in the P25 drop-coated slides when pre-exposed to UV light for 30 
minutes (P = 0.8917) and 60 minutes (P = 0.2402). Likewise, there was no statistically 
significant decrease in the Br200 drop-coated slides when pre-exposed to UV light for 30 
minutes (P = 0.6831) and 60 minutes (P = 0.9591).  
In addition, the amount of bacterial cells remained the same even when cells were 
exposed to slides with lower concentrations of nanoparticle coatings. At the concentration 
of 7.5mg/mL (Figure 54B), there was no statistically significant reduction in the P25 
drop-coated slides when pre-exposed to UV light for 30 minutes (P = 0.8404) and 60 
minutes (P = 0.8231). Comparably, there was no statistically significant reduction in the 
Br200 drop-coated slides when pre-exposed to UV light for 30 minutes (P = 0.3810) and 
60 minutes (P = 0.8354).  
Furthermore, at the concentration of 2.5mg/mL (Figure 54C), there was no 
statistically significant difference in the P25 drop-coated slides when pre-exposed to UV 
light for 30 minutes (P = 0.8091) and 60 minutes (P = 0.5972). Similarly, there was no 
statistically significant difference in the Br200 drop-coated slides when pre-exposed to 
UV light for 30 minutes (P = 0.1485) and 60 minutes (P = 0.4993).  
 
4.7.5 Staphylococcus. aureus 1199B
To ascertain the effects of UV light on nanoparticles and whether continuous 
activation with UV light is required in order for nanoparticles to exhibit antibacterial 
properties, the drop-coated slide bioassay was employed. Various concentrations of drop-
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coated slides were tested, namely 15, 7.5, and 2.5mg/mL (Figure 55) against MDR S.
aureus 1199B. 
As controls, various slides containing bacterial samples were incubated in the 
dark, without any UV light activation, for 0, 30, and 60 minutes. The viable cell counts 
did not change on the unexposed slides (Figure 55) as there was no significant increase 
or decrease noted after recovery. In addition, as observed (Figure 55) there was no 
significant change on the control and binder when they were pre-exposed to UV light for 
30 minutes. When exposed for a longer amount of time for 60 minutes (Figure 55) there 
was still no difference on the control and binder slides.  
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Figure 55: Antibacterial Effects of Pre-Ultraviolet Light Exposed Coatings on 
Staphylococcus aureus 1199B at Concentrations of  
(A) 15mg/mL; (B) 7.5mg/mL; and (C) 2.5mg/mL 
Samples were plated at 0, 30, and 60 minutes. Control slide represents plain, uncoated slides; Binder slide 
represents slides coated with the inorganic binder; P25 slide represents slides coated with P25 
nanoparticles; and Br200 slide represents slides coated with Br200 nanoparticles. The first 3 time intervals 
of 0, 30, and 60 minutes represent controls, without UV light activation. The next 2 time intervals of 30 and 
60 minutes (UV LIGHT) represent samples that were pre-treated under UV light activation. The data 
represents the mean + standard error of 3 experiments. 
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At the concentration of 15mg/mL (Figure 55A), there was no statistically 
significant decrease in the P25 drop-coated slides when pre-exposed to UV light for 30 
minutes (P = 0.6382) and 60 minutes (P = 0.8892). Likewise, there was no statistically 
significant decrease in the Br200 drop-coated slides when pre-exposed to UV light for 30 
minutes (P = 0.2997) and 60 minutes (P = 0.8515). 
In addition, the amount of bacterial cells remains the same even when cells were 
exposed to slides with lower concentrations of nanoparticle coatings. At the concentration 
of 7.5mg/mL (Figure 55B), there was no statistically significant reduction in the P25 
drop-coated slides when pre-exposed to UV light for 30 minutes (P = 0.3815) and 60 
minutes (P = 0.7495). Comparably, there was no statistically significant reduction in the 
Br200 drop-coated slides when pre-exposed to UV light for 30 minutes (P = 0.7157) and 
60 minutes (P = 0.5545).  
Furthermore, at the concentration of 2.5mg/mL (Figure 55C), there was no 
statistically significant difference in the P25 drop-coated slides when pre-exposed to UV 
light for 30 minutes (P = 0.4781) and 60 minutes (P = 0.06642). Similarly, there was no 
statistically significant difference in the Br200 drop-coated slides when pre-exposed to 
UV light for 30 minutes (P = 0.6127) and 60 minutes (P = 0.1269).  
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4.8 Morphological Effects of Ultraviolet Light Activated Anatase and Brookite 
Nanoparticles on Bacterial Cells 
4.8.1 Escherichia coli ATCC 23848 
Non-activated P25 and Br200 nanoparticles alone could be seen in clusters and 
grouped together (Figure 56 and 57).  It was obvious that P25 nanoparticles (Figure 56)
appeared larger than Br200 nanoparticles (Figure 57). Control bacteria, i.e., bacteria that 
were not in contact with activated or non-activated nanoparticles or UV light, had well 
preserved cells (Figure 58). The cells demonstrated typical thick, uniform, and rod-
shaped characteristics (Figure 58).  
 
Figure 56: Scanning Electron Microscopy Images of  
Unexposed P25 Anatase Nanoparticles (10mg/mL) Magnified  
at (A) 100,000X and (B) 100,000X  
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Figure 57: Scanning Electron Microscopy Images of  
Unexposed Br200 Nanoparticles (10mg/mL) Magnified  
at (A) 150,000X and (B) 350,000X  
 
Figure 58: Scanning Electron Microscopy Images of  
Unexposed Escherichia coli Cells (10mL of 109 CFU/mL) Magnified  
at (A) 13,000X and (B) 18,000X 
A B
A B
164
Images of the bacterial cells mixed with TiO2 nanoparticles were obtained at 0 
minutes before any incubation (Figure 59). It was obvious that nanoparticles aggregated 
and formed clusters around the bacterial cells. Exposure to UV light activated 
nanoparticles for 30 minutes did not cause any significant damage to the cells (Figure 
60). Exposure of cells to UV light activated nanoparticles for 180 minutes (Figure 61)
caused a significant amount of damage to the cells. The damage could be seen as tiny 
indentions (Figure 61), which caused the deformities observed in cell shapes. In addition, 
untreated cells presented smooth and rod-shaped cell surfaces (Figure 58) while treated 
cells presented rough and crinkled surfaces (Figure 61). Of note is that the cells exposed 
to UV light alone did not reveal a significant amount of damage. There were more 
undamaged cells present in the sample then damaged cells.  
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Figure 59: Scanning Electron Microscopy Images of 
Unexposed Escherichia coli Cells (10mL of 109 CFU/mL) with  
(A) P25 Nanoparticles (3mL of 10mg/mL) Magnified at 15,000X;  
(B) P25 Nanoparticles (3mL of 10mg/mL) Magnified at 20,000X;  
(C) Br200 Nanoparticles (5mL of 0.1mg/mL) Magnified at 20,000X; and 
(D) Br200 Nanoparticles (3mL of 0.1mg/mL) Magnified at 20,000X 
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Figure 60: Scanning Electron Microscopy Images of 
Escherichia coli Cells (10mL of 109 CFU/mL)  
Post 30 Minutes Exposure to Ultraviolet Light Activated  
(A) P25 Nanoparticles (5mL of 0.1mg/mL) Magnified at 8,000X;  
(B) P25 Nanoparticles (5mL of 0.1mg/mL) Magnified at 20,000X;  
(C) Br200 Nanoparticles (5mL of 0.1mg/mL) Magnified at 18,000X; and  
(D) Br200 Nanoparticles (3mL of 0.1mg/mL) Magnified at 20,000X 
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Figure 61: Scanning Electron Microscopy Images of 
Escherichia coli Cells (10mL of 109 CFU/mL)  
Post 180 Minutes Exposure to Ultraviolet Light Activated  
(A) P25 Nanoparticles (5mL of 0.1mg/mL) Magnified  at 20,000X;  
(B) P25 Nanoparticles (5mL of 0.1mg/mL) Magnified at 30,000X;  
(C) Br200 Nanoparticles (5mL of 0.1mg/mL) Magnified at 20,000X; and  
(D) Br200 Nanoparticles (3mL of 0.1mg/mL) Magnified at 35,000X 
 
Bacterial cells that were incubated in the dark without any UV light exposure did 
not reveal any damage after 180 minutes (Figure 62). However, after 180 minutes of UV 
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light exposure, damage on the cells was evident (Figure 63). The physical damage was 
similar to the damage observed due to the activated TiO2 nanoparticles although the 
amount of damaged cells on the TiO2 activated samples was greater than the amount of 
damaged cells on the UV light exposed samples.  
 
Figure 62: Scanning Electron Microscopy Images of 
Escherichia coli Cells (10mL of 109 CFU/mL)  
Post 180 Minutes Incubation in the Dark,  
Without Ultraviolet Light Activation Magnified at (A) 13,000X and (B) 13,000X 
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Figure 63: Scanning Electron Microscopy Images of 
Escherichia coli Cells (10mL of 109 CFU/mL)  
Post 180 Minutes Exposure to Ultraviolet Light Magnified  
at (A) 11,000X and (B) 15,000X 
 
4.8.2 Staphylococcus aureus 1199B
Control bacteria, i.e., bacteria that were not in contact with activated or non-
activated nanoparticles or UV light, had well preserved cells (Figure 64). The cells 
demonstrated typical thick, uniform, and rounded characteristics (Figure 64).  
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Figure 64: Scanning Electron Microscopy Images of 
Unexposed Staphylococcus aureus Cells (10mL of 109 CFU/mL) Magnified at (A) 
11,000X and (B) 20,000X 
 
Images of the bacterial cells mixed with TiO2 nanoparticles were obtained at 0 
minutes before any incubation (Figure 65). It was obvious that nanoparticles aggregated 
and formed clusters around the bacterial cells. Similar to the E. coli cells, exposure to UV 
light activated nanoparticles for 30 minutes did not cause any significant damage to the 
cells of MDR S. aureus 1199B (Figure 66). Exposure of cells to UV light activated 
nanoparticles for 180 minutes (Figure 67) caused a significant amount of damage to the 
cells. The damage could be seen as malformations in the circular shapes (Figure 67) of
the cells. Apparently, untreated cells presented smooth surfaces (Figure 64) while treated 
cells presented irregular-shaped surfaces (Figure 67). It is important to note that cells 
BA
171
exposed to UV light alone did not reveal a significant amount of damage. There were 
more undamaged cells present in the sample then damaged cells.  
Figure 65: Scanning Electron Microscopy Images of 
Unexposed Staphylococcus aureus Cells (10mL of 109 CFU/mL) with  
(A) P25 Nanoparticles (5mL of 0.1mg/mL) Magnified at 11,000X;  
(B) P25 Nanoparticles (5mL of 0.1mg/mL) Magnified at 15,000X,  
(C) Br200 Nanoparticles (5mL of 0.1mg/mL) Magnified at 35,000X; and  
(D) Br200 Nanoparticles (3mL of 0.1mg/mL) Magnified at 45,000X 
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Figure 66: Scanning Electron Microscopy Images of 
Staphylococcus aureus Cells (10mL of 109 CFU/mL)  
Post 30 Minutes Exposure to Ultraviolet Light Activated  
(A) P25 Nanoparticles (5mL of 0.1mg/mL) Magnified at 15,000X;  
(B) P25 Nanoparticles (5mL of 0.1mg/mL) Magnified at 30,000X;  
(C) Br200 Nanoparticles (5mL of 0.1mg/mL) Magnified at 35,000X; and  
(D) Br200 Nanoparticles (3mL of 0.1mg/mL) Magnified at 35,000X 
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Figure 67: Scanning Electron Microscopy Images of 
Staphylococcus aureus Cells (10mL of 109 CFU/mL)  
Post 180 Minutes Exposure to Ultraviolet Light Activated  
(A) P25 Nanoparticles (5mL of 0.1mg/mL) Magnified at 30,000X;  
(B) P25 Nanoparticles (5mL of 0.1mg/mL) Magnified at 45,000X;  
(C) Br200 Nanoparticles (5mL of 0.1mg/mL) Magnified at 40,000X; and  
(D) Br200 Nanoparticles (3mL of 0.1mg/mL) Magnified at 45,000X 
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Bacterial cells that were incubated in the dark without any UV light exposure did 
not reveal any damage after 180 minutes (Figure 68). However, after 180 minutes of UV 
light exposure, damage on the cells was evident (Figure 69). The physical damage was 
similar to the damage observed due to the activated TiO2 nanoparticles although the 
amount of damaged cells on the TiO2 activated samples was greater than the amount of 
damaged cells on the UV light exposed samples.  
 
Figure 68: Scanning Electron Microscopy Images of 
Staphylococcus aureus Cells (10mL of 109 CFU/mL)  
Post 180 Minutes Incubation in the Dark,  
Without Ultraviolet Light Activation Magnified at (A) 13,000X and (B) 15,000X 
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Figure 69: Scanning Electron Microscopy Images of 
 Staphylococcus aureus Cells (10mL of 109 CFU/mL)  
Post 180 Minutes Exposure to Ultraviolet Light Magnified  
at (A) 25,000X and (B) 45,000X 
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4.9 Antibacterial Effects of Visible Light Activated Anatase and Brookite 
Nanoparticles 
4.9.1 Escherichia coli ATCC 23848 
Visible light activation alone (Figure 70) did not cause any increase or decrease 
in viable cell counts over time. In addition, cells incubated in the dark without any light 
source did not illustrate any increase of decrease in viable cell counts over time.  
 
Figure 70: Antibacterial Effects of Visible Light Activated Anatase and Brookite 
Nanoparticles on Escherichia coli ATCC 23848 
Samples were plated at 0, 4, and 8 hours. The following samples were plated: Control: Cells incubated in 
the dark, without visible light exposure; VLA: Cells under visible light exposure without nanoparticles; 
VLA-P25: Cells exposed to visible light activated P25 nanoparticles; VLA-Br200: Cells exposed to visible 
light activated Br200 nanoparticles; P25: Cells with nanoparticles incubated in the dark, without visible 
light exposure; and Br200: Cells with nanoparticles incubated in the dark, without visible light exposure. 
For P25 and Br200 samples, distilled water was utilized as the medium of treatment instead of nanoparticle 
suspensions. The data represents the mean + standard error of 3 experiments. 
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At the concentration of 10mg/mL (Figure 70), after exposure of cells to activated 
P25 nanoparticles there was a less than three log reduction in cell growth after 4 hours. 
This reduction was statistically significant (P = 0.0007254). After 8 hours of exposure to 
activated P25 nanoparticles there was a three log reduction in cell growth, which was 
statistically significant (P = 0.0007237). Similarly, there was a three log reduction in cell 
growth after 4 hours of exposure to visible light activated Br200 nanoparticles, which 
eventually led to a five log reduction after 8 hours of exposure to visible light activated 
Br200 nanoparticles. Both these reductions were also statistically significant (P =
0.0006960 and P = 0.0006946, respectively).  
Appropriate controls were established which represented the action of TiO2
nanoparticles on the cells incubated in the dark (Figure 70) without visible light 
activation. At the concentration of 10mg/mL, non-activated P25 nanoparticles exhibited 
one log statistically significant decrease (P = 0.001143) in cell growth after 4 hours of 
incubation which led to a two log reduction after 8 hours. Non-activated Br200 
nanoparticles exhibited caused a greater amount of decrease in cell growth compared to 
non-activated P25 nanoparticles. At the concentration of 10mg/mL, non-activated Br200 
nanoparticles exhibited a two log statistically significant decrease (P = 0.0007342) in cell 
growth after 4 hours of incubation which led to a three log reduction after 8 hours.  
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4.9.2 Escherichia coli DH10B/pK21 
Visible light activation alone (Figure 71) did not cause any increase or decrease 
in viable cell counts over time. In addition, cells incubated in the dark without any light 
source did not illustrate any increase of decrease in viable cell counts over time.  
 
Figure 71: Antibacterial Effects of Visible Light Activated Anatase and Brookite 
Nanoparticles on Escherichia coli DH10B/pK21 
Samples were plated at 0, 4, and 8 hours. The following samples were plated: Control: Cells incubated in 
the dark, without visible light exposure; VLA: Cells under visible light exposure without nanoparticles; 
VLA-P25: Cells exposed to visible light activated P25 nanoparticles; VLA-Br200: Cells exposed to visible 
light activated Br200 nanoparticles; P25: Cells with nanoparticles incubated in the dark, without visible 
light exposure; and Br200: Cells with nanoparticles incubated in the dark, without visible light exposure. 
For P25 and Br200 samples, distilled water was utilized as the medium of treatment instead of nanoparticle 
suspensions. The data represents the mean + standard error of 3 experiments. 
 
At the concentration of 10mg/mL (Figure 71), after exposure of cells to activated 
P25 nanoparticles there was a less than three log reduction in cell growth after 4 hours. 
This reduction was statistically significant (P = 0.002838). After 8 hours of exposure to 
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activated P25 nanoparticles there was a three log reduction in cell growth, which was 
statistically significant (P = 0.002831). Similarly, there was a three log reduction in cell 
growth after 4 hours of exposure to visible light activated Br200 nanoparticles, which 
eventually led to a five log reduction after 8 hours of exposure to visible light activated 
Br200 nanoparticles. Both these reductions were also statistically significant (P =
0.001837 and P = 0.001834, respectively)  
Appropriate controls were established which represented the action of TiO2
nanoparticles on the cells incubated in the dark (Figure 71) without visible light 
activation. At the concentration of 10mg/mL, non-activated P25 nanoparticles exhibited 
one log statistically significant decrease (P = 0.002524) in cell growth after 4 hours of 
incubation which led to a two log reduction after 8 hours. Non-activated Br200 
nanoparticles exhibited caused a greater amount of decrease in cell growth compared to 
non-activated P25 nanoparticles. At the concentration of 10mg/mL, non-activated Br200 
nanoparticles exhibited a two log statistically significant decrease (P = 0.001336) in cell 
growth after 4 hours of incubation which led to a three log reduction after 8 hours.  
 
4.9.3 Staphylococcus aureus 25923 
Visible light activation alone (Figure 72) did not cause any increase or decrease 
in viable cell counts over time. In addition, cells incubated in the dark without any light 
source did not illustrate any increase of decrease in viable cell counts over time.  
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Figure 72: Antibacterial Effects of Visible Light Activated Anatase and Brookite 
Nanoparticles on Staphylococcus aureus ATCC 25923
Samples were plated at 0, 4, and 8 hours. The following samples were plated: Control: Cells incubated in 
the dark, without visible light exposure; VLA: Cells under visible light exposure without nanoparticles; 
VLA-P25: Cells exposed to visible light activated P25 nanoparticles; VLA-Br200: Cells exposed to visible 
light activated Br200 nanoparticles; P25: Cells with nanoparticles incubated in the dark, without visible 
light exposure; and Br200: Cells with nanoparticles incubated in the dark, without visible light exposure. 
For P25 and Br200 samples, distilled water was utilized as the medium of treatment instead of nanoparticle 
suspensions. The data represents the mean + standard error of 3 experiments. 
 
At the concentration of 10mg/mL (Figure 72), after exposure of cells to activated 
P25 nanoparticles there was a less than one log reduction in cell growth after 4 hours. 
However, this reduction was statistically significant (P = 0.006424). After 8 hours of 
exposure to activated P25 nanoparticles there was an almost two log reduction in cell 
growth, which was statistically significant (P = 0.0002743). Similarly, there was a one 
log reduction in cell growth after 4 hours of exposure to visible light activated Br200 
nanoparticles, which eventually led to a four log reduction after 8 hours of exposure to 
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visible light activated Br200 nanoparticles. Both these reductions were also statistically 
significant (P = 0.001105 and P = 0.001100, respectively).  
Appropriate controls were established which represented the action of TiO2
nanoparticles on the cells incubated in the dark (Figure 72) without visible light 
activation. At the concentration of 10mg/mL, non-activated P25 nanoparticles exhibited a 
less than one log statistically significant decrease (P = 0.04080) in cell growth after 4 
hours of incubation which led to a one log reduction after 8 hours. Non-activated Br200 
nanoparticles exhibited caused a greater amount of decrease in cell growth compared to 
non-activated P25 nanoparticles. At the concentration of 10mg/mL, non-activated Br200 
nanoparticles exhibited one log statistically significant decrease (P = 0.002524) in cell 
growth after 4 hours of incubation which led to a two log reduction after 8 hours.  
 
4.9.4 Staphylococcus aureus 1199 
Visible light activation alone (Figure 73) did not cause any increase or decrease 
in viable cell counts over time. In addition, cells incubated in the dark without any light 
source did not illustrate any increase of decrease in viable cell counts over time.  
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Figure 73: Antibacterial Effects of Visible Light Activated Anatase and Brookite 
Nanoparticles on Staphylococcus aureus 1199
Samples were plated at 0, 4, and 8 hours. The following samples were plated: Control: Cells incubated in 
the dark, without visible light exposure; VLA: Cells under visible light exposure without nanoparticles; 
VLA-P25: Cells exposed to visible light activated P25 nanoparticles; VLA-Br200: Cells exposed to visible 
light activated Br200 nanoparticles; P25: Cells with nanoparticles incubated in the dark, without visible 
light exposure; and Br200: Cells with nanoparticles incubated in the dark, without visible light exposure. 
For P25 and Br200 samples, distilled water was utilized as the medium of treatment instead of nanoparticle 
suspensions. The data represents the mean + standard error of 3 experiments. 
 
At the concentration of 10mg/mL (Figure 73), after exposure of cells to activated 
P25 nanoparticles there was a less than one log reduction in cell growth after 4 hours. 
However, this reduction was statistically significant (P = 0.008238). After 8 hours of 
exposure to activated P25 nanoparticles there was an almost two log reduction in cell 
growth, which was statistically significant (P = 0.001078). Similarly, there was a one log 
reduction in cell growth after 4 hours of exposure to visible light activated Br200 
nanoparticles, which eventually led to a four log reduction after 8 hours of exposure to 
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visible light activated Br200 nanoparticles. Both these reductions were also statistically 
significant (P = 0.002029 and P = 0.001797, respectively).  
Appropriate controls were established which represented the action of TiO2
nanoparticles on the cells incubated in the dark (Figure 73) without visible light 
activation. At the concentration of 10mg/mL, non-activated P25 nanoparticles exhibited a 
less than one log statistically significant decrease (P = 0.03133) in cell growth after 4 
hours of incubation which led to a one log reduction after 8 hours. Non-activated Br200 
nanoparticles exhibited caused a greater amount of decrease in cell growth compared to 
non-activated P25 nanoparticles. At the concentration of 10mg/mL, non-activated Br200 
nanoparticles exhibited one log statistically significant decrease (P = 0.002945) in cell 
growth after 4 hours of incubation which led to a two log reduction after 8 hours.  
 
4.9.5 Staphylococcus aureus 1199B
Visible light activation (Figure 74) alone did not cause any increase or decrease 
in viable cell counts over time. In addition, cells incubated in the dark without any light 
source did not illustrate any increase of decrease in viable cell counts over time.  
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Figure 74: Antibacterial Effects of Visible Light Activated Anatase and Brookite 
Nanoparticles on Staphylococcus aureus 1199B 
Samples were plated at 0, 4, and 8 hours. The following samples were plated: Control: Cells incubated in 
the dark, without visible light exposure; VLA: Cells under visible light exposure without nanoparticles; 
VLA-P25: Cells exposed to visible light activated P25 nanoparticles; VLA-Br200: Cells exposed to visible 
light activated Br200 nanoparticles; P25: Cells with nanoparticles incubated in the dark, without visible 
light exposure; and Br200: Cells with nanoparticles incubated in the dark, without visible light exposure. 
For P25 and Br200 samples, distilled water was utilized as the medium of treatment instead of nanoparticle 
suspensions. The data represents the mean + standard error of 3 experiments. 
 
At the concentration of 10mg/mL (Figure 74), after exposure of cells to activated 
P25 nanoparticles there was a less than one log reduction in cell growth after 4 hours. 
However, this reduction was statistically significant (P = 0.01314). After 8 hours of 
exposure to activated P25 nanoparticles there was an almost two log reduction in cell 
growth, which was statistically significant (P = 0.0001969). Similarly, there was a one 
log reduction in cell growth after 4 hours of exposure to visible light activated Br200 
nanoparticles, which eventually led to a four log reduction after 8 hours of exposure to 
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visible light activated Br200 nanoparticles. Both these reductions were also statistically 
significant (P = 0.001632 and P = 0.001595, respectively).  
Appropriate controls were established which represented the action of TiO2
nanoparticles on the cells incubated in the dark (Figure 74) without visible light 
activation. At the concentration of 10mg/mL, non-activated P25 nanoparticles exhibited a 
less than one log statistically significant decrease (P = 0.009952) in cell growth after 4 
hours of incubation which led to a one log reduction after 8 hours. Non-activated Br200 
nanoparticles exhibited caused a greater amount of decrease in cell growth compared to 
non-activated P25 nanoparticles. At the concentration of 10mg/mL, non-activated Br200 
nanoparticles exhibited one log statistically significant decrease (P = 0.002510) in cell 
growth after 4 hours of incubation which led to a two log reduction after 8 hours.  
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CHAPTER 5 
DISCUSSION 
 
5.1 Antibacterial Effects of Ultraviolet Light Activated Anatase versus Brookite 
Nanoparticles 
Ultraviolet light alone, at a wavelength of 365nm with an energy level of 
370>w/cm2 exhibited limited bactericidal properties as expected. There was a slight 
decrease in viable cell counts over time. After 30 minutes of exposure, UV light alone 
caused minimal reduction.  After 120 minutes of exposure, UV light alone caused a one 
log reduction, which was less efficient than photocatalysis with nanoparticles. This was 
consistent with previous studies which have demonstrated that UV light alone at a 
wavelength of 365nm did not cause a significant decrease in cell growth.  
At concentrations of 10 and 1mg/mL, UV light activated anatase and brookite 
nanoparticles exhibited similar antibacterial properties on both strains of E. coli, namely 
non-drug-resistant E. coli ATCC 23848 and MDR E. coli DH10B/pK21. Both P25 and 
Br200 nanoparticles caused a 100% decline in E. coli cell growth within 30 minutes of 
exposure. However, at similar concentrations, Br200 nanoparticles caused a 100% 
reduction of all S. aureus cells within 30 minutes of exposure to UV light while P25 
nanoparticles did not. Instead, at 10 and 1mg/mL concentrations, activated P25 
nanoparticles caused a 100% decrease in non-drug-resistant S. aureus cell counts after 75 
minutes of exposure and a 100% decrease in MDR S. aureus cell counts after 120 
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minutes of exposure. This implies that there was a difference in the antibacterial effects 
of P25 and Br200 nanoparticles against S. aureus.
The reason that Br200 nanoparticles exhibited stronger antibacterial activities 
than P25 nanoparticles may be due to the higher specific surface area of the Br200 
nanoparticles. Brookite nanoparticles have a specific surface area that is almost three 
times larger than that of anatase nanoparticles. Due to the higher specific surface area, 
there is an increase in active sites which increases the probability of electrons and holes 
to reach the surface and react thus, leading to a faster degradation process.  
 The Br200 nanoparticles exhibited stronger bactericidal effects on E. coli cells 
than on S. aureus cells. The difference in susceptibility may be due to the cell wall 
structures of the gram-negative E. coli and gram-positive S. aureus. Since gram-positive 
cell walls are thicker than gram-negative cell walls, it may be more feasible for the 
radicals and anions to damage the thinner cell walls. Additionally, gram-positive cell 
walls contain teichoic acids which are not present in gram-negative cell walls. Teichoic 
acids are polymers of glycerol or ribitol connected by phosphate groups. Amino acids 
such as D-alanine or sugars like glucose are attached to the glycerol and ribitol groups. 
Teichoic acids appear to extend to the surface of the peptidoglycan layer and past studies 
have indicated that teichoic acids may be important in maintaining the structure of the 
cell walls of gram-positive bacteria such as S. aureus. Furthermore, even though the cell 
and nanoparticle mixtures were thoroughly mixed on a vortex, one of the characteristics 
of S. aureus is to form clumps. The clumping of S. aureus may have provided some level 
of protection to the cells. 
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UV light activated brookite nanoparticles resulted in a reduction in viable cell 
counts within 30 minutes, at concentrations of 10 and 1mg/mL. Although it was obvious 
that complete killing was achieved within 30 minutes, the exact time required to achieve 
complete killing is not known since the first set of samples for the free suspension 
bioassay were plated at 0 minutes and the second set of samples were plated at 30 
minutes. The  second set of samples were not obtained in less than 30 minutes due to the 
processing time required for the number of samples plated on TSA plates. For future 
studies, 0 minute samples may be omitted and instead samples may be obtained at 
another time interval of less than 30 minutes in order to determine the exact time required 
to achieve complete killing with brookite nanoparticles.  
 The control, non-activated nanoparticles, caused a slight reduction in cell growth. 
However, activated nanoparticles caused a greater reduction of seven logs in cell growth 
within 30 minutes. The reason for the effects of the non-activated nanoparticles may be 
due to the toxicity present in the samples which is further explained in Section 5.5. 
 
5.2 Antibacterial Effects of Ultraviolet Light Activated Anatase versus Brookite 
Coatings 
Plain, uncoated slides exposed to UV light alone at a wavelength of 365nm with 
an energy level of 370>w/cm2 demonstrated antibacterial properties as predicted. There 
was a consistent decrease in viable cell counts over time. After 30 minutes of exposure, 
UV light alone, caused a one log reduction and a two log reduction after 60 minutes of 
exposure, which was less efficient than the antibacterial properties exhibited by the 
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nanoparticle coatings. These results were consistent with past studies that have 
demonstrated that UV light alone at a wavelength of 365nm does not cause a significant 
decrease in viable cell counts.  
Slides coated with the binder exhibited minimal antibacterial properties after 30 
minutes of UV light exposure. However, after 60 minutes of UV light exposure the slides 
resulted in an almost one log reduction in cell viability. The reason for the slower 
decrease in viable cell counts may have been due to the texture of the coatings. The 
coatings on the slide did not allow the bacterial culture to spread evenly on the surface. 
Instead, the bacterial culture formed droplets on the slide which in turn may have 
protected the cells from UV light exposure until the UV light penetrated through the 
droplet due to prolonged exposure, i.e., 60 minutes of exposure, which eventually 
resulted in a further decrease in viable cell counts.  
At concentrations of 15, 7.5, and 2.5mg/mL, P25 coatings resulted in a one log 
reduction post 30 minutes of UV light exposure and a two log reduction post 60 minutes 
of UV light exposure with E. coli and S. aureus cells. In contrast, Br200 coatings resulted 
in a greater decrease, a two log reduction after 30 minutes of exposure and a three log 
reduction after 60 minutes of exposure with E. coli and S. aureus cells.  
It was obvious that the coatings did not cause a complete 100% reduction in cell 
growth at any time point and this may have been due to the nature of the coatings. The 
coatings were exposed to UV light constantly but due to the droplets that were formed on 
the coated slides rather than the smooth spreading of the bacterial culture, UV light may 
not have been able to penetrate in all areas of the coatings effectively. This may have 
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prevented the complete killing of the bacterial cells found on the surface. However, it can 
be accurately confirmed that activated Br200 coatings were more effective at killing 
bacterial cells than P25 coatings which caused a one log reduction in viable cell counts 
compared to the two log reductions caused by Br200 coatings within 30 minutes.  
 
5.3 Antibacterial Effects of Various Concentrations of Ultraviolet Light Activated 
Brookite Nanoparticles 
At 10 and 1mg/mL concentrations, Br200 nanoparticles exhibited similar 
antibacterial properties when exposed to UV light. At extreme concentrations of 100, 0.1, 
0.01, and 0.001mg/mL, the effectiveness of the activated nanoparticles was reduced. 
There was a consistent decrease in cell growth at 100 and 0.1mg/mL concentrations 
within 120 minutes of UV light exposure, although neither concentration led to a 100% 
reduction in cell growth within 120 minutes of UV light exposure. On the other hand, 
concentrations of 0.01 and 0.001mg/mL did not cause any significant decrease or 
increase in cell growth at any exposure times, which indicates that extremely low 
concentrations are ineffective as photocatalysts within 120 minutes.  
A possible explanation for nanoparticle concentrations greater than 10mg/mL to 
result in a decreased killing efficiency may have been related to the fact that there were 
too many TiO2 nanoparticles which did not allow UV light illumination to reach evenly 
throughout all the nanoparticles. Therefore, there may have been a decrease in UV light 
absorption due to the large amount of particle to particle contact. Similarly, at a 
concentration lower than 1mg/mL such as 0.1mg/mL, the killing efficiency was reduced 
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because there were too few nanoparticles for reactions to occur even after consistent UV 
light illumination for 120 minutes. Extremely low concentrations of 0.01mg/mL and 
0.001mg/mL did not result in any cell death, even after 120 minutes of UV light 
exposure. This suggested that brookite nanoparticles at such low concentrations protected 
the bacterial cells from UV light exposure since the decrease seen when cells were 
exposed to UV light was not seen at these concentrations of brookite nanoparticles. 
Scanning electron microscopy images have also revealed that the brookite nanoparticles 
aggregate around the bacterial cells which may protect them from exposure to UV light.  
As a result, the minimum concentration which was optimum for obtaining 
successful killing with Br200 nanoparticles within 30 minutes of UV light exposure was 
1mg/mL. Of particular note was the effect of UV light irradiation alone, which was not as 
effective in causing cell death as the activated Br200 nanoparticles were, especially the 
10 and 1mg/mL concentrations of Br200 nanoparticles, which caused a 100% decrease 
within 30 minutes of UV light illumination. 
 
5.4 Antibacterial Effects of Various Concentrations of Ultraviolet Light Activated 
Brookite Coatings 
Slides coated with Br200 concentrations of 15, 7.5, and 2.5mg/mL depicted 
similar antibacterial properties within 30 and 60 minutes of UV light exposure. Since 
changes in viable cell counts were not observed among the different concentrations, the 
optimum concentration of coatings required to obtain maximum killing could not be 
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stated. A larger range of higher and lower concentrations of brookite coatings should be 
tested in order to determine the optimum concentration of coatings.   
At higher concentrations of coatings, there may be too many nanoparticles 
clustered together during the preparation of the slides which will not allow UV light 
exposure to activate all nanoparticles on the coatings effectively. Similarly, at lower 
concentrations of coatings, there may not be enough nanoparticles in the coatings to 
cause a reduction in cell counts once activated by UV light.  
Therefore, an optimum concentration of coatings that can effectively, when 
activated, exhibit antibacterial properties, needs to be determined. Of particular note was 
the effect of UV light irradiation alone, which resulted in a one log decrease in viable cell 
counts within 30 minutes but was not as effective in causing cell death as the activated 
Br200 coatings were. The 7.5mg/mL concentration of Br200 nanoparticle coatings 
caused a two log reduction within 30 minutes of UV light illumination.  
 
5.5 Toxic Effects of Non-Activated Brookite Nanoparticles 
 Bacterial cells incubated with distilled water in the dark did not cause any 
reduction in cell growth which represented an excellent control for this toxicity study 
since it proved that the distilled water alone was not the cause of the reductions in viable 
cell counts. Non-activated Br200 nanoparticles, obviously, resulted in toxicity. At 
concentrations of 100, 10, 1, and 0.1mg/mL, nanoparticles exhibited decreasing levels of 
toxicity. In addition, longer times of contact led to more toxic effects of the nanoparticles. 
At low concentrations of 0.01 and 0.001mg/mL, the nanoparticles did not exhibit any 
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toxicity. At higher concentrations of up to 100mg/mL, there was a larger degree of 
toxicity than at lower concentrations of 0.1mg/mL because there were a greater number 
of nanoparticles in the higher concentrations and a lesser number of nanoparticles in the 
lower concentrations.  
 Br200 nanoparticles may have exhibited toxicity due to the contamination or 
impurities present in the sample which caused the decomposition of organic substances. 
The synthesis of Br200 nanoparticles involves the utilization of the compound, TiCl4,
which generates HCl upon reactions with water and produces TiO2. During the sample 
preparation, residual HCl may have persisted in the Br200 samples that caused the 
samples to become acidic. Due to this presumption, the pH of the Br200 nanoparticles 
was measured at various concentrations. Distilled water, which was the medium used to 
suspend the nanoparticles had a pH of 6.82. At concentrations of 10mg/mL Br200 
nanoparticles had a pH of 2.00, at concentrations of 1mg/mL Br200 nanoparticles had a 
pH of 2.98, and at concentrations of 0.1mg/mL Br200 nanoparticles had a pH of 4.10. 
This confirmed the speculation that due to the sample preparation the Br200 
nanoparticles may have exhibited toxicity effects of outstanding acids, which may have 
resulted in some direct damage to the cells.  
 In addition, TiO2 as a chemical may possess inherent toxicity due to its properties 
which may cause the decline in cell growth over time. Additionally, bacterial cell counts 
may have decreased due to the changes in their natural environment caused by TiO2
nanoparticles.  
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It is important to note that the decrease in viable cell counts when nanoparticles 
were activated under UV light may have been partially due to the effects of toxicity. 
However, when the nanoparticles were activated under UV light, there was a 100% 
reduction in viable cell counts within 30 minutes, which was significantly lower than the 
viable cell counts obtained when nanoparticles were non-activated.  
 
5.6 Antibacterial Effects of Pre-Ultraviolet Light Exposed Coatings 
Uncoated slides pre-exposed to UV light and then incubated with cells did not 
exhibit any changes in viable cell counts within 30 or 60 minutes. This was consistent 
with other studies because when cells were not directly exposed to UV light, there was no 
decrease in viable cell counts.  
At concentrations of 15, 7.5, and 2.5mg/mL of nanoparticle coatings, there was no 
reduction in cell growth after pre-exposure to UV light for 30 or 60 minutes. The viable 
cell counts remained the same throughout the experiment. 
As expected pre-exposure of nanoparticle coatings to UV light did not cause a 
decrease in viable cell counts. This was due to the concept that nanoparticles need to be 
under constant UV light activation in order to release reactive radicals that destroy 
organic compounds. Therefore, it can be concluded that it is the simultaneous action of 
the TiO2 photocatalysts and UV light irradiation that has a synergistic effect on organic 
substances. Subsequently, when there is no UV light exposure, no antibacterial activity 
will be observed from the nanoparticles.  
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This also confirms that the released radicals are short-lived and do not extend 
their effects for a long period of time. They exhibit a limited amount of decomposing 
effects which do not last further without UV light activation.  
The nanoparticle coatings did not indicate toxic effects since the slides did not 
inhibit bacterial growth when unexposed to UV light. As previously seen the nanoparticle 
cell suspensions resulted in a decrease in viable cell counts when incubated in the dark. 
The reason the coatings did not cause a reduction in viable cell counts in the dark may be 
due to the preparation of the slides with the inorganic binder. The effects of the binder 
may have inhibited the toxic effects of the brookite nanoparticles or may have, somehow, 
protected the cells from the toxic effects of the brookite nanoparticles in the coatings.  
 
5.7 Morphological Effects of Ultraviolet Light Activated Anatase and Brookite 
Nanoparticles on Bacterial Cells 
The SEM images revealed the effects of activated nanoparticles on bacterial cells. 
After 1010 CFU of bacterial cells were exposed for 180 minutes to 0.1mg/mL 
concentrations of nanoparticles, there was a significant amount of damage to the bacterial 
cells as could be observed by the abnormal cell shapes and structures in the SEM images.  
Evidently, there was an increase in abnormal-shaped cells and a decrease in 
normal-shaped cells in the sample, compared to the images obtained after UV light 
irradiation alone. Ultraviolet light exposure at the same time without TiO2 nanoparticles 
did not cause a significant amount of damage to the cells as bacteria with intact cells were 
consistently observed while imaging the UV light exposed bacterial samples. There was a 
196
significantly greater amount of damaged cells in the activated TiO2-treated sample than 
the UV light-treated sample.  
Also, as can be noted, there was no difference in the sizes of the cells post 
treatment with activated TiO2 nanoparticles. Although the shapes of the cells were 
different post treatment with TiO2 nanoparticles, there was no evidence of cell lysis. Due 
to the processing methodology for obtaining SEM images, the smaller cell debris might 
not have been recovered. Overall, the cells lost their original shapes but the sizes 
remained the same.  
Thus, it can be concluded, that the action of the photocatalysts along with UV 
light irradiation causes physical damage to the bacterial cells, as could be noted by the 
abnormal cell shapes. It can also be implied that at higher concentrations of 1 or 
10mg/mL, and the same amount of bacterial cells and exposure times, a significant 
amount of damage may occur on the activated nanoparticle-treated cells compared to the 
cells treated with UV light alone.  
 
5.8 Antibacterial Effects of Visible Light Activated Anatase and Brookite 
Nanoparticles 
Cells incubated with distilled water under visible light did not result in any 
reduction in viable cell counts over time which indicates that visible light activation alone 
does not cause a reduction in viable cell counts. Similarly, the control cells, incubated in 
the dark, away from all light sources did not show any reduction in viable cell counts 
over time.  
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However, there was a decrease in viable cell counts post exposure to visible light 
activated nanoparticles at a concentration of 10mg/mL. When tested against E. coli cells, 
visible light activated anatase nanoparticles caused a three log reduction after 8 hours of 
exposure while brookite nanoparticles caused a greater decrease of five logs after 8 hours 
of exposure. The cells incubated with non-activated nanoparticles also caused a 
statistically significant decrease over time. After 8 hours of exposure with non-activated 
P25 nanoparticles, there was a two log reduction and after 8 hours of exposure with non-
activated Br200 nanoparticles, there was a three log reduction.  
When tested against S. aureus cells, visible light activated anatase nanoparticles 
induced a two log reduction after 8 hours of exposure while brookite nanoparticles 
induced a greater decrease of four logs after 8 hours of exposure. The cells incubated 
with non-activated nanoparticles also caused a statistically significant decrease over time. 
After 8 hours of exposure with non-activated P25 nanoparticles, there was a one log 
reduction and after 8 hours of exposure with non-activated Br200 nanoparticles, there 
was a two log reduction.  
The nanoparticles utilized in this study did not contain any other elements hence 
they could function efficiently under UV light exposure. They could function less 
efficiently under visible light (400nm to 700nm) exposure due to the current band gap 
energy of the nanoparticles which under optimal conditions are activated via a 
wavelength of 365nm at an energy intensity of 370>w/cm2. However, the experiments in 
this study indicated that there was a reduction in viable cell counts when activated under 
visible light at a nanoparticle concentration of 10mg/mL for an extended period of time.  
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The decrease in viable cell counts may be due to the longer exposure times. Since 
the energy intensity of the light source utilized for the experiments was low, the 
activation time under visible light was extended. This infers that if the nanoparticles are 
doped with an element that results in a lower band gap energy, shorter times of exposure 
to visible light may be sufficient to inhibit growth. The reduction may also have been 
partially due to the toxicity of the nanoparticles or the chemical nature of the 
nanoparticles which may have inhibited the growth of the bacterial cells, as observed by 
the results of the non-activated nanoparticles.  
Similar studies, with lower concentrations of nanoparticles and more time 
intervals should be conducted. If samples are obtained at several time intervals within 8 
hours, it would be possible to see a gradual decline in cell growth over time. Finally, it 
was evident that Br200 nanoparticles have stronger antibacterial properties than P25 
nanoparticles which suggests that brookite nanoparticles may also be more efficient 
under visible light activation than anatase nanoparticles.  
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CHAPTER 6 
CONCLUSIONS AND RECOMMENDATIONS 
 
6.1 Conclusions 
 Despite many advances with antibiotics and their increased production, the 
treatment of MRSA with antibiotics still remains a temporary solution or a solution that 
can be utilized only until MRSA expresses resistance to those certain antibiotics. Due to 
the high rates of resistance, the use of a treatment different from antibiotics is being 
tested by many researchers.  
 Nanoparticles, in particular TiO2 nanoparticles, offer promise for the prevention 
and treatment of MRSA infections. The experiments conducted in this study have shown 
that TiO2 nanoparticles, in both the anatase and brookite forms, caused death of bacterial 
cells. E. coli cells were more susceptible to the decomposing effects of TiO2
nanoparticles than S. aureus cells. Collectively all strains of bacteria tested showed a 
significant reduction in viable cell counts at brookite nanoparticle concentrations of 
1mg/mL which strongly suggests that brookite may be used against bacteria where 
multiple drug resistance is evident.  
This study concludes that TiO2 nanoparticles under UV light irradiation, 
particularly the brookite forms, have stronger antibacterial effects than UV light or TiO2
nanoparticles alone. Within 30 minutes of exposure to a 1mg/mL concentration of 
activated brookite nanoparticles, there was a 100% reduction in MDR S. aureus, while 
activated anatase nanoparticles at the same concentration required longer exposure times. 
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Brookite phase nanoparticles exhibited antibacterial properties that were effective as 
suspensions and as coatings. The effective concentration of the suspensions was 
approximately 1mg/mL while the effective concentration of the coatings is yet to be 
determined. Non-activated brookite nanoparticles exhibited some level of toxicity.  
However, the decrease in viable cell counts due to non-activated brookite nanoparticles 
was significantly less than that caused by activated brookite nanoparticles. In addition, 
constant activation under UV light was required in order for the nanoparticles to exhibit 
antibacterial properties. It could also be concluded that activated TiO2 nanoparticles 
resulted in bacterial cell damage, as observed on the SEM images. Finally, visible light 
activation caused a decrease in viable cell counts when exposure times were increased to 
8 hours.  
 To validate the widespread use of these nanoparticles and coatings, as 
antimicrobial agents, it will be necessary to validate their effects on other 
microorganisms such as viruses and fungi. It would also be important to determine the 
safety of the long term usage of activated nanoparticles. Coatings of nanoparticles may be 
utilized as antimicrobial agents on inanimate objects. Eventually, suspensions of 
nanoparticles may be used as antimicrobial agents for the elimination of infections on 
body surfaces. Currently, there are no reports of bacterial resistance to nanoparticle 
coatings since the nanoparticles result in physical damage to the cells. However, the 
emergence of a mutant strain of bacteria that may develop resistance to the physical 
damage caused by nanoparticles is a possibility.  
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6.2 Recommendations for Future Studies 
Titanium dioxide exhibits excellent photocatalytic properties under UV light 
activation because of its high reactivity and chemical stability. In this study, brookite 
nanoparticles exhibited more destruction to cells than anatase nanoparticles.  
The ultimate aim of this research is to develop nanoparticles that are active under 
visible light (400nm to 700nm). If these nanoparticles can be activated under white light, 
their utilization under solar beams will increase (Umebayashi et al., 2003). Once 
activated under white light, nanoparticles can be used for applications in clinics and 
hospitals where MRSA is prevalent. The applications could be in the form of paints or 
coatings which can be applied onto surfaces such as bench tops and walls, medical 
equipment, and various other materials used in clinics and hospitals.  
The development of TiO2 nanoparticles that can yield high reactivity under visible 
light activation (smaller than a band gap of 3.2eV or greater than an absorption 
wavelength of 380nm) would eventually lead to the production of doped-TiO2
nanoparticles (Asahi et al., 2001). Studies have shown that doping transition metals such 
as Cr and Co extends the spectral response of TiO2 into the visible light region by 
inducing optical transitions from d level electrons of the transition metal ions to the 
conduction bands of TiO2 (Morikawa et al., 2001). Other researchers have shown that the 
substitution of a non-metal atom such as nitrogen and fluorine for oxygen may shift the 
optical absorption edge to a lower energy, thereby increasing the reactivity of the 
nanoparticles in the visible light region (Umebayashi et al., 2003). Therefore, 
nanoparticles with dopants would lead to the practical utilization of these nanoparticles.  
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Next, this study indicates that UV light activated brookite phase TiO2
nanoparticles can effectively inhibit bacterial growth. Further studies should be 
performed to determine the effectiveness of brookite nanoparticles against cancer and 
tumor cells. In one study, Zhang and colleagues (2004) performed experiments to 
determine the effects of TiO2 nanoparticles on Ls-174-t human colon carcinoma cells. 
They concluded that in the presence of 1mg/ml TiO2, 44% of cells were killed within 10 
minutes of UVA irradiation and 88% of cells were killed after 30 minutes of irradiation. 
Studies utilizing cancer cell lines such as MCF7 (human breast cancer), SiHa 
(human cervical cancer), HT29 (human colon cancer), and HepG2 (Human hepatocellular 
liver carcinoma) can be conducted to determine the effects of TiO2 nanoparticles on 
eukaryotic cells. The photocatalytic killing of human cancer cells by TiO2 nanoparticles 
would imply that TiO2 nanoparticles together with light irradiation may be used to treat 
various types of cancer. This mechanism could be adapted to an anticancer therapy by the 
local or regional treatment of cancer or tumor with TiO2 nanoparticles, followed by light 
irradiation.  
Free radicals are cells that have lost an electron, thus, are unstable cells. These 
free radicals basically steal electrons from other cells, ultimately creating new radicals in 
the process. By stealing electrons, radicals can cause DNA damage, possibly leading to 
the development of cancer. Therefore, the release of radicals from the TiO2 nanoparticles 
may result in the development of cancer. If TiO2 nanoparticles will be used for treatment 
against cancer and tumor cells, the release of radicals and their potential to cause DNA 
damage will need to be addressed.  
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In conclusion, by activating TiO2 nanoparticles under visible light, the practical 
usage of nanoparticles is possible. Furthermore, if the activated nanoparticles display 
killing effects on cancerous and tumor cells, there is promise for use as an anti-cancer and 
an anti-tumor treatment modality.  
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